methotrexate has been researched along with Disease Exacerbation in 740 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.14) | 18.7374 |
| 1990's | 66 (8.92) | 18.2507 |
| 2000's | 228 (30.81) | 29.6817 |
| 2010's | 377 (50.95) | 24.3611 |
| 2020's | 68 (9.19) | 2.80 |
| Authors | Studies |
|---|---|
| Dimopoulou, D; Maritsi, DN; Spyridis, N; Tsolia, MN; Vartzelis, G | 1 |
| Beattie, S; Durez, P; Fleischmann, R; Kartman, CE; Mo, D; Schlichting, D; Tanaka, Y; van der Heijde, D; Xie, L | 1 |
| Dandis, R; Eysbouts, YK; Hoeijmakers, YM; Inthout, J; Massuger, LFAG; Ottevanger, PB; Sweep, FCGJ; Thomas, CMG; van Trommel, NE | 1 |
| Abba, A; Ali, H; Diaby, LM; Niasse, M | 1 |
| Matthijssen, XME; van der Helm-van Mil, AHM; Verstappen, M | 1 |
| Baraliakos, X; Chen, S; Durez, P; Enejosa, JV; Friedman, A; Hall, S; Li, Y; Mysler, E; Peterfy, CG; Shaw, T; Song, IH; Strand, V | 1 |
| Meza-Romero, R; Moll-Manzur, C; Ramírez-Cornejo, C; Vera-Kellet, C; Wortsman, X | 1 |
| Aletaha, D; de la Torre, I; Haladyj, E; Lopez-Romero, P; Smolen, JS | 1 |
| Certan, M; Garcia Garrido, HM; Goorhuis, A; Grobusch, MP; Heijmans, J; Wong, G | 1 |
| Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Takeuchi, T; Tanaka, Y; van der Heijde, D | 1 |
| Conejero Del Mazo, R; Fuentelsaz Del Barrio, MV; Genzor Ríos, C; López Campos, M; Valer Martínez, A; Vázquez Sánchez, M | 1 |
| Akinde, M; Amy de la Bretêque, M; Bachelerie, M; Bachelez, H; Beauchet, A; Bellissen, A; Belloni Fortina, A; Bourrat, E; Brzezinski, P; Bursztejn, AC; Chiriac, A; Di Lernia, V; Epishev, R; Flohr, C; Lasek, A; Lesiak, A; Luca, C; Luna, PC; Mahé, E; Mahil, SK; Mallet, S; Maruani, A; McPherson, T; Murashkin, N; Neri, I; Smith, CH; Sonkoly, E; Steff, M; Thomas, J; Topkarci, Z; Torres, T; van den Reek, JMPA; Vidaurri de la Cruz, H; Zafiriou, E; Zitouni, J | 1 |
| Biln, N; Brahe, CH; Hetland, ML; Hørslev-Petersen, K; Junker, P; Midtbøll Ørnbjerg, L; Raft, MB; Stengaard-Pedersen, K; Østergaard, M | 1 |
| Bae, WH; Canonico, MM; Shimabukuro, KA; Song, L; Verhoef, PA; Yee, M | 1 |
| Kumagai, J; Mochimatsu, Y; Ohgaki, F; Paku, S; Shuto, T; Takemoto, Y; Tatezuki, J | 1 |
| Daa, T; Iwasaki, H; Kadowaki, M; Kawauchi, S; Kimura, S; Ogata, M; Oshiro, Y; Sakata, T; Takamatsu, Y; Takeshita, M; Wang, Z | 1 |
| Chang, YL; Chen, WM; Chou, YC; Huang, KW; Hung, GY; Lee, HC; Wang, SF; Wu, PK | 1 |
| Ahmad, N; Andev, R; Dubey, S; Verdiyeva, A | 1 |
| Burmester, G; Fiore, S; Hagino, O; Praestgaard, A; Shadick, N; Weinblatt, M | 1 |
| DeAngelis, LM; Grommes, C; Nandakumar, S; Omuro, AMP; Schaff, LR; Therkelsen, KE | 1 |
| DeHoratius, RJ; Hsia, EC; Kafka, S; Tesser, J; Turkiewicz, A; Xu, S | 1 |
| Aletaha, D; Chen, S; Florentinus, S; Furtner, D; Maa, JF; Nicholls, D; Park, SH; Smolen, JS | 1 |
| Burmester, GR; Genovese, MC; Gómez-Reino, JJ; Kivitz, A; Lin, Y; Maldonado-Cocco, JA; Seriolo, B; St John, G; Stanislav, M; van der Heijde, D; van Hoogstraten, H; Wang, S | 1 |
| Allaart, CF; Bergstra, SA; Brinkman, DMC; Hemke, R; Hissink Muller, PCE; Koopman-Keemink, Y; Kuijpers, TW; Maas, M; Nusman, CM; Schonenberg-Meinema, D; Schreurs, D; Ten Cate, R; van Braak, WG; van den Berg, JM; van Rossum, MAJ; van Suijlekom-Smit, LWA | 1 |
| Ahn, MJ; Arora, RS; Bello, M; Chan, A; Cohen, EEW; Dechaphunkul, A; Geng, Y; Guo, Y; He, X; Kamble, K; Kandil, A; Kang, JH; Kim, SB; Kumar, V; Li, P; Li, W; Tang, PZ; Wang, CH; Zhang, Q; Zografos, E | 1 |
| Baeten, DLP; de Jong, HMY; Kok, MR; Nurmohamed, MT; van de Sande, MGH; van Kuijk, AWR; van Mens, LJJ | 1 |
| Bagot, M; Bouaziz, JD; de Masson, A; Jachiet, M; Lepelletier, C; Macaux, L; Vignon, MD; Weiss, M | 1 |
| Agarwal, A; Kumar, A; Sharma, A | 1 |
| Andrews, J; Bowes, MA; Chapman, D; Conaghan, PG; Guillard, G; Koenig, A; Stein, A; Troum, O; Wilkinson, B; Xie, Z; Østergaard, M | 1 |
| Baars, PA; Lim, J; Ten Dam, L; Van der Kooi, AJ | 1 |
| Aletaha, D; Allaart, CF; Combe, B; Fautrel, B; Saevarsdottir, S; Smolen, JS; Van Vollenhoven, R; Vanier, A; Vastesaeger, N; Verschueren, P; Visser, K | 1 |
| Baron, M; Baxter, CA; Nevskaya, T; Pope, JE; Ramey, DR; Zheng, B | 1 |
| Iwagaitsu, S; Kajiura, M; Naniwa, T | 1 |
| Ahmad, HA; Bergman, MJ; Keystone, EC; Yazici, Y | 1 |
| Amigo, ML; Bravo-Perez, C; Escobar, H; Garcia, J; Garcia-Malo, MD; Muiña, B; Ortuño, FJ; Pajares, I; Piris, MA; Rodriguez-Pinilla, SM | 1 |
| Bijlsma, JWJ; Borm, MEA; Bos, R; Bruyn, GAW; de Hair, MJH; Griep, EN; Jacobs, JWG; Klaasen, R; Lafeber, FPJG; Pethö-Schramm, A; Tekstra, J; van Laar, JM; Verhoeven, MMA; Welsing, PMJ | 1 |
| Akella, S; Barmettler, A; Kumthekar, A; Park, SSE | 1 |
| Chen, H; Liu, Z; Xu, J; Yang, J; Yang, Y | 1 |
| El-Waseef, DAEA | 1 |
| Beham-Schmid, C; Deutsch, A; Greinix, H; Hatzl, S; Neumeister, P; Pichler, M; Posch, F; Prochazka, KT; Stöger, H | 1 |
| England, BR; Hershberger, D | 1 |
| Akutsu, Y; Mori, M; Morio, T; Shimbo, A; Takase, H; Yamazaki, S | 1 |
| Boyapati, A; Burmester, GR; Choy, E; Genovese, MC; Graham, NMH; Kimura, T; Lam, G; Msihid, J; Sadeh, J; Schwartzman, S; Weinreich, DM; Yancopoulos, GD | 1 |
| Behrens, F; Burkhardt, H; Gnann, H; Greger, G; Koehm, M; Schmalzing, M; Schwaneck, EC; Tony, HP | 1 |
| Aazami, H; Kamali, M; Khoshmirsafa, M; Mansouri, D; Mohsenzadegan, M; Pornour, M; Seif, F | 1 |
| Allaart, CF; Bergstra, SA; Goekoop-Ruiterman, YPM; Huizinga, TWJ; Kerstens, PJSM; Lems, W; Riyazi, N; Van Der Pol, JA | 1 |
| Fang, C; Jing, X; Wang, N; Xu, Z; Zhang, Q | 1 |
| Biester, K; Hirsch, K; Hörn, H; Janke, K; Kerekes, MF; Kohlepp, P; Krause, D; Richter, B; Schürmann, C; Wieseler, B | 1 |
| Endo, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Okamoto, M; Origuchi, T; Shimizu, T; Sumiyoshi, R; Tamai, M; Tsuji, S | 1 |
| Cornec, D; Dernis, E; Dieude, P; Dubost, JJ; Fauchais, AL; Felten, R; Giannini, M; Gottenberg, JE; Guellec, D; Hachulla, E; Lannes, B; Larroche, C; Le Guern, V; Levy, D; Mariette, X; Meyer, A; Nespola, B; Perdriger, A; Seror, R; Sibilia, J; Vittecoq, O | 1 |
| Bang, H; de la Torre, I; Feist, E; Holzkämper, T; López-Romero, P; Martinez-Gamboa, L | 1 |
| Bager, C; Bay-Jensen, AC; Blair, JPM; Brunak, S; Frederiksen, P; Karsdal, M; Tang, MH | 1 |
| Bang, J; Han, SW; Jung, WY; Ko, Y; Lim, YJ; Seo, HM; Yi, JH; Yu, MY | 1 |
| Bijlsma, JWJ; de Hair, MJH; Jacobs, JWG; Jurgens, MS; Lafeber, FPJG; Safy-Khan, M; Sasso, EH; Tekstra, J; Welsing, PMJ | 1 |
| England, BR; Johnson, TM; Luedders, BA; Mikuls, TR; O'Dell, JR; Sayles, H; Thiele, GM | 1 |
| Huizinga, TWJ; Matthijssen, XME; Niemantsverdriet, E; van der Helm-van Mil, AHM | 1 |
| Hong, S; Kim, YG; Lee, CK; Lee, JS; Oh, JS; Yoo, B | 1 |
| Chen, F; Guo, H; Huang, L; Jiang, X; Li, W; Liang, Z; Liu, S; Ou, Q; Pang, D; Wei, X; Wu, X; Zhou, D | 1 |
| Chen, J; Chen, T; Gao, Y; He, L; Huang, Y; Li, X; Lin, K; Sun, Y; Wang, Z | 1 |
| Abdulah, R; Destiani, DP; Dewi, S; Naja, S; Rahmadi, AR; Sulaiman, SAS | 1 |
| Bijlsma, JWJ; Borm, MEA; Jacobs, JWG; Lafeber, FPJ; Pethö-Schramm, A; Tekstra, J; van Laar, JM; Verhoeven, MMA; Welsing, PMJ | 1 |
| Church, T; Holtzclaw, A; Shumar, J; Zeman, J | 1 |
| Duan, M; Yao, ZZ; Ye, XL; Zhang, JF; Zhao, JX; Zhou, XL | 1 |
| Wells, AU | 1 |
| do Rocio Valenga Baroni, E; Morandi Stumpf, MA; Schafranski, MD | 1 |
| Domján, A; Gaál, J; Géher, P; Gömöri, E; Kovács, A; Kovács, L; Nagy, K; Posta, EF; Szekanecz, Z; Szűcs, G; Tamási, L; Tóth, E; Varga, E; Végh, E | 1 |
| Billiet, T; D'Hooge, R; Deprez, S; Elens, I; Labarque, V; Lemiere, J; Sleurs, C; Uyttebroeck, A; Van Gool, S | 1 |
| Baldi, GG; Bardelli, A; Bertulli, R; Bini, F; Casale, A; Casali, PG; Ciniselli, CM; Colombo, C; Ferrari, A; Fiore, M; Greco, FG; Gronchi, A; Morosi, C; Palassini, E; Provenzano, S; Stacchiotti, S; Verderio, P; Zanchetta, E | 1 |
| Laasonen, L; Leirisalo-Repo, M; Moilanen, E; Nieminen, R; Tuure, L; Vuolteenaho, K | 1 |
| Carotti, M; Di Carlo, M; Giovagnoni, A; Salaffi, F; Tardella, M | 1 |
| Bagchi, A; Bhattacharjee, D; Chakrabarti, P; Chatterjee, M; Chatterjee, S; Chattopadhyay, A; Ghosh, A; Misra, S; Mondal, S; Niyogi, S; Saha, A; Sarkar, A; Sinhamahapatra, P | 1 |
| Chen, H; Dai, X; Ji, Z; Jiang, L; Jin, X; Kong, X; Ma, L; Sun, Y; Wang, L | 1 |
| Alfagemeb, F; Laverde-Saad, A; Lopez-Negrete, E; Roustan, G | 1 |
| Gion, Y; Iwaki, N; Nishida, K; Orita, Y; Sato, Y; Tachibana, T; Takata, K; Takeuchi, M; Yoshino, T | 1 |
| Blanco, R; Burmester, GR; Dimonaco, S; Kadva, A; Kay, J; Rigby, WF; Rubbert-Roth, A; van Vollenhoven, RF | 1 |
| Bermas, BL | 1 |
| Bai, X; Chen, Y; Ji, N; Liu, F; Liu, J; Liu, Y; Qian, J; Qiu, X; Sun, S; Sun, X; Wang, Y; Zhu, H | 1 |
| Becker, ML; Chan, MA; Funk, RS | 1 |
| Almquist, H; Bläckberg, M; Cwikiel, M; Gudjonsson, S; Kollberg, P; Liedberg, F; Lyttkens, K; Patschan, O | 1 |
| Yoo, DH | 1 |
| Koyama, A; Tanaka, A; To, H | 1 |
| Boers, M; Bultink, IEM; den Uyl, D; Kerstens, PJSM; Konijn, NPC; Lems, WF; Nurmohamed, MT; Ter Wee, MM; van der Wijden, LKM; van Schaardenburg, D; van Tuyl, LHD; Voskuyl, AE | 1 |
| Chhabra, A; Lam, JM; Rhemus, W | 1 |
| Combe, B; Dougados, M; Fautrel, B; Gaujoux-Viala, C; Rincheval, N | 1 |
| Becerra-Alvarado, IN; Bonilla-Lara, D; Gamez-Nava, JI; Gonzalez-Lopez, L; Gonzalez-Ponce, F; Murillo-Vazquez, JD; Perez-Guerrero, EE; Ponce-Guarneros, JM; Rodriguez-Jimenez, NA; Saldaña-Cruz, AM; Vazquez-Villegas, ML; Vera-Navarrete, EY; Zuñiga-Mora, JA | 1 |
| Beukelman, T; Brandon, TG; Feudtner, C; Morgan-DeWitt, E; Pagnini, I; Weiss, PF; Wright, TB; Xiao, R | 1 |
| Everts-Graber, J; Finckh, A; Florentinus, S; Kupper, H; Li, Y; Möller, B | 1 |
| Cleland, LG; Lee, A; McWilliams, L; Proudman, S; Wabe, N; Wechalekar, MD; Wiese, MD; Wojciechowski, J | 1 |
| Allaart, CF; Bergstra, SA; Huizinga, TWJ; Landewé, RBM | 1 |
| de Jong, P; Hazes, J; Kuijper, TM; Luime, JJ; Tchetverikov, I; van der Lubbe, P; van Zeben, D; Weel, A; Xiong, H | 1 |
| Akdemir, G; Allaart, CF; Bergstra, SA; de Sonnaville, PBJ; Goekoop, RJ; Grillet, BAM; Heimans, L; Huizinga, TWJ; Lard, LR; Peeters, AJ; Steup-Beekman, GM; van Groenendael, JHLM; van Oosterhout, M | 1 |
| Calley, CSJ; Campbell, SC; Chiorean, MV; Fadda, HM; Fischer, M; Helper, DJ | 1 |
| Bijlsma, JWJ; Borm, MEA; Jacobs, JWG; Lafeber, FPJG; Pethö-Schramm, A; Teitsma, XM; van Laar, JM; Welsing, PMJ | 1 |
| Bananis, E; Burmester, GR; Charles-Schoeman, C; Connell, CA; Fan, H; Fleischmann, R; Kwok, K; Nash, P; van der Heijde, D; Zerbini, CAF | 1 |
| Brenaut, E; Costa, S; Huet, F; Lemasson, G; Misery, L; Sonbol, H | 1 |
| Barbieri, L; de Paulis, A; Lobasso, A; Marone, G; Mercurio, V; Rivellese, F; Rossi, FW; Tocchetti, CG | 1 |
| Contreras-Yáñez, I; Ortiz-Haro, AB; Pascual-Ramos, V; Pérez-Román, DI; Ruiz-Medrano, E | 1 |
| Brahe, CH; Dehlendorff, C; Ellingsen, T; Hansen, I; Hetland, ML; Hørslev-Petersen, K; Jacobsen, S; Johansen, JS; Junker, P; Jurik, AG; Lindegaard, H; Lottenburger, T; Stengaard-Pedersen, K; Ørnbjerg, LM; Østergaard, M | 1 |
| Aletaha, D; Barton, A; Burmester, GR; Emery, P; Firestein, GS; Kavanaugh, A; McInnes, IB; Smolen, JS; Solomon, DH; Strand, V; Yamamoto, K | 1 |
| Horneff, G; Klotsche, J; Minden, K; Niewerth, M | 1 |
| Al, MJ; Alemao, E; Johal, S; Rutten-van Mölken, M | 1 |
| Hachulla, E; Hatron, PY; Launay, D; Leurs, A; Quartier, P; Terriou, L | 1 |
| Ørnbjerg, LM | 1 |
| Birchwood, C; Gill, D; Kremer, JM; Michalska, M; Pei, J; Reiss, W; Rigby, W; Singer, NG | 1 |
| Bleck, E; Brinks, R; Le, L; Lesch, J; Mansmann, U; Ostendorf, B; Pongratz, G; Schleich, C; Schneider, M; Sengewein, R; Sewerin, P; Vordenbäumen, S | 1 |
| Chen, H; Fei, YY; Huang, LF; Jin, H; Li, H; Li, Z; Liao, X; Lipsky, PE; Liu, B; Liu, H; Liu, X; Lv, QW; Shi, Q; Tang, FL; Wang, DF; Wang, J; Wei, W; Wu, QJ; Zhang, FC; Zhang, W; Zhang, X; Zhang, Y; Zhao, LD; Zheng, WJ; Zhou, YZ | 1 |
| Fujiwara, M; Kanazawa, Y; Kato, S; Leppold, C; Morita, T; Ochi, S; Oikawa, T; Shineha, R; Tsubokura, M | 1 |
| Fan, C; Genovese, MC; Graham, NMH; Huizinga, TWJ; Mangan, EK; Parrino, J; Spindler, A; van Adelsberg, J; van der Heijde, D; van Hoogstraten, H | 1 |
| Cheng, IT; Kun, EW; Kwok, KY; Lao, VW; Lau, XS; Lee, AP; Lee, VK; Li, EK; Li, TK; Mak, QW; Pang, SH; Shang, Q; Tam, LH; Tam, LS; Wong, PC; Yim, IC; Yip, RM; Zhu, TY | 1 |
| Bessette, L; Burmester, GR; Camp, HS; Kivitz, A; Kremer, JM; Li, Y; Othman, AA; Pangan, AL; Van den Bosch, F; Zhou, Y | 1 |
| Ahlquist, P; Ammitzbøll, C; Bolce, R; Brahe, CH; Dam, MY; Defranoux, N; Ellingsen, T; Hansen, I; Hetland, ML; Hørslev-Petersen, K; Johansen, JS; Junker, P; Jørgensen, A; Krintel, SB; Linauskas, A; Lindegaard, H; Lottenburger, T; Raun, J; Sasso, EH; Schlemmer, A; Stengaard-Pedersen, K; Wang, X; Ørnbjerg, LM; Østergaard, M | 1 |
| Anderson, J; Barton, A; Hope, HF; Hyrich, KL; Kopec-Harding, K; Sergeant, JC; Symmons, DPM; Verstappen, SMM | 1 |
| Chen, S; Florentinus, S; Kavanaugh, A; Smolen, JS; Suboticki, JL; van Vollenhoven, RF | 1 |
| de la Torre, I; De Leonardis, F; Durez, P; Fleischmann, R; López-Romero, P; Meszaros, G; Nantz, E; Naredo, E; Schett, G; Schlichting, D; van der Heijde, D; Østergaard, M | 1 |
| Butylkova, Y; Ellis, A; Garg, V; Kalabic, J; Murray, E; Skup, M | 1 |
| Eso, Y; Marusawa, H; Mimori, T; Mishima, M; Morita, M; Sawada, K; Seno, H; Takahashi, K; Takai, A; Ueda, Y; Yoshiji, S | 1 |
| Doostkam, S; Fritsch, B; Guggenberger, K; Schaefer, HE; Venhoff, N; Whittaker, K | 1 |
| Kurzinski, KL; Torok, KS; Zigler, CK | 1 |
| Chen, B; Chen, K; Ding, T; Fan, N; Kang, H; Lai, J; Lin, Z; Ma, J; Ma, Y; Wang, Q; Xu, X; Yuan, Y; Zeng, Q; Zhuang, L | 1 |
| Adegun, O; Carey, B; Hodgson, T | 1 |
| Ahn, MJ; Burtness, B; Cheng, J; Cohen, EEW; Dinis, J; Harrington, KJ; Le Tourneau, C; Licitra, L; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Zhang, P | 1 |
| Chang, Y; Jia, X; Wang, C; Wei, W; Wu, Y; Yang, X; Zhang, L; Zhao, Y | 1 |
| Genant, HK; Ishiguro, N; Ohira, T; Okubo, N; Takeuchi, T; Tanaka, Y; van der Heijde, D; Yamanaka, H; Yoneda, T | 1 |
| Aletaha, D; Coates, LC; Ganz, F; Hojnik, M; Landewé, R; Ritchlin, CT; Zhang, Y | 1 |
| Cohen, S; Galai, T; Moran-Lev, H; Yerushalmy-Feler, A | 1 |
| Beattie, SD; DiCarlo, J; Emery, P; Genovese, MC; Keystone, EC; Luchi, M; Macias, W; Peterfy, C; Schlichting, DE; Taylor, PC | 1 |
| Dann, EJ; Darawshy, F; Gatt, ME; Goldschmidt, N; Heffes, V; Horowitz, NA; Mashiach, T; Shaulov, A | 1 |
| Boers, M; Poppelaars, PBM; van Tuyl, LHD | 1 |
| Andres, E; Niazi, R; Pennaforte, JL; Zulfiqar, AA | 1 |
| Cocks, K; Contente, M; DeRosa, M; Shaw, JW; Simpson, S; Taylor, FC | 1 |
| Burmester, GR; Bykerk, VP; Combe, BG; Emery, P; Furst, DE; Huizinga, TW; Maldonado, MA | 1 |
| Hinze, C | 1 |
| Abdelaal, NH; Abdulmonem, SR; Elhefnawy, NG; Saleh, MA; Saleh, NA; Sayed, S | 1 |
| Ichikawa, A; Imaizumi, Y; Kato, K; Kawamoto, K; Kizaki, M; Kurita, D; Miyoshi, H; Muto, R; Nagafuji, K; Ohshima, K; Sasaki, Y; Sato, K; Seki, R; Shimono, J; Tamaru, JI; Tokuhira, M; Yamada, K | 1 |
| Figueiredo, CP; Finzel, S; Kocijan, R; Kraus, S; Rech, J; Regensburger, A; Schett, G | 1 |
| Bull, J; Ebbers, MNB; Engelmann, R; Kneitz, S; Kreikemeyer, B; Lang, H; Lübcke, PM; Müller-Hilke, B; Volzke, J | 1 |
| Birchwood, C; Gill, D; Kremer, J; Michalska, M; Pei, J; Peterfy, C; Reiss, W; Rigby, W; Singer, N | 1 |
| Bo, J; Sun, L; Wang, Q; Yuan, L; Zhao, Y | 1 |
| Fleischmann, R; Issa, M; Lisse, J; Martinez-Osuna, P; Rooney, T; Schiff, M; Schlichting, D; Stoykov, I; Takeuchi, T; Xie, L; Zerbini, CAF | 1 |
| Jones, H; Mahgoub, E; Marshall, L; Pedersen, R; Smolen, JS | 1 |
| Jamil, H; Khawla, K; Moez, J; Raida, BS; Saida, G; Sameh, M; Yosra, C; Zouhir, B | 1 |
| Behrens, F; Burkhardt, H; Gnann, H; Greger, G; Koehm, M; Schmalzing, M; Schwaneck, EC; Tony, HP; Wittig, BM | 1 |
| Bessette, L; Durez, P; Enejosa, JV; Fleischmann, RM; Genovese, MC; Li, Y; Mysler, E; Ostor, A; Peterfy, C; Song, IH | 1 |
| Almon, RR; DuBois, DC; Jusko, WJ; Liu, DY; Lon, HK; Wang, YL | 1 |
| Chen, D; Emery, P; Fan, H; Fleischmann, RM; Hsia, EC; Mack, M; Wagner, C | 1 |
| Forslind, K; Geborek, P; Petersson, IF; Rezaei, H; Saevarsdottir, S; van Vollenhoven, RF | 1 |
| Arakawa, F; Ichikawa, A; Ishibashi, Y; Kimura, Y; Kiyasu, J; Miura, O; Miyoshi, H; Nakashima, S; Niino, D; Ohshima, K; Sato, K; Sugita, Y; Takeuchi, M; Yoshida, M | 1 |
| De Smet, MD; Haas, A; Julian, K; Langner-Wegscheider, BJ | 1 |
| Bridges, SL; Cofield, SS; Curtis, JR; McVie, T; Mikuls, TR; Moreland, LW; Navarro-Millán, I; O'Dell, J; Ranganath, VK; Reynolds, RJ | 1 |
| Barath, S; Bodolay, E; Gogolak, P; Hajas, A; Nakken, B; Szegedi, G; Szekanecz, Z; Szodoray, P; Zeher, M; Zold, E | 1 |
| Chandran, V; Eder, L; Gladman, DD; Thavaneswaran, A | 1 |
| Bossuyt, X; Malemba, JJ; Mbuyi Muamba, JM; Mukaya, J; Verschueren, P; Westhovens, R | 1 |
| Abrahamsen, B; Andersen, LS; Ellingsen, T; Hansen, I; Hansen, MS; Hetland, ML; Hyldstrup, L; Hørslev-Petersen, K; Jensen, TW; Junker, P; Jurik, AG; Langdahl, B; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Skjødt, H; Stengaard-Petersen, K; Svendsen, AJ; Tarp, U; Vestergaard, A; Zerahn, B; Østergaard, M | 1 |
| Bae, SC; Genovese, MC; Hall, S; Hsia, EC; Keystone, EC; Miranda, PC; Palmer, W; Wu, Z; Xu, S | 1 |
| Gu, X; Li, W; Tu, P; Wang, Y; Zhang, G | 1 |
| Bridges, SL; Cofield, SS; Curtis, JR; Mikuls, TR; Moreland, LW; O'Dell, JR; Ranganath, VK | 1 |
| Gollard, RP; Selco, S | 1 |
| Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Speyer, I; van Oosterhout, M; Visser, K; Wevers-de Boer, KV | 1 |
| Kameda, H; Kaneko, Y; Kuwana, M; Nishina, N; Takeuchi, T | 1 |
| Guérette, B; Kavanaugh, A; Keystone, EC; Kupper, H; Liu, S; Mozaffarian, N; van der Heijde, D | 1 |
| Amante, E; Churchill, M; Doyle, MK; Durez, P; Emery, P; Fleischmann, RM; Hsia, EC; Nash, P; Park, W; Pons-Estel, B; Strusberg, I; Wu, Z; Xu, S; Xu, W | 1 |
| Baker, DG; Baker, JF; Conaghan, PG; Emery, P; Hsia, EC; Lu, J; Ostergaard, M | 1 |
| Belke-Voss, E; Fiehn, C; Krause, D; Rau, R; Wassenberg, S | 1 |
| Benessiano, J; Berenbaum, F; Cantagrel, A; Combe, B; Daurès, JP; Dougados, M; Fardellone, P; Fautrel, B; Flipo, RM; Goupille, P; Guillemin, F; Le Loët, X; Logeart, I; Mariette, X; Meyer, O; Ravaud, P; Rincheval, N; Saraux, A; Schaeverbeke, T; Sibilia, J | 1 |
| Andersen, LS; Christensen, AF; Ellingsen, T; Hansen, I; Hetland, ML; Hørslev-Petersen, K; Jacobsen, S; Junker, P; Jurik, AG; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Møller, BK; Pedersen, JK; Skjødt, H; Stengaard-Pedersen, K; Svendsen, A; Tarp, U; Thorsen, J; Vestergaard, A; Østergaard, M | 1 |
| Ciszak, L; Frydecka, I; Kosmaczewska, A; Swierkot, J; Szteblich, A; Wiland, P | 1 |
| García-Romero, MT; Laxer, R; Pope, E; Taylor, G | 1 |
| Boire, G; Bonner, AJ; Bykerk, VP; Haraoui, B; Harris, JA; Hazlewood, G; Hitchon, CA; Keystone, EC; Pope, JE; Thorne, JC | 1 |
| Deleuran, B; Greisen, SR; Hetland, ML; Hvid, M; Hørslev-Petersen, K; Rasmussen, TK; Stengaard-Pedersen, K | 1 |
| Ikeda, K; Iwamoto, T; Kawashima, H; Nakagomi, D; Nakajima, H; Okubo, A; Sanayama, Y; Takahashi, K; Yamagata, M | 1 |
| Arulmani, U; Breedveld, FC; Florentinus, S; Kavanaugh, A; Keystone, EC; Kupper, H; Landewé, R; Liu, S; van der Heijde, D | 1 |
| Amano, K; Kameda, H; Kishimoto, M; Kurasawa, T; Nagasawa, H; Takeuchi, T | 1 |
| Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Harbers, JB; Heimans, L; Huizinga, TW; Kälvesten, J; Steup-Beekman, M; van Oosterhout, M; Visser, K; Wevers-de Boer, KV | 1 |
| Guérette, B; Haraoui, B; Kavanaugh, A; Keystone, EC; Liu, S; Mozaffarian, N | 1 |
| Eguchi, K; Ishiguro, N; Koike, T; Miyasaka, N; Origasa, H; Sakamaki, Y; Shoji, T; Takeuchi, T; Tanaka, Y; van der Heijde, D; Watanabe, A; Yamamoto, K; Yamanaka, H | 1 |
| Biggioggero, M; Favalli, EG; Meroni, PL; Pregnolato, F | 1 |
| Belkacemi, MC; Combe, B; Dadoun, S; Daurès, JP; Dougados, M; Logeart, I; Schaeverbeke, T | 1 |
| Cao, XX; Duan, MH; Li, J; Shen, T; Zhang, W; Zhou, DB | 1 |
| Alasti, F; Aletaha, D; Smolen, JS | 4 |
| Cope, AP; Dahanayake, C; Lewis, CM; Ma, MH; Scott, DL; Scott, IC; Seegobin, SD | 1 |
| Akama, H; Arora, V; Ishiguro, N; Kupper, H; Matsubara, T; Miyasaka, N; Mukai, M; Takeuchi, T; Tanaka, Y; Uchida, S; Yamanaka, H | 2 |
| Junckerstorff, R; McLean-Tooke, A; Tu, J | 1 |
| Amital, H; Bernasconi, C; Conaghan, PG; Dougados, M; Gerli, R; Hansen, MS; Huizinga, TW; Kissel, K; Mola, EM; Schett, G; Troum, O; Xavier, RM | 1 |
| Kamath, V; Rios, AL | 1 |
| Deangelis, LM; Omuro, A; Pentsova, E | 1 |
| Bizzi, E; Bruzzese, V; Cassol, M; Diamanti, AP; Laganà, B; Massafra, U; Migliore, A | 1 |
| Conaghan, PG; Devenport, J; Dicarlo, J; Friedman, J; Kaine, J; Olech, E; Peterfy, C; Ridley, D; Troum, O | 1 |
| Arima, K; Horai, Y; Kawakami, A; Kawashiri, SY; Nakamura, H; Nakashima, Y; Okada, A; Suzuki, T; Tamai, M | 1 |
| Brodmerkel, C; Gottlieb, AB; Kavanaugh, A; Li, S; McInnes, IB; Mendelsohn, AM; Noonan, L; Puig, L; Rahman, P; Ritchlin, C; Song, M; Wang, Y | 1 |
| Eguchi, K; Ishiguro, N; Koike, T; Miyasaka, N; Origasa, H; Shoji, T; Takeuchi, T; Tanaka, Y; Watanabe, A; Yamamoto, K; Yamanaka, H | 1 |
| Imamura, Y | 1 |
| Becker, I; Horneff, G | 1 |
| Arstila, L; Elfving, P; Kaipiainen-Seppänen, O; Kononoff, A; Koskela, H; Rutanen, J | 1 |
| Antoch, G; Brinks, R; Buchbender, C; Klein, S; Miese, F; Ostendorf, B; Scherer, A; Schneider, M; Sewerin, P; Vordenbäumen, S; Wittsack, HJ | 1 |
| Albertsson, K; Ernestam, S; Forslind, K; Geborek, P; Petersson, I; Rezaei, H; Saevarsdottir, S; van Vollenhoven, RF | 1 |
| Arzu, I; Dabaja, BS; Fayad, LE; Hagemeister, FB; Hess, K; Kedir, A; Mawlawi, O; Medeiros, LJ; Oki, Y; Podoloff, DA; Reed, VK; Rodriguez, A; Shihadeh, F; Wogan, CF | 1 |
| Abud-Mendoza, C; Becker, JC; Emery, P; Genant, HK; Kremer, JM; Peterfy, C; Russell, AS; Sibilia, J; Westhovens, R | 1 |
| Brunner, HI; Chira, P; Giannini, EH; Gottlieb, BS; Hashkes, PJ; Higgins, GC; Huang, B; Ilowite, NT; Johnson, A; Kimura, Y; Lovell, DJ; Milojevic, DS; O'Neil, KM; Punaro, MG; Ringold, S; Schanberg, LE; Spalding, SJ; Sundel, RP; Szer, IS; Wallace, CA; Zeft, AS | 1 |
| de Jong, PH; de Sonnaville, PB; Gerards, AH; Han, HK; Hazes, JM; Huisman, M; Luime, JJ; van der Lubbe, PA; van Krugten, MV; van Schaeybroeck, B; van Zeben, D; Weel, AE | 1 |
| Bolce, R; Chernoff, D; Cruickshank, SE; Forslind, K; Geborek, P; Hambardzumyan, K; Petersson, IF; Saevarsdottir, S; Sasso, EH; van Vollenhoven, RF | 1 |
| Alexeeva, E; Baildam, E; Brunner, HI; Calvo, I; Chasnyk, V; Cuttica, R; De Benedetti, F; Gámir, ML; Harari, O; Horneff, G; Keane, C; Keltsev, V; Kenwright, A; Lovell, D; Lu, P; Martin, A; Martini, A; Nikishina, I; Opoka-Winiarska, V; Quartier, P; Rietschel, C; Rubio-Pérez, N; Ruperto, N; Silva, CA; Silverman, E; Siri, D; Smolewska, E; Spindler, A; Xavier, RM; Zuber, Z | 1 |
| Acquaviva, A; Bauerova, K; Drafi, F; Gardi, C; Harmatha, J; Hradkova, I; Kuncirova, V; Mihalova, D; Nosal, R; Ponist, S | 1 |
| Davies, R; Deighton, C; Fu, B; Lunt, M; Norton, S; Scott, DL; Symmons, DP; Tosh, J; Verstappen, SM; Wailoo, AJ; Young, A | 1 |
| Cope, AP; Dahanayake, C; Ma, MH; Scott, DL; Scott, IC | 1 |
| Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
| Eguchi, K; Ishiguro, N; Iwai, K; Koike, T; Miyasaka, N; Origasa, H; Sakamaki, Y; Takeuchi, T; Tanaka, Y; van der Heijde, D; Watanabe, A; Yamamoto, K; Yamanaka, H | 1 |
| Baba, H; Fukai, R; Ito, H; Katayama, K; Okubo, T; Sato, T | 1 |
| Baker, D; Emery, P; Fleischmann, RM; Hsia, EC; Xu, S; Zhou, Y | 1 |
| Hashida, R; Hatano, M; Hori, M; Nishida, H; Obara, K | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Biró, AJ; Héjj, G; Juhász, P; Mester, A; Poór, G | 1 |
| Florentinus, S; Keystone, EC; Landewé, R; Liu, S; van der Heijde, D; Østergaard, M | 1 |
| Aassi, M; Amital, H; Bernasconi, C; Conaghan, PG; Dougados, M; Huizinga, TW; Martin-Mola, E; Schett, G; Troum, O; Xavier, RM | 1 |
| Benhamou, C; Duffield, EL; Fudman, E; Genovese, MC; Kavanaugh, A; Keystone, EC; Lampl, K; O'Brien, C; Poiley, J; Spindler, AJ; van der Heijde, DM; Weinblatt, ME | 1 |
| Allaart, CF; de Vries-Bouwstra, JK; Han, KH; Huizinga, TW; Kerstens, PJ; Lems, WF; Markusse, IM; Schouffoer, AA; van der Lubbe, PA | 1 |
| Jansen, TL; Lamers-Karnebeek, F; van Ingen, IL | 1 |
| Foster, DJ; Proudman, SM; Upton, RN; Wiese, MD; Wojciechowski, J | 1 |
| Allaart, CF; Collée, G; de Sonnaville, PB; Grillet, BA; Heimans, L; Huizinga, TW; Ronday, HK; Wevers-deBoer, KV | 1 |
| Sicilia, B | 1 |
| Akagi, T; Hofmann, WK; Jann, JC; Kato, M; Kawamata, N; Klaumünzer, M; Koeffler, HP; Liem, NL; Lock, RB; Marshall, GM; Mossner, M; Nowak, D; Nowak, V; Ogawa, S; Okamoto, R; Papa, RA; Sanada, M; Thoennissen, NH | 1 |
| Ernestam, S; Forslind, K; Geborek, P; Karlsson, JA; Kastbom, A; Klareskog, L; Lundberg, K; Petersson, IF; Saevarsdottir, S; van Vollenhoven, RF | 1 |
| Fautrel, B; Gaujoux-Viala, C; Tsonaka, R; van der Helm-van Mil, AH; van Nies, JA | 1 |
| Huang, CF; Shen, LJ; Wu, CC; Wu, FL | 1 |
| Hirohata, S; Ishigatsubo, Y; Kikuchi, H; Kuwana, M; Nagafuchi, H; Sawada, T; Takeno, M | 1 |
| O'Dell, JR; Sethi, MK | 1 |
| Abbasi, MM; Hamishehkar, H; Jahanban-Esfahlan, R; Khiavi, MM; Monfaredan, A; Seidi, K | 1 |
| Iizawa, N; Koiwa, M; Mochizuki, Y; Nakamura, H; Sato, A; Takahashi, K; Takai, S; Takenouchi, K; Watanabe, H | 1 |
| Aricò, M; Basso, G; Buffardi, S; Carraro, E; Casale, F; Cesaro, S; Conter, V; d'Amore, ES; D'Angelo, P; Garaventa, A; Lo Nigro, L; Lombardi, A; Moleti, ML; Mura, R; Mussolin, L; Piglione, M; Pillon, M; Porta, F; Rosolen, A; Sala, A; Santoro, N | 1 |
| Chakraborty, S; Côté, I; Humphrey-Murto, S; Michaud, J; van der Pol, CB | 1 |
| Baker, JF; Cannon, GW; Caplan, L; Haroldsen, C; Ibrahim, S; Mikuls, TR | 1 |
| Gruszecka, K; Matuszewska, A; Świerkot, J; Wiland, P | 1 |
| Chagai, G; Gil, B; Merav, L; Pnina, L | 1 |
| Aromdee, E; Chiowchanwesawakit, P; Katchamart, W; Koolvisoot, A; Muengchan, C | 1 |
| Abe, A; Azuma, C; Ishikawa, H; Ito, S; Kobayashi, D; Murasawa, A; Nakazono, K; Narita, I; Oh, K; Otani, H; Unno, M | 1 |
| Burnham, JM; Chauvin, NA; Jaramillo, D; Zhao, Y | 1 |
| Forslind, K; Levitsky, A; van Vollenhoven, RF | 1 |
| Furuta, M; Hirayanagi, K; Ikeda, Y; Makioka, K; Nagamine, S; Sato, M | 1 |
| Baumhoer, D; Bernstein, M; Bielack, SS; Böhling, T; Brennan, B; Butterfass-Bahloul, T; Calaminus, G; Deffenbaugh, C; Dhooge, C; Eriksson, M; Gebhardt, M; Gelderblom, H; Gerss, J; Goorin, A; Gorlick, R; Helmke, K; Hogendoorn, PC; Hoogerbrugge, PM; Hook, JM; Jovic, G; Jürgens, H; Kager, L; Krailo, MD; Kühne, T; Lau, CC; Letson, GD; Marina, N; Meyer, J; Meyers, P; Michelagnoli, M; Morris, C; Nadel, H; Nagarajan, R; Pápai, Z; Picton, S; Randall, RL; Reichardt, P; Renard, M; Schomberg, P; Seddon, B; Smeland, S; Sundby Hall, K; Sydes, MR; Teot, LA; Tunn, PU; van den Berg, H; Werner, M; Whelan, JS; Windhager, R | 1 |
| Aassi, M; Bernasconi, C; Bingham, CO; Choy, EH; Dougados, M; Huizinga, TW | 1 |
| Feld, J; Shupak, A; Zisman, D | 1 |
| Botteman, MF; Cifaldi, MA; Stephens, S; van Hout, BA | 1 |
| Gaillez, C; Gomez-Reino, JJ; Grassi, W; Le Bars, M; Poncet, C; Smolen, JS; Westhovens, R; Wollenhaupt, J | 1 |
| Acebo-Mariñas, E; Aperribay-Esparza, A; de Quintana-Sancho, A; Gardeazabal-García, J | 1 |
| Andersen, T; Deleuran, B; Hetland, ML; Hvid, M; Hørslev-Petersen, K; Johansen, C; Junker, P; Stengaard-Pedersen, K; Østergaard, M | 1 |
| Bachta, A; Bogusławska-Walecka, R; Duda, K; Juszkiewicz, A; Kisiel, B; Kruszewski, R; Kłos, K; Płoski, R; Raczkiewicz, A; Staniszewska-Varga, J; Tłustochowicz, M; Tłustochowicz, W | 1 |
| Baker, DG; Baker, JF; Conaghan, PG; Emery, P; Østergaard, M | 1 |
| Bończak, A; Czukiewska, A; Jeleniewicz, R; Koszarny, A; Koszła, B; Kurlej, S; Majdan, M; Markowicz, J; Suszek, D; Szymczyk, A | 1 |
| Böttcher, J; Hansch, A; Oelzner, P; Pfeil, A; Renz, DM; Wolf, G | 1 |
| Dale, J | 1 |
| Horovitz, Y; Lidar, M | 1 |
| Go, DJ; Kang, EH; Kwon, HM; Lee, EB; Lee, YJ; Park, JK; Song, YW | 1 |
| Kaneko, T; Kobayashi, T; Okamura, K; Okura, C; Takagishi, K; Takeuchi, K; Tsushima, Y; Yonemoto, Y | 1 |
| Combe, B; Emery, P; Furst, DE; Goel, N; Ionescu, L; Keystone, EC; Luijtens, K; van der Heijde, D | 1 |
| Allaart, CF; Fujii, T; Furu, M; Hamaguchi, M; Hashimoto, M; Ikari, K; Ito, H; Markusse, IM; Matsuda, F; Mimori, T; Momohara, S; Murakami, K; Ohmura, K; Raychaudhuri, S; Tabara, Y; Takahashi, M; Taniguchi, A; Terao, C; Yamakawa, N; Yamanaka, H; Yano, K; Yoshida, S | 1 |
| Battafarano, DF; del Rincón, I; Doria, M; Escalante, A; Haas, RW; Restrepo, JF | 1 |
| Bains, A; Kumaran, MS; Parsad, D; Singh, H | 1 |
| Forslind, K; Svensson, B | 1 |
| Allaart, CF; Dirven, L; Gerards, AH; Huizinga, TW; Kerstens, PJ; Lems, WF; Markusse, IM; Ronday, HK; van Groenendael, JH | 1 |
| Haraoui, B; Keystone, EC; Phan-Chronis, K; Pope, JE; Poulin-Costello, M; Thorne, JC; Vieira, A | 1 |
| Koike, T | 1 |
| Hazes, JM; Jacobs, JW; Kuijper, TM; Lamers-Karnebeek, FB; Luime, JJ | 1 |
| Baker, D; Harigai, M; Ishiguro, N; Ishii, Y; Koike, T; Miyasaka, N; Nakajima, H; Takeuchi, T; Tanaka, Y; Yamamoto, K; Yamanaka, H | 1 |
| Baker, D; Harigai, M; Ishiguro, N; Ishii, Y; Koike, T; Miyasaka, N; Takeuchi, T; Tanaka, Y; Yamamoto, K; Yamanaka, H; Yoshinari, T | 1 |
| Ahlquist, P; Ammitzbøll, CG; Dam, MY; Ellingsen, T; Hansen, I; Hetland, ML; Hørslev-Petersen, K; Johansen, JS; Junker, P; Jørgensen, A; Krintel, SB; Linauskas, A; Lindegaard, H; Lottenburger, T; Pødenphant, J; Raun, J; Schlemmer, A; Stengaard-Pedersen, K; Ørnbjerg, LM; Østergaard, M | 1 |
| Burmester, GR; Dimonaco, S; Kay, J; Kelman, A; Mitchell, N; Rigby, WF; Rubbert-Roth, A; van Vollenhoven, RF | 1 |
| Cantarini, L; Galeazzi, M; Iannone, F; Lapadula, G; Lopalco, G | 1 |
| de Jong, EM; Hoppenreijs, EP; Knaapen, HK; Marsman, D; Mertens, JS; Radstake, TR; Seyger, MM; van de Kerkhof, PC | 1 |
| Arndt, U; Behrens, F; Burkhardt, H; Greger, G; Koehm, M; Scharbatke, E; Thaçi, D; Tony, HP; Wittig, BM | 1 |
| Ardeshna, K; Badat, M; Cheesman, S; D'Sa, S; Joshi, R; Lambert, J; Linch, D; Maciocia, P; Mohamedbhai, S; Pule, M | 1 |
| Aldredge, L; Armstrong, AW; Yamauchi, PS | 1 |
| Amano, K; Atsumi, T; Hirata, S; Inoo, M; Kaneko, Y; Kobayashi-Haraoka, H; Miyasaka, N; Miyata, M; Murakawa, Y; Nagasawa, H; Takeuchi, T; Tanaka, E; Tanaka, Y; Yamamoto, K; Yamanaka, H; Yasuoka, H | 1 |
| Akdemir, G; Allaart, CF; Boer, KV; de Sonnaville, PB; Goekoop-Ruiterman, YP; Grillet, BA; Heimans, L; Huizinga, TW; Lard, LR; Molenaar, ET; Peeters, AJ; Steup-Beekman, GM; van Groenendael, JH | 1 |
| Burmester, GR; Bykerk, VP; Combe, BG; Conaghan, PG; DiCarlo, JC; Emery, P; Furst, DE; Huizinga, TW; Peterfy, C; Wong, DA | 1 |
| Abrahamowicz, M; Beauchamp, ME; Bernatsky, S; Bessette, L; Boire, G; Bombardier, C; Feldman, D; Fortin, PR; Hanly, JG; Huang, A; Moura, CS; Paterson, JM; Wang, Y; Widdifield, J | 1 |
| Imura, S; Murata, M; Shiozawa, K; Shiozawa, S; Tsumiyama, K; Yamane, T; Yoshihara, R | 1 |
| Jalali, N; Niemann, N; Rouah, E | 1 |
| Deleuran, B; Greisen, SR; Hetland, ML; Hvid, M; Hørslev-Petersen, K; Junker, P; Kragstrup, TW; Nielsen, MA; Rhodes, C; Robinson, WH; Sokolove, J; Stengaard-Pedersen, K; Vorup-Jensen, T; Østergaard, M | 1 |
| Bowes, MA; Bradley, JD; Conaghan, PG; Fuerst, T; Hrycaj, P; Irazoque-Palazuelos, F; Soma, K; Soto-Raices, O; van der Heijde, D; Wilkinson, B; Wu, C; Wyman, BT; Xie, Z; Zhang, R; Østergaard, M | 1 |
| Conaghan, PG; Dale, J; Foley, J; McConnachie, A; McInnes, IB; Porter, D; Purves, D; Sambrook, M; Stirling, A; van der Heijde, D; Zhang, R | 1 |
| Aletaha, D; Baker, DG; Boers, M; Mela, CM; Smolen, JS | 1 |
| Calvo-Paramo, E; Iglesias-Gamarra, A; Mantilla, RD; Quintana-Duque, MA; Restrepo, JF; Rondon-Herrera, F; Varela-Nariño, A; Yunis, JJ | 1 |
| Kuroda, T; Moriyama, H; Nakano, M; Nakatsue, T; Narita, I; Nozawa, Y; Sato, H; Takeuchi, H; Wada, Y | 1 |
| Iwamoto, N; Kawakami, A | 1 |
| Andersen, T; Deleuran, B; Etzerodt, A; Hetland, ML; Hvid, M; Hørslev-Petersen, K; Junker, P; Kragstrup, TW; Moestrup, SK; Nielsen, MA; Rasmussen, TK; Stengaard-Pedersen, K; Østergaard, M | 1 |
| Grossi, V; Hyams, JS | 1 |
| Cleland, LG; Hall, C; Lee, AT; McWilliams, L; Metcalf, RG; Proudman, SM; Sorich, MJ; Spargo, LD; Wabe, NT; Wechalekar, MD; Wiese, MD | 1 |
| Bae, SH; Eom, HS; Hong, J; Jeong, SH; Kang, HJ; Kim, SJ; Kim, WS; Kwak, JY; Lee, H; Lee, JH; Lee, MH; Park, SK; Shin, DY; Suh, C; Yang, DH; Yhim, HY; Yoon, DH | 1 |
| Ahmed, I; Bahlas, S; El Gaafary, M; El Miedany, Y; Hegazi, M; Nasr, A; Youssef, S | 1 |
| Bolce, R; Brahe, CH; Chernoff, D; Døhn, UM; Ejbjerg, BJ; Hansen, A; Hansen, MS; Hasselquist, M; Hetland, ML; Knudsen, LS; Krabbe, S; Madsen, OR; Møller, J; Sasso, EH; Østergaard, M | 1 |
| Goyal, N; Lavian, M; Mozaffar, T | 1 |
| Argento, G; D'Amelio, R; Giovagnoli, S; Laganà, B; Markovic, M; Picchianti Diamanti, A; Ricci, A | 1 |
| Bananis, E; Connell, CA; Fleischmann, R; Hwang, LJ; Mease, PJ; Schwartzman, S; Soma, K; Takiya, L | 1 |
| Bastecka, D; Bradna, P; Brtkova, J; Dosedel, M; Nekvindova, J; Pavek, P; Soukup, T; Toms, J; Vlcek, J | 1 |
| Basu, N; Baxter, D; Dale, J; Harvie, J; Kumar, V; McInnes, I; McKay, ND; McLaren, J; McMahon, M; Munro, R; Paterson, C; Porter, D; Ralston, SH; Reid, DM; Richmond, R; Saunders, S; Siebert, S; Tierney, A; Wilson, H | 1 |
| Balzarotti, M; Cabrera, ME; Ceriani, L; Chiappella, A; Cunningham, D; Ferreri, AJ; Giovanella, L; Gospodarowicz, MK; Guarini, A; Johnson, PW; Martelli, M; Ricardi, U; Stelitano, C; Zinzani, PL; Zucca, E | 1 |
| Hossain, A; Mudano, AS; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Tanaka, Y | 1 |
| Aicart, M; Alcaín, G; Almela, P; Arguelles-Arias, F; Arias-Rivera, ML; Barreiro-de Acosta, M; Barrio, J; Beltrán, B; Benítez, JM; Bermejo, F; Botella, B; Bujanda, L; Busquets, D; Calvet, X; Casanova, MJ; Castaño-Milla, C; Castro, E; Castro, L; Ceballos, D; Chaparro, M; Cortés, X; Domènech, E; Domínguez, M; Domínguez-Antonaya, M; Dueñas, C; Esteve, M; Fernández-Salazar, L; García-Herola, A; García-López, S; García-Planella, E; García-Sánchez, V; García-Sepulcre, MF; Garrido, E; Gisbert, JP; Gómez-García, M; Gomollón, F; González-Lama, Y; Guardiola, J; Gutiérrez, A; Hernández-Martínez, A; Hervías, D; Hinojosa, J; Huguet, JM; Jauregui-Amezaga, A; Khorrami, S; Leo, E; Llaó, J; Lorente-Poyatos, R; Mañosa, M; Marín-Jiménez, I; Marrero, JM; Martín-Arranz, M; Martinez-Montiel, MP; Menacho, M; Merino, O; Monfort, D; Moraleja, I; Muñoz, C; Muñoz, F; Nantes, O; Navarro-Llavat, M; Novella, MT; Opio, V; Pajares, R; Pérez-Calle, JL; Pérez-Martínez, I; Pineda, JR; Ponferrada, A; Ramírez-de la Piscina, P; Ramos, L; Robles-Alonso, V; Rodríguez, C; Rodríguez, GE; Rodríguez-Pérez, A; Rojas-Feria, M; Roncedo, O; Sánchez-Torres, A; Sicilia, B; Taxonera, C; Tosca, J; Van Domselaar, M; Vázquez, JM; Vega-López, AB | 1 |
| Carter, JD; Patel, AA; Raturi, R | 1 |
| Aldridge, T; Brennan, PA; Ilankovan, V | 1 |
| Blegvad, J; Ellingsen, T; Hedemann-Nielsen, A; Herly, M; Kristensen, LD; Laurbjerg, TB; Løgstrup, BB; Masic, D; Urbonaviciene, G | 1 |
| Atsumi, T; Eguchi, K; Ishiguro, N; Iwamoto, M; Kita, Y; Koike, T; Matsubara, T; Miyasaka, N; Okada, T; Origasa, H; Shoji, T; Takeuchi, T; Tanaka, Y; Togo, O; van der Heijde, D; Watanabe, A; Yamamoto, K; Yamanaka, H; Yamanishi, Y; Yasuda, S | 1 |
| Arida, A; Fragiadaki, K; Kitas, GD; Konstantonis, G; Protogerou, AD; Sfikakis, PP | 1 |
| Ababneh, B; Al-Azzam, S; Alawneh, K; Alazzeh, O; Alkhatatbeh, M; Alqudah, MAY; Alzoubi, K | 1 |
| Chickermane, PR; Cimaz, R; Dewoolkar, M; Khubchandani, RP | 1 |
| Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Agata, N; Ishiguro, N; Kawana, K; Kimura, J; Miyasaka, N; Takeuchi, T; Tanaka, Y; Yamanaka, H | 1 |
| Meyer, V; Sachse, MM; Wagner, G | 1 |
| de Jong, EMGJ; Mertens, JS; Radstake, TRDJ; Seyger, MMB; Thurlings, RM | 1 |
| Sizova, L | 1 |
| Aletaha, D; Baker, D; Bala, M; Bathon, JM; Emery, P; Han, C; Han, J; Kalden, JR; Keystone, E; Maini, RN; Smolen, JS; St Clair, EW; van der Heijde, DM | 1 |
| Monk, JP; Rathmell, WK | 1 |
| Allaart, CF; Breedveld, FC; de Beus, WM; de Vries-Bouwstra, JK; Dijkmans, BA; Goekoop-Ruiterman, YP; Grillet, BA; Güler-Yüksel, M; Huizinga, TW; Kerstens, PJ; Ronday, HK; van der Kooij, SM; van der Lubbe, PA; Zwinderman, AH | 1 |
| Hakenberg, OW; Klebingat, HJ; Protzel, C | 1 |
| Burmester, G; Chang, D; Codreanu, C; Freundlich, B; Koenig, A; Martin Mola, E; Melo-Gomes, J; Pedersen, R; Robertson, D; van der Heijde, D | 1 |
| Hirose, M; Hirose, W; Nanki, T; Nishikawa, K; Sugimoto, H | 1 |
| Alarcón, GS; Gaffo, AL | 1 |
| Adams-Huet, B; Barnes, D; Bass, N; Boyer, J; Boyer, T; Butsch, R; Combes, B; Contos, M; Di Bisceglie, A; Garcia-Tsao, G; Getachew, Y; Lake, J; Luketic, V; Markin, RS; Martinez, E; Mayo, MJ; Mills, AS; Parkes, J; Peters, M; Rosenberg, WM; Rubin, R; Saldana, S; West, AB; Wheeler, D | 1 |
| Byrne, A; Collins, S; Cox, D; Irvine, A; O' Regan, G; Watson, R | 1 |
| Chang, ST; Cho, CY; Chuang, SS; Hsiao, SC; Ichinohasama, R; Liao, YL; Lin, SH | 1 |
| Aletaha, D; Baker, D; Han, J; Smolen, JS; St Clair, EW; van der Heijde, DM; Xu, S | 1 |
| Combe, B; Desai, C; Emery, P; Heijde, Dv; Keystone, E; Landewé, R; Mason, D; Mease, P; Pavelka, K; Strand, V; Vollenhoven, RV | 1 |
| Dorff, TB; Miranda, G; Quinn, DI; Skinner, DG; Stein, JP; Tsao-Wei, D | 1 |
| Fatenejad, S; Landewé, R; Lukas, C; van der Heijde, D | 1 |
| Avshovich, N; Ben-Arieh, Y; Boulman, N; Feld, J; Rosner, I; Rozenbaum, M; Slobodin, G | 1 |
| Aletaha, D; Dougados, M; Lafosse, C; Le Bars, M; Schiff, M; Schmidely, N; Smolen, JS; van Riel, P; Wells, G | 1 |
| Bathon, J; Becker, JC; Covucci, A; Durez, P; Genant, H; Gomez-Reino, J; Grassi, W; Haraoui, B; Helfrick, R; Nayiager, S; Park, SH; Peterfy, C; Robles, M; Shergy, W; Westhovens, R; Wollenhaupt, J; Ximenes, AC | 1 |
| Matsumoto, K | 1 |
| Blair, IA; Huang, Y; Jensen, LE; Kealey, C; Lu, ZY; Whitehead, AS | 1 |
| Candy, S; Heckmann, JM; O'Ryan, S | 1 |
| Claudepierre, P; Derot, G; Maitre, B; Marini-Portugal, A | 1 |
| Dejaco, C; Duftner, C; Schirmer, M; Wipfler, E | 1 |
| Gran, JT; Nossent, JC | 1 |
| Mimori, T; Yukawa, N | 1 |
| Ahmed, N; Cang, S; Liu, D; Mathews, T; Primanneni, S; Seiter, K; Tan, J | 1 |
| Keystone, E | 1 |
| Emery, P; Genovese, MC; Patra, K; Sasso, EH; Sharp, JT; van Vollenhoven, R | 1 |
| Usui, J; Yamagata, K | 1 |
| Hirayama, K; Kobayashi, M; Koyama, A; Yamagata, K | 1 |
| Conaghan, PG; Emery, P; Haugeberg, G; Quinn, M | 1 |
| Aletaha, D; Breedveld, FC; Funovits, J; Segurado, O; Sharp, J; Smolen, JS | 1 |
| Boers, M; Dijkmans, BA; Han, H; Huizinga, TW; Jacobs, P; Landewé, RB; Lems, WF; Peeters, AJ; van de Brink, H; van de Laar, M; van Denderen, JC; van der Linden, S; van Tuyl, LH; Voskuyl, AE; Westedt, ML; Westhovens, R | 1 |
| Baraliakos, X; Braun, J | 1 |
| Arai, K; Endo, N; Fujisawa, J; Hanyu, T; Ito, T; Kondo, N; Murai, T; Netsu, T; Saeki, T; Sano, H | 1 |
| Garssen, J; Hartog, A; Hulsman, J | 1 |
| Huysentruyt, LC; Seyfried, TN; Shelton, LM | 1 |
| Aletaha, D; Smolen, JS; St Clair, EW; Vastesaeger, N; Xu, S | 1 |
| Enk, A; Gholam, P; Hartmann, M; Sehr, T | 1 |
| Katayama, K; Matsuno, T | 1 |
| Cai, Y; Lin, L; Ling, JY; Sun, XF; Tong, GL; Xia, Y; Zhen, ZJ | 1 |
| Abe, S; Hashiramoto, A; Komai, K; Koyama, K; Murata, M; Nakagawa, N; Saegusa, Y; Sakai, Y; Shiozawa, K; Shiozawa, S; Tanaka, C; Tanaka, Y; Terashima, Y; Tsumiyama, K; Yamane, T; Yoshihara, R | 1 |
| Brown, RW; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Crivellari, D; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Golouh, R; Gusterson, BA; Karlsson, P; Maiorano, E; Mallon, E; Mastropasqua, MG; Öhlschlegel, C; Price, KN; Regan, MM; Sonzogni, A; Viale, G | 1 |
| Conrad, AL; Go, RS | 1 |
| Esparza, J; Hinojosa, J; Iglesias, S; Muñoz, MJ; Otero-Rodríguez, A; Ricoy, JR; Rodríguez-Gil, Y | 1 |
| Avery, P; Deehan, D; Foster, H; Johnson-Lynn, S; Malviya, A | 1 |
| Berenbaum, F; Combe, B; Dougados, M; Fardellone, P; Flipo, RM; Mariette, X; Meyer, O; Mulleman, D; Puéchal, X; Schaeverbeke, T; Sibilia, J; Soubrier, M; Zarnitsky, C | 1 |
| Cakiroglu, H; Fischer, L; Kiewe, P; Korfel, A; Pfeiffer, S; Thiel, E; Volk, HD; Widmann, T | 1 |
| Anoop, P; Bain, BJ; Dearden, CE; Matutes, E; Osuji, N; Ravindranathan, G; Wotherspoon, A | 1 |
| Czumbil, L; Gyánó, G; Iványi, JL; Marton, E; Plander, M; Tóth, C | 1 |
| Aletaha, D; Baker, D; Funovits, J; Köller, MD; Pangan, A; Smolen, JS | 1 |
| Fatenajad, S; Landewé, R; Lukas, C; van der Heijde, D | 1 |
| Agostinelli, C; Baccarani, M; Broccoli, A; Castellucci, P; Derenzini, E; Fanti, S; Fina, MP; Gandolfi, L; Lopci, E; Pellegrini, C; Pileri, S; Stefoni, V; Venturini, F; Zinzani, PL | 1 |
| Anis, AH; Bansback, N; Finckh, A; Liang, MH; Lubin, S; Marra, CA; Michaud, K; Sizto, S; White, M | 1 |
| Jacobsson, LT; Lindroth, Y; Söderlin, MK; Turesson, C | 1 |
| Eguchi, K; Hayashida, T; Izumi, Y; Kawakami, A; Koga, T; Makiyama, J; Migita, K; Miyashita, T; Nishino, Y; Tamai, M | 1 |
| Baldi, C; De Stefano, R; Frati, E; Galeazzi, M; Hammoud, M; Menza, L; Nargi, F | 1 |
| Albertsson, K; Bokarewa, M; Forslind, K; Hafström, I; Svensson, B; Tarkowski, A | 1 |
| Allaart, CF; Guchelaar, HJ; Huizinga, TW; Kooloos, WM; van der Straaten, T; Wessels, JA | 1 |
| Erwig, LP; Savage, CO | 1 |
| Feng, J; Hooper, M; Kavanaugh, A; Keystone, E | 1 |
| Breedveld, F; Dougados, M; Emery, P; Ferraccioli, G; Freundlich, B; Koenig, AS; Pedersen, R; Robertson, D; van der Heijde, D | 1 |
| de Souza, CB; Ferriani, VP; Pileggi, GS | 1 |
| Acholonu, S; Champlin, R; Dabaja, B; Donato, M; Duvic, M; Hosing, C; Khouri, I; Richmond, H; Singh, L; Wei, W | 1 |
| Chan, CC; Faia, LJ; Nussenblatt, RB; Sangave, A; Sen, HN; Yeh, S | 1 |
| Jones, G | 1 |
| Arkema, EV; Bykerk, VP; Keystone, EC; Kuriya, B | 1 |
| Drouin, J; Haraoui, B | 1 |
| Cohen, SB; Cravets, M; Emery, P; Genovese, MC; Hagerty, D; Keystone, E; Peterfy, C; Shaw, T; Tak, PP | 1 |
| Andersen, LS; Ejbjerg, BJ; Ellingsen, T; Hansen, I; Hetland, ML; Hørslev-Petersen, K; Jacobsen, S; Junker, P; Jurik, AG; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Pødenphant, J; Stengaard-Pedersen, K; Svendsen, A; Tarp, U; Vestergaard, A; Østergaard, M | 1 |
| De Keyser, F; Durez, P; Vander Cruyssen, B; Westhovens, R | 1 |
| Allaart, CF; de Vries-Bouwstra, JK; Dijkmans, BA; Gerards, AH; Goekoop-Ruiterman, YP; Güler-Yüksel, M; Huizinga, TW; Klarenbeek, NB; Lems, WF; Ronday, HK; van der Kooij, SM | 1 |
| Allaart, CF; de Vries-Bouwstra, JK; Dijkmans, BA; Goekoop-Ruiterman, YP; Huizinga, TW; Kerstens, PJ; Ronday, HK; Seys, PE; Visser, K | 1 |
| Fransen, J; Huizinga, T; van der Heijde, DM; van Dongen, H; van Riel, PL; Visser, K | 1 |
| Puccio, LM; Sadiq, SA; Simon, EV | 1 |
| Bonder, A; Bonis, PA; Kaplan, MM; Ruthazer, R | 1 |
| Atsumi, T; Hidaka, T; Kameda, H; Kasama, T; Nagaoka, S; Saito, K; Shiozawa, S; Takeuchi, T; Tanaka, Y; Tsukano, M; Ueki, Y | 1 |
| Blåfield, H; Hannonen, P; Järvenpää, S; Karjalainen, A; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Möttönen, T; Puolakka, K; Rantalaiho, V | 1 |
| Allaart, CF; de Sonnaville, PB; Dijkmans, BA; Güler-Yüksel, M; Huizinga, TW; Hulsmans, HM; Kerstens, PJ; Klarenbeek, NB; Molenaar, TH; van der Heijde, DM | 1 |
| Karjalainen, A; Pettersson, T | 1 |
| Kobayashi, S; Kumon, Y; Shimamura, Y; Taniguchi, Y; Terada, Y | 1 |
| Bertz, S; Danenberg, KD; Danenberg, PV; Hartmann, A; Hoffmann, AC; Lehmann, J; Leicht, C; Schuler, M; Stöckle, M; Stöhr, R; Wild, P | 1 |
| Allaart, CF; de Vries-Bouwstra, JK; Dijkmans, BA; Goekoop-Ruiterman, YP; Güler-Yüksel, M; Huizinga, TW; Kloppenburg, M; Lems, WF; van Krugten, MV; van Schaardenburg, D; Watt, I | 1 |
| Al-Muderis, O; Constantinidou, A; Jones, RL; Judson, I; Scurr, M | 1 |
| Ballman, KV; Brown, PD; Carrero, XW; Colgan, JP; Fitch, TR; Gilbert, MR; Habermann, TM; Hawkins, RB; Kurtin, PJ; Laack, NN; Morton, RF; O'Fallon, JR; O'Neill, BP; Pajon, ER; Scheithauer, BW; Windschitl, HE | 1 |
| Landewé, RB; Ramiro, S; van Tubergen, AM | 1 |
| Breedveld, FC; Kavanaugh, A; Keystone, EC; Landewé, R; Pangan, AL; Patra, K; van der Heijde, D | 1 |
| Chen, A; Hessey, E; Peterfy, CG; Rigby, WF; Rubbert-Roth, A; Shaw, TM; Stohl, W; Tak, PP; Tyrrell, H; van Vollenhoven, RF | 1 |
| Choi, CW; Kim, H; Kim, JS; Kim, SJ; Kim, WS; Lee, GW; Oh, SY; Park, J; Shin, HJ; Suh, C; Won, JH; Yang, DH | 1 |
| Boonen, A; Døhn, UM; Ejbjerg, B; Hansen, A; Hansen, MS; Hasselquist, M; Hetland, ML; Knudsen, LS; Madsen, OR; Møller, JM; Ostergaard, M | 1 |
| Allaart, CF; Dijkmans, BA; Güler-Yüksel, M; Han, KH; Huizinga, TW; Kerstens, PJ; Klarenbeek, NB; van der Kooij, SM; van Groenendael, JH | 1 |
| Baumgartner, SW; Chon, Y; Cohen, MD; Freundlich, B; Keystone, EC; Li, J; Weinblatt, ME | 1 |
| Albaladejo, C; Blanco, FJ; Cañete, JD; Engel, P; Hernández, MV; Laínez, B; López-Armada, MJ; Pinto, JA; Ramírez, J; Rodríguez-Cros, JR; Sanmartí, R | 1 |
| Christopher-Stine, L; Connors, GR; Danoff, SK; Oddis, CV | 1 |
| Alfonso, R; Miralles, J; Moragón, M; Onrubia, J; Pérez-Crespo, M; Requena, L; Sevila, A | 1 |
| Dougados, M; Fautrel, B; Gossec, L; Lukas, C; Patternotte, S; Roux, F; Sibilia, J; Soubrier, M | 1 |
| Kavanaugh, A; Keystone, EC; Pangan, AL; Patra, K; Weinblatt, ME | 1 |
| Baratelle, A; Beutler, A; Conaghan, PG; Emery, P; Fleischmann, R; Genovese, MC; Hsia, EC; Keystone, EC; Rahman, MU; van der Heijde, D; Xu, W | 1 |
| Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y | 1 |
| Lian, F; Liang, L; Qiu, Q; Xu, H; Yang, X; Ye, Y; Zhan, Z | 1 |
| Bakker, MF; Bijlsma, JW; Jacobs, JW; Lafeber, FP; Linn-Rasker, SP; Ton, E; van Booma-Frankfort, C; Vreugdenhil, SA; Welsing, PM | 1 |
| Allaart, CF; Dijkmans, BA; Güler-Yüksel, M; Han, KH; Huizinga, TW; Kerstens, PJ; Klarenbeek, NB; Ronday, HK; Seys, PE; van der Kooij, SM | 1 |
| Bosello, S; Fedele, AL; Ferraccioli, G; Gremese, E; Peluso, G; Tolusso, B | 1 |
| Allaart, CF; Dijkmans, BA; Dirven, L; Huizinga, TW; Hulsmans, HM; Kerstens, PJ; Klarenbeek, NB; van den Broek, M; van Schaardenburg, D | 1 |
| Bakker, MF; Bijlsma, JW; Jacobs, JW; Jahangier, ZN; Lafeber, FP; van der Veen, MJ; Verstappen, SM; Welsing, PM | 1 |
| Atsumi, T; Hidaka, T; Kameda, H; Kanbe, K; Kasama, T; Nagaoka, S; Saito, K; Sato, E; Shiozawa, S; Takeuchi, T; Tanaka, Y; Tsukano, M; Ueki, Y; Yamanaka, H | 1 |
| Britsemmer, K; Gerritsen, M; Ursum, J; van Schaardenburg, D; van Tuyl, L; van Tuyl, LH | 1 |
| Breedveld, FC; Combe, B | 1 |
| Brus, HL; Haagsma, CJ; Hoekstra, M; Kuper, HH; Posthumus, MD; van de Laar, MA; van Riel, PL; Vermeer, M | 1 |
| Brandão, M; Marinho, A | 1 |
| Batchelor, TT; Egerer, G; Engert, A; Herrlinger, U; Kowoll, A; Lamprecht, M; Linnebank, M; Patrij, K; Pels, H; Reiser, M; Schackert, G; Schlegel, U; Schmidt-Wolf, IG; Vogt-Schaden, M; Wätzel, L | 1 |
| Amano, H; Kageyama, M; Kempe, K; Kusaoi, M; Matsudaira, R; Matsushita, M; Morimoto, S; Nawata, M; Ogasawara, M; Onuma, S; Sekiya, F; Tada, K; Takasaki, Y; Tamura, N; Toyama, S; Yamaji, K | 1 |
| Conaghan, PG; Emery, P; Genovese, MC; Hsia, EC; Keystone, EC; Rahman, MU; Xu, W; Østergaard, M | 1 |
| Delgado Frías, E; Díaz González, JF | 1 |
| Cyriac, S; Rajendranath, R; Sagar, TG; Sridevi, V | 1 |
| Bathon, J; Becker, JC; Covucci, A; Durez, P; Genant, H; Gomez-Reino, J; Grassi, W; Haraoui, B; Helfrick, R; Moniz Reed, D; Nayiager, S; Park, SH; Peterfy, C; Robles, M; Shergy, W; Westhovens, R; Wollenhaupt, J; Ximenes, AC | 1 |
| Carlson, EM; Meskin, SW | 1 |
| Cao, W; Jiang, Q; Tang, XP; Wang, L; Wang, P; Yu, W; Zhou, XY | 1 |
| Díaz-López, C; Díaz-Torné, C; Hernández, MV; Narváez, J; Nolla, JM; Rodriguez de la Serna, A; Ros, S; Ruiz, JM; Sanmartí, R; Torrente-Segarra, V | 1 |
| Becker, JC; Covucci, A; Fanti, L; Keystone, EC; Reed, DM; Wells, AF; Westhovens, R | 1 |
| Abud-Mendoza, C; Aranda, R; Becker, JC; Emery, P; Genant, HK; Kremer, JM; Li, T; Peterfy, C; Russell, AS; Szechinski, J; Westhovens, R; Zhou, X | 1 |
| Amano, K; Hirata, S; Kameda, H; Kaneko, Y; Kimura, N; Kubo, S; Kurasawa, T; Nagasawa, H; Saito, K; Shidara, K; Takeuchi, T; Tanaka, E; Tanaka, Y; Yamanaka, H | 1 |
| Arena, U; Assarat, A; Benucci, M; Cammelli, D; Maddali-Bongi, S; Mannoni, A; Marra, F; Pinzani, M; Stasi, C | 1 |
| Albertsson, K; Bratt, J; Ernestam, S; Forslind, K; Geborek, P; Pettersson, IF; Rezaei, H; Saevarsdottir, S; van Vollenhoven, RF; Wallin, H | 1 |
| Aletaha, D; Smolen, JS | 1 |
| Aoyagi, K; Arima, K; Eguchi, K; Ida, H; Iwamoto, N; Kawakami, A; Kawashiri, SY; Kita, J; Koga, T; Nakamura, H; Nakashima, Y; Okada, A; Origuchi, T; Suzuki, T; Tamai, M; Uetani, M; Yamasaki, S | 1 |
| Healy, E; Hessey, E; Peterfy, C; Reynard, M; Rigby, W; Rubbert-Roth, A; Shaw, T; Stohl, W; Tak, PP; van Vollenhoven, RF | 1 |
| Aguilar, D; Alpizar-Rodríguez, D; Cruz-Robles, D; Escobar-Hernández, S; Férez-Blando, K; Furuzawa-Carballeda, J; Galindo-Feria, AS; Llorente, L; Macip-Rodríguez, P; Soto-Abraham, V | 1 |
| Altiner, A; Berger, E; Chu, J; Latkowski, JA; Patel, R; Sanders, S | 1 |
| Lubrano, E; Spadaro, A | 1 |
| Allaart, CF; Dijkmans, BA; Dirven, L; Ewals, JA; Han, KH; Huizinga, TW; Kerstens, PJ; Klarenbeek, NB; Peeters, AJ; Visser, K | 1 |
| Abouqal, R; Amine, B; Atouf, O; Benbouazza, K; Benbrahim, L; Benchekroun, B; Bzami, F; Dougados, M; Essakalli, M; Hajjaj-Hassouni, N; Rkain, H | 1 |
| Baker, D; Harigai, M; Ishiguro, N; Kanazawa, M; Koike, T; Miyasaka, N; Oba, T; Takeuchi, T; Tanaka, Y; Yamamoto, K; Yamanaka, H; Yoshinari, T | 1 |
| Aletaha, D; Avila, JC; Smolen, JS | 1 |
| Conaghan, PG; Emery, P; Fleischmann, R; Hsia, EC; Rahman, MU; Xu, W; Østergaard, M | 1 |
| Bakker, MF; Bijlsma, JW; Jacobs, JW; Kruize, AA; Lafeber, FP; van Booma-Frankfort, C; van der Veen, MJ; Vreugdenhil, SA; Welsing, PM | 1 |
| Symmons, DP; Verstappen, SM | 1 |
| Boers, M; Dijkmans, BA; Nielen, MM; Tijhuis, GJ; van der Horst-Bruinsma, I; van Eijk, IC; van Schaardenburg, D | 1 |
| Dieval, C; Guiboux, AL; Haramburu, F; Herrador, C; Mercié, P | 1 |
| Holodny, A; Omuro, A; Palomba, ML; Pentsova, E; Rosenblum, M | 1 |
| Andersson, SE; Bokarewa, MI; Erlandsson, MC; Forslind, K; Lund, A | 1 |
| Fiehn, C | 1 |
| Ashrafzadeh, A; Bieraugel, R; Dudler, J; Dummer, W; Fleischmann, RM; Francom, S; Gomez-Reino, J; Green, J; Grzeschik, S; Olech, E; Stohl, W; Zerbini, CA | 1 |
| Alten, R; Choy, E; Davies, O; Goel, N; McKenna, F; Stahl, HD; Valente, R; Vanlunen, B; Vencovsky, J | 1 |
| Gaudin, P; Gilson, M; Juvin, R; Muslmani, M; Sudre, A | 1 |
| Bananis, E; Combe, B; Emery, P; Ferdousi, T; Freundlich, B; Koenig, AS; Kvien, TK; Pedersen, R; Robertson, D | 1 |
| Battafarano, DF; Mathew, SD; Morris, MJ | 1 |
| Ghosh, B; Pusp, P; Roy, S; Sannigrahi, S; Vaddepalli, RP | 1 |
| Ajeganova, S; de Faire, U; Frostegård, J; Hafström, I; Jogestrand, T | 1 |
| Bakker, MF; Bijlsma, JW; Cavet, G; Centola, M; Haney, DJ; Hesterberg, LK; Jacobs, JW; Lafeber, FP; Shen, Y; Smith, DR; van Roon, JA; Welsing, PM | 1 |
| de Groot, K; Faurschou, M; Flossmann, O; Höglund, P; Jayne, DR; Rasmussen, N; Westman, K | 1 |
| Argyropoulou, MI; Drosos, AA; Kosta, PE; Tsampoulas, K; Voulgari, PV; Zikou, AK | 1 |
| Combe, B; Dougados, M; Gaujoux-Viala, C; Paternotte, S | 1 |
| Aoyagi, K; Arima, K; Eguchi, K; Horai, Y; Ida, H; Iwamoto, N; Kawakami, A; Kawashiri, SY; Kita, J; Koga, T; Nakamura, H; Nakashima, Y; Okada, A; Origuchi, T; Suzuki, T; Tamai, M; Uetani, M; Yamasaki, S | 1 |
| Alten, R; Bastian, H; Braun, T; Burmester, GR; Buttgereit, F; Detert, J; Egerer, K; Gremmelsbacher, E; Höhne-Zimmer, V; Krüger, K; Liebhaber, A; Listing, J; Marsmann, B; Rau, R; Rockwitz, K; Simon, C; Wassenberg, S; Weiß, A | 1 |
| Blåfield, H; Hannonen, PJ; Ilva, K; Julkunen, HA; Kaipiainen-Seppänen, O; Karjalainen, A; Kauppi, MJ; Kautiainen, H; Korpela, M; Laasonen, L; Leirisalo-Repo, M; Luosujärvi, R; Luukkainen, R; Moilanen, E; Möttönen, T; Paimela, L; Puolakka, K; Uutela, T | 1 |
| Chen, N; Cifaldi, MA; Goldring, MB; Guérette, B; Keystone, EC; Landewé, RB; Liu, S; Smolen, JS; van der Heijde, DM; van Vollenhoven, RF | 1 |
| Engelke, K; Englbrecht, M; Finzel, S; Hueber, A; Kraus, S; Rech, J; Schett, G; Schmidt, S | 1 |
| Chui, RK; Kuan, WP; Kun, EW; Lee, KL; Leung, MH; Leung, YY; Li, EK; Li, M; Li, RJ; Li, TK; Shang, Q; Tam, LS; Tseung, L; Wong, S; Yim, CW; Ying, KY; Yu, CM; Yu, SL; Zhu, TY | 1 |
| Alarcón, GS; Alfaro-Lozano, JL; Boggio, G; Cavalcanti, F; Costallat, LT; de la Torre, IG; Del Pozo, MJ; Esteva-Spinetti, MH; Gómez, LA; Guibert-Toledano, M; Hachuel, L; Massardo, L; Pons-Estel, BA; Pons-Estel, GJ; Saurit, V; Silveira, LH; Wojdyla, D | 1 |
| Bryer, D; Buch, MH; Church, LD; Cooper, DL; Coulthard, LR; Dickie, LJ; Emery, P; Geiler, J; Mathews, RJ; McDermott, MF; Morgan, AW; Savic, S; Wong, C | 1 |
| Felea, I; Rednic, S; Tamas, MM | 1 |
| Alvarez, D; Fletcher, T; Miyasaka, N; Takeuchi, T; Vlahos, B; Wajdula, J; Yuasa, H; Zang, C | 1 |
| Anastasilakis, AD; Kapetanos, GA; Sakellariou, GT; Sayegh, FE | 1 |
| Barnetche, T; Issa, N; Pierreisnard, A; Richez, C; Schaeverbeke, T | 1 |
| Allaart, CF; Boers, M; Kostense, PJ; van den Broek, M; van Tuyl, L | 1 |
| Combe, B; Fautrel, B; Granger, B; Guillemin, F; Le Loet, X; Saraux, A | 1 |
| Kay, J; Upchurch, KS | 2 |
| Brandt-Jürgens, J | 1 |
| Cheng, AL; Huang, HC; Kuo, SH; Lin, CW | 1 |
| Agarwal, V; Aggarwal, A; Lawrence, A; Misra, R; Reddy Munagala, VV | 1 |
| Cornec, D; Le Nen, D; Saraux, A | 1 |
| Hoshi, D; Inoue, E; Momohara, S; Nakajima, A; Sato, E; Seto, Y; Shidara, K; Sugimoto, N; Tanaka, E; Taniguchi, A; Yamanaka, H | 1 |
| Brzosko, M; Burgos-Vargas, R; Fleischmann, RM; Halland, AM; Kremer, JM; Mela, C; Vernon, E | 1 |
| Allaart, CF; Gillet-van Dongen, H; Heimans, L; Huizinga, TW; Peeters, AJ; Ronday, HK; Speyer, I; van Aken, J; Visser, K | 1 |
| Benda, B; Bradley, JD; Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Krishnaswami, S; Nash, P; Song, YW; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Wyman, BT; Zerbini, C; Zwillich, SH | 1 |
| Barnetche, T; Combe, B; Goulabchand, R; Lukas, C; Morel, J; Mouterde, G | 1 |
| Combe, B; Knevel, R; Lukas, C; Rincheval, N; van der Heijde, D; van der Helm-van Mil, AH | 1 |
| Hayashi, M; Ishikawa, H; Kanamono, T; Kobayakawa, T; Takanashi, T; Yamazaki, H | 1 |
| Bathon, JM; Cannon, GW; Finck, BK; Fleischmann, RM; Genovese, MC; Keystone, EC; Markenson, J; Martin, RW; Moreland, LW; Schiff, MH; Spencer-Green, G; Tesser, JR; Wasko, MC; Weaver, AL | 1 |
| Davis, GL; Keeffe, EB | 1 |
| Startsev, VY | 1 |
| Baughman, RP | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| Arpino, G; Bianco, AR; Carlomagno, C; Catalano, G; Costanzo, R; De Laurentiis, M; De Placido, S; Ferrara, C; Lauria, R; Massarelli, E; Milano, A; Vernaglia Lombardi, A | 1 |
| Pender, MP; Wolfe, NP | 1 |
| Boers, M; Boonen, A; Christgau, S; Garnero, P; Geusens, P; Landewé, R; Van Der Heijde, D; Van Der Linden, S; Verhoeven, A | 1 |
| D'Arcy, CA; Willkens, RF | 1 |
| Manger, B | 1 |
| Seitz, M; Villiger, PM; Zwicker, M | 1 |
| Chamberlain, MC | 1 |
| Henderson, RD; Nicol, AJ; Rajah, T; Read, SJ | 1 |
| Eberhardt, K; Jönsson, L; Kobelt, G; Young, A | 1 |
| Awada, A; Caponigro, F; Comella, G; Cupissol, D; Gedouin, D; Gérard, B; Giroux, B; Guardiola, E; Kerger, J; Lopez-Pousa, JJ; Pivot, X; Rolland, F; Schneider, M | 1 |
| Fabry, DA; Lowe, VJ; Matteson, EL; Mazlumzadeh, M; McDonald, TJ; Mullan, BP | 1 |
| Gross, WL; Hellmich, B | 1 |
| Bruijn, GA; Bruyn, GA; Dijkmans, BA; Gerards, AH; Goei Thé, HS; Laan, RF; Landewé, RB; Prins, AP | 1 |
| Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP | 1 |
| Lauterbach, I; Mann, G; Niemeyer, C; Parwaresch, R; Reiter, A; Riehm, H; Schrappe, M; Seidemann, K; Simonitsch, I; Stankewitz, K; Tiemann, M; Zimmermann, M | 1 |
| Berry, DA; Bothun, S; Cirrincione, CT; Demakos, E; Falkson, G; Henderson, IC; Holland, JF; Norton, L; Robbins, A; Weiss, RB; Woolf, SH | 1 |
| Pettersson, H; Svensson, B | 1 |
| Chamberlain, MC; Cole, BF; Glantz, MJ; Jaeckle, KA; Mackowiak, JI | 1 |
| Eberhardt, K; Jonsson, K; Lindqvist, E; Saxne, T | 1 |
| Arreghini, M; Battafarano, N; Gallazzi, M; Marchesoni, A; Panni, B; Tosi, S | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V | 1 |
| Aljama, P; Espinosa, M; Fernández-Roldán, JC; Medina, I; Moreno, JC; Ocaña, MS; Valverde, F; Vélez, A | 1 |
| Konrad, A; Seibold, F | 1 |
| Ruderman, EM | 1 |
| Aramaki, K; Hirohata, S; Kikuchi, H | 1 |
| Chillura, G; Colombo, E; Gelosa, G; Giannetta, L; Moroni, M; Secondino, S; Siena, S | 1 |
| Al-Mwalad, M; Albers, P; Becker, T; Brauers, A; Brkovic, D; Bub, P; Derigs, HG; Fassmann, C; Hamza, A; Hartlapp, J; Henss, H; Hertle, L; Jaeger, E; Jakse, G; Kälble, T; Kaldenbach, U; Knuth, A; Koser, M; Lehmann, J; Lippert, C; Loch, T; Melchior, H; Muschter, R; Otto, C; Piechota, HJ; Pomer, S; Potratz, C; Retz, M; Richter, AE; Roloff, J; Roth, S; Steiner, G; Stockamp, K; Stöckle, M; Tunn, U; Van Ahlen, H; Walz, P; Weinknecht, S; Weissbach, L; Winter, E; Wirth, M | 1 |
| Ben Miled, M; Boussema, F; Cherif, O; Kochbati, S; Ouanane, H; Rokbani, L | 1 |
| Blasco Colmenarejo, MM; Navarro Martínez, A; Polo Romero, FJ; Tirado Miranda, R | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Bamias, C; Deliveliotis, C; Dimopoulos, MA; Gika, D; Kalofonos, C; Kosmidis, P; Kourousis, C; Koutras, A; Mitropoulos, D; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Xiros, N; Zervas, A | 1 |
| Davidson, KL; Devaney, MB; Dunlop, DJ; Johnson, PR; Mackie, MJ; Rogers, SY; Thomas, RV; Tighe, JE | 1 |
| Breedveld, FC; Emery, P; Furst, DE; Kalden, JR; Keystone, E; Lipsky, PE; Maini, RN; Patel, K; Smolen, J; St Clair, EW; Weisman, M | 1 |
| Abrey, LE; DeAngelis, LM; Lai, R; Rosenblum, MK | 1 |
| Baumann, A; Häusler, R; Helbling, A; Oertle, S; Vibert, D | 1 |
| Abrahams, A; Eggener, SE; Keeler, TC | 1 |
| Darmawan, J; Nuralim, H; Rasker, JJ | 1 |
| Elinder, G; Kimby, E; Sverrisdottir, A | 1 |
| Klareskog, L; Lindblad, S; van Vollenhoven, RF; Weiss, RJ; Wick, MC | 2 |
| Boers, M; Garnero, P; Geusens, P; Landewé, R; Lems, W; te Koppele, J; van der Heijde, D; van der Linden, S | 1 |
| Abu-Saad, HH; Candel, MJ; Courtens, AM; de Jong, N; Schouten, HC | 1 |
| Cohen, SB | 1 |
| Weinblatt, ME | 1 |
| Boehmer, LN; John, J; Siegel, JM; Wu, MF | 1 |
| De Ramón, E; Fernández, O; Fernández, V | 1 |
| Häntzschel, H; Pierer, M; Seidel, W | 1 |
| Goldschmidt, N; Gural, A; Kornberg, A; Paltiel, O; Shopen, A; Spectre, G | 1 |
| Fleischmann, RM; Iqbal, I; Stern, RL | 1 |
| Kawaguchi, T; Kumabe, T; Tominaga, T; Watanabe, M | 1 |
| Cabras, A; Carlo-Stella, C; Devizzi, L; Di Nicola, M; Gandola, L; Gianni, AM; Guidetti, A; Magni, M; Mariotti, J; Massimino, M; Matteucci, P | 1 |
| Acquatella, G; Carneiro, M; García, R; Gómez, R; Hernández, M; Insausti, CL; Nouel, A; Santos, S | 1 |
| Adams, AE; Curiel, C; Drews, R; Falchuk, KR; Kadin, ME; Kupper, TS; Zwicker, J | 1 |
| Behrens, F | 1 |
| Billet, AL; Billups, C; Cowan, T; Donaldson, SS; Friedmann, AM; Howard, S; Hudson, MM; Hurwitz, CA; Kaste, S; Krasin, M; Kun, L; Link, MP; Marcus, KC; Merchant, TE; Rai, S; Tarbell, NJ; Weinstein, HJ; Young, JA | 1 |
| Baker, DE | 1 |
| Issa, SN; Ruderman, EM | 1 |
| Chi, SN; Finlay, JL; Gardner, SL; Knopp, EA; Levy, AS; Miller, DC; Weiner, HL; Wisoff, JH | 1 |
| Fatenejad, S; Klareskog, L; Landewé, R; Pedersen, R; Rodríguez-Valverde, V; Settas, L; van der Heijde, D | 1 |
| Abrey, LE; DeAngelis, LM; Koutcher, JA; Lis, E; Panageas, KS; Raizer, JJ; Xu, S; Zakian, KL | 1 |
| Inui, K; Koike, T; Tada, M; Takaoka, K | 1 |
| Battesti, JP; Brauner, M; Chambellan, A; Nunes, H; Turbie, P; Valeyre, D | 1 |
| Baslund, B; Duer, A; Ejbjerg, BJ; Johansen, JS; Møller, JM; Narvestad, E; Nielsen, H; Petersen, J; Thomsen, HS; Østergaard, M | 1 |
| Brockhurst, I; Chapman, CS; Harris, KP | 1 |
| Benko, A; Boudrias, M; Desjardins, A; Fortin, D; Niyonsega, T | 1 |
| Openshaw, H | 1 |
| Fath, R | 1 |
| Blomqvist, C; Larsson, R; Nygren, P; Villman, K | 1 |
| Ahmed, M; Foster, CS; Kiss, S; Letko, E | 1 |
| Albers, P; Beck, J; Becker, T; Frohneberg, D; Funke, PJ; Kälble, T; Langbein, S; Lehmann, J; Miller, K; Reiher, F; Retz, M; Roth, S; Schiller, M; Sternberg, D; Stöckle, M; Thüroff, J; Walz, P; Weining, C; Wellek, S; Wiemers, C | 1 |
| Bathon, JM; Fleischmann, RM; Genovese, MC; Leff, JA; Martin, RW; Moreland, LW; Tsuji, WH; Whitmore, JB | 1 |
| Dillenschneider, E; Greiner, GF | 1 |
| Bariakh, EA; Chernova, NG; Egorova, EK; Gabeeva, NG; Kaplanskaia, IB; Krasil'nikova, BB; Kravchenko, SK; Kremenetskaia, AM; Lorie, IuIu; Magomedova, AU; Mar'in, DS; Moiseeva, TN; Obukhova, TN; Samoĭlova, RS; Vorob'ev, AI; Vorob'ev, IA; Zvonkov, EE; Zybunova, EE | 1 |
| Curran, W; DeAngelis, L; Fisher, B; Mehta, M; Nelson, D; Schold, SC; Schultz, C; Seiferheld, W | 1 |
| Appenzeller, S; Bértolo, MB; Costallat, LT; Werner de Castro, GR | 1 |
| Deesomchok, U; Osiri, M; Tugwell, P | 1 |
| Genth, E; Hunzelmann, N; Kaufmann, J; Krieg, T | 1 |
| Ferraccioli, G | 1 |
| Breedveld, FC; Cohen, SB; Kavanaugh, AF; Pavelka, K; Perez, JL; Sharp, J; Spencer-Green, GT; van Vollenhoven, R; Weisman, MH | 1 |
| Baldassano, RN; Jacobstein, DA; Leonard, M; Mamula, P; Markowitz, JE | 1 |
| Garcia-Porrua, C; Gonzalez-Gay, MA; Gonzalez-Juanatey, C; Llorca, J; Martin, J | 1 |
| Gordon, KB; Ruderman, EM | 1 |
| Baker, D; Bala, M; Bathon, JM; Emery, P; Han, C; Han, J; Kalden, JR; Keystone, E; Maini, RN; Schiff, M; Smolen, JS; St Clair, EW; Van Der Heijde, DM | 1 |
| Barabás, J; Cséplo, K; Németh, Z; Szabó, G; Szigeti, K; Vaszilkó, M; Velich, N | 1 |
| Bösenberg, H; Holl-Ulrich, K; Schittko, G; Schwarz-Eywill, M; Simon, S | 1 |
| Antoneli, CB; Arias, VE; Chojniak, MM; Novaes, PE; Ribeiro, Kde C; Sakamoto, LH | 1 |
| Cho, SG; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Lesiak, A; McCauliffe, DP; Salamon, M; Sysa-Jedrzejowska, A; Wozniacka, A | 1 |
| Caggiari, L; De Re, V; De Vita, S; Fabris, M; Ferraccioli, G; Franzolini, N; Gasparotto, D; Marzotto, A; Quartuccio, L; Scott, CA | 1 |
| Abud-Mendoza, C; Becker, JC; Emery, P; Ge, Z; Genant, HK; Kremer, JM; Li, T; Moreland, LW; Russell, AS; Szechinski, J; Westhovens, R | 1 |
| Arning, M; Conte, PF; Dogliotti, L; Moore, MJ; Oliver, T; Roberts, JT; Sengeløv, L; von der Maase, H; Zimmermann, A | 1 |
| Ali, M; Chen, TS; Crues, JV; Troum, OM | 1 |
| Fatenejad, S; Klareskog, L; Landewé, R; van der Heijde, D; van Vollenhoven, R | 2 |
| Sharp, JT | 1 |
| Briot, K | 1 |
| Harper, JI; Howell, KJ; Sampaio, MC; Visentin, MT; Weibel, L; Woo, P | 1 |
| Lade, S; McCormack, C; Prince, HM; Rodrigues, M; Westerman, D | 1 |
| Froehner, M; Hakenberg, OW; Nippgen, JB; Wirth, MP; Zastrow, S | 1 |
| Hay, J; Spalding, JR | 1 |
| Tollefson, MM; Witman, PM | 1 |
| Breedveld, FC; Huizinga, TW; le Cessie, S; Toes, RE; van der Helm-van Mil, AH; van Dongen, H | 1 |
| Choy, EH; Gladman, DD; Mease, PJ; Ory, PA; Perdok, RJ; Ritchlin, CT; Sasso, EH; Sharp, JT | 1 |
| Blom, M; van Riel, PL | 1 |
| Saito, E; Suwa, A; Suzuki, Y; Wakabayashi, T | 2 |
| Allaart, CF; Breedveld, FC; Huizinga, TW; Hulsmans, HM; Lard, LR; Peeters, AJ; Ronday, HK; Speyer, I; Toes, RE; van Aken, J; van Dongen, H; Visser, K; Westedt, ML | 1 |
| Hashimoto, J; Kawai, S; Kishimoto, T; Miyasaka, N; Murata, N; Nishimoto, N; Takeuchi, T; van der Heijde, D; Yamamoto, K | 1 |
| Fujishima, M; Fujishima, N; Hirokawa, M; Inomata, M; Kameoka, Y; Saitoh, H; Saitoh, K; Sawada, K; Takahashi, N; Yamanaka, Y; Yoshioka, T | 1 |
| Bijlsma, JW; Blaauw, AA; Heurkens, AH; Jacobs, JW; Schenk, Y; ter Borg, EJ; van der Veen, MJ; Verstappen, SM | 1 |
| Colleoni, M; Johansson, HA; Maisonneuve, P; Passerini, R; Peruzzotti, G; Rocca, A; Salvatici, M; Sandri, MT; Zorzino, L | 1 |
| Albertson, DG; Byrd, KN; Fridlyand, J; Huey, B; Roydasgupta, R; Snijders, AM | 1 |
| Arima, T; Inoue, Y; Kohno, Y; Shimojo, N; Suzuki, S; Tomemori, T; Tomiita, M | 1 |
| Menkes, DL; Smyth, S | 1 |
| Moudgil, KD; Tong, L | 1 |
| Hara, M; Inoue, E; Kamatani, N; Nakajima, A; Singh, G; Tanaka, E; Taniguchi, A; Tomatsu, T; Yamanaka, H | 1 |
| Fransen, J; van Riel, PL | 1 |
| Andersen, LS; Ellingsen, T; Hansen, GV; Hansen, I; Hetland, ML; Hørslev-Petersen, K; Junker, P; Jurik, AG; Lauridsen, UB; Lindegaard, H; Lottenburger, T; Pedersen, JK; Skjødt, H; Stengaard-Pedersen, K; Svendsen, A; Tarp, U; Vestergaard, A; Østergaard, M | 1 |
| Announ, N; Guerne, PA | 1 |
| Corluy, L; Depresseux, G; Durez, P; Houssiau, FA; Lauwerys, BR; Luyten, FP; Malghem, J; Nzeusseu Toukap, A; Verschueren, P; Westhovens, R | 1 |
| Agrawal, S; Batley, M; Bharadwaj, A; Hammond, A | 1 |
| Bell, S; Doolittle, ND; Fortin, D; Jahnke, K; Knight, KR; Kraemer, DF; Muldoon, LL; Neuwelt, EA | 1 |
| Chandran, V; Gladman, DD; Schentag, CT | 1 |
| Bevan, M; Ho, S; Srinivasan, U | 1 |
| Batchelor, TT; Carson, KA; Gerstner, ER; Grossman, SA | 1 |
| Dehler, S; Finckh, A; Gabay, C | 1 |
| Conaghan, PG; Emery, P; Hensor, E; Jarrett, S; Mackie, S; Nizam, S; Quinn, M; Saleem, B | 1 |
| Berry, D; Bhalla, K; Cirrincione, C; Duggan, DB; Henderson, IC; Hudis, C; Kimmick, GG; Lemke, S; Norton, L; Robert, N; Winer, E | 1 |
| Fischer, L; Kiewe, P; Korfel, A; Martus, P; Thiel, E | 1 |
| Lantos, G; Revercomb, CH; Warren, FA; Zelefsky, JR | 1 |
| Maclean, R; Massarotti, E; Oster, G; Shadick, N; Sofrygin, O; Vera-Llonch, M; Westhovens, R; Wolfe, F; Yuan, Y | 1 |
| Ranganathan, P | 1 |
| Burmester, GR; Cohen, S; Cravets, MW; Dougados, M; Emery, P; Genovese, MC; Greenwald, M; Hagerty, D; Keystone, E; Kvien, TK; Peterfy, CG; Shaw, T; Tak, PP; Williams, S | 1 |
| Arnold, S; Baerwald, CG; Häntzschel, H; Malysheva, OA; Pierer, M; Wagner, U; Wahle, M | 1 |
| Aggarwal, A; Haroon, N; Misra, R | 1 |
| Allaart, CF; Breedveld, FC; de Vries, RR; de Vries-Bouwstra, JK; Dijkmans, BA; Ewals, JA; Goekoop-Ruiterman, YP; Huizinga, TW; Kerstens, PJ; Ronday, HK; Schreuder, GM; Terwiel, JP; Toes, RE; Verpoort, KN | 1 |
| Barbui, T; Benedetti, F; Boccadoro, M; Ciceri, F; Corradini, P; Cortelazzo, S; Gallamini, A; Gianni, AM; Magni, M; Majolino, I; Mirto, S; Passera, R; Patti, C; Pileri, A; Pizzolo, G; Rambaldi, A; Tarella, C; Zanni, M | 1 |
| Dinarello, CA; Kaplan, MM; McKusick, AF; Miller, LC; Sharma, A; Tassoni, JP | 1 |
| Bijlsma, JW; Jacobs, JW; Schenk, Y; van der Heide, A | 1 |
| Carter, M; Clark, PI; Ganjoo, RK; Gregory, W; Johnson, PW; Lim, JM; Love, SB; Mahmoud, MM; Malpas, JS; Williams, AH | 1 |
| Breedveld, FC | 1 |
| Dunphy, CH; Kitchen, S; Saravia, O; Velasquez, WS | 1 |
| Ben-Arieh, Y; Ben-Shahar, M; Epelbaum, R; Freidin, N; Haim, N; Leviov, M; Reshef, R | 1 |
| Andersen, D; Baker, AL; Blackstone, M; Nourmand, AD; Stathopoulos, G | 1 |
| Audouin, J; Bernadou, A; Chauvenet, L; Ciaudo, M; Favier, R; Horellou, MH; Rossert, J; Samama, M | 1 |
| Ahmed, AR; Carson, PJ; Hameed, A | 1 |
| Bertelli, G; Bruzzi, P; Del Mastro, L; Garrone, O; Guelfi, M; Pastorino, S; Rosso, R; Sertoli, MR; Venturini, M | 1 |
| Bastit, D; Boulet, D; Fruchart, C; Moncondult, M; Piguet, H; Stamatoullas, A; Tilly, H | 1 |
| Brégeon, C; Coste, J; Guillemin, F; Pouchot, J; Sany, J | 1 |
| Aschele, C; Grossi, F; Guglielmi, A; Sobrero, A; Tixi, L | 1 |
| Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC | 1 |
| Cuevas, MA; De Lena, M; Lacava, J; Leone, B; Machiavelli, M; Paradiso, A; Perez, J; Rabinovich, M; Rodriquez, R; Romero, A; Sapia, MG; Simone, G; Vallejo, C | 1 |
| Herborn, G; Rau, R | 1 |
| Alarcón, GS | 1 |
| Golding, PF; Hamilton, CR; Kerr, J; Mead, GM; Milne, AE; O'Callaghan, A; Simmonds, PD; Smartt, P; Sweetenham, JW; Whitehouse, JM | 1 |
| Malmström, P; Sjövall, MP | 1 |
| Kaplan, MM | 1 |
| Aravantinos, G; Christodoulou, C; Dimopoulos, K; Fountzilas, G; Giannakakis, T; Kastriotis, I; Kostakopoulos, CA; Linardou, E; Picramenos, D; Skarlos, DV | 1 |
| Colwell, SJ; Eastwood, BJ; Malatjalian, DA; Ross, JB; Williams, CN | 1 |
| Lundberg, LG; Samuelsson, J | 1 |
| Dahrouge, S; Stewart, DJ | 1 |
| Herborn, G; Karger, T; Rau, R; Schleusser, B | 1 |
| Edelman, MJ; Houston, J; Lauder, I; Meyers, FJ | 1 |
| Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A | 1 |
| Dyck, PJ; Hunder, GG | 1 |
| Bianchi, S; Ferroni, C; Galante, E; Maymone, S; Megale, C; Molinaro, S | 1 |
| Bonadonna, G; Brambilla, C; Ferrari, L; Moliterni, A; Terenziani, M; Valagussa, P; Zambetti, M | 1 |
| Ashley, S; Baum, M; Ebbs, S; Ellis, P; McKinna, J; Sacks, N; Smith, I; Walsh, G | 1 |
| Lacki, JK; Mackiewicz, SH | 1 |
| Cheng, AL; Hung, RL; Liu, MY; Uen, WC; Wang, CH; Yeh, KH | 1 |
| Fradet, Y | 1 |
| Lyn, BE; Mahendra, P; McMillan, AM; Shaw, B; Somers, LJ | 1 |
| Beluffi, G; Martini, A; Ramenghi, B; Ravelli, A; Viola, S; Zonta, LA | 1 |
| Hashimoto, T; Hirohata, S; Suda, H | 1 |
| Benesch, M; Kerbl, R; Lackner, H; Oberbauer, R; Pakisch, B; Schwinger, W; Urban, C | 1 |
| Clark, P; Cowan, R; Griffiths, GO; Harland, SJ; Harper, PG; Mead, GM; Parmar, MK; Roberts, JT; Russell, M; Uscinska, BM | 1 |
| Bibo, JC; Boers, M; Engel, GL; van der Linden, S; Verhoeven, AC | 1 |
| Bruckner, P; Caravatti, M; Häuselmann, HJ; Michel, BA; Seifert, B; Stucki, G; Wang, K | 1 |
| Favre, H; Lemoine, R; Miescher, PA; Tamagnini, P | 1 |
| Barendsen, BC; Bruyn, GA; Houtman, PM; Speerstra, F; Stenger, AA; Van Leeuwen, MA; van Rijswijk, MH; Velthuysen, E | 1 |
| Herborn, G; Menninger, H; Rau, R; Sangha, O | 1 |
| Pincus, T | 1 |
| Kremer, JM | 1 |
| Burmester, GR; Franz, J; Gromnica-Ihle, E; Jung, K; Keysser, C; Keysser, M; Keyszer, G; Lambiri, I; Nagel, R | 1 |
| Alarcón, GS; Moreland, LW; Rich, E | 1 |
| Bologna, C; Combe, B; Daures, JP; Jorgensen, C; Maravic, M; Sany, J | 1 |
| Boers, M; Boonen, A; Edmonds, J; Lassere, M; Saudan, A; van der Heijde, D; Verhoeven, AC | 1 |
| Abeloff, MD; Davidson, NE; Donehower, RC; Fetting, JH; Kennedy, MJ; Mikhak, B; Waterfield, W; Zahurak, M | 1 |
| Paget, SA | 1 |
| Wilke, WS | 1 |
| Hall, RR; Reading, J; Roberts, JT; Thomas, DJ | 1 |
| Andersson, M; Dombernowsky, P; Madsen, EL; Mouridsen, HT; Overgaard, M; Rose, C | 1 |
| Katzman, GL; Koby, M; Langford, CA; Patronas, NJ; Sneller, MC | 1 |
| Jacyk, WK | 1 |
| Adjei, AA; Ingle, JN; Rayson, D; Suman, VJ; Wold, LE | 1 |
| Edmonds, P; Gallagher, CJ; LeVay, J; Oliver, RT; Ong, J; Ostrowski, MJ; Raja, M; Shamash, J; Williams, M | 1 |
| Florescu, A; Hansen, M; Hørslev-Petersen, K; Johansen, JS; Lorenzen, I; Price, PA; Stoltenberg, M | 1 |
| Fushiki, H; Hasegawa, K; Izumi, R; Kono, I; Nishida, M; Noda, K; Noguchi, H; Okuda, H; Sugimori, H; Takizawa, K; Tanaka, T; Udagawa, Y; Umesaki, N; Yamamoto, K | 1 |
| Matherly, LH; Taub, JW | 1 |
| Rau, R; Wassenberg, S | 1 |
| Bonadonna, G; Ferreri, AJ; Giardini, R; Rampinelli, I; Siracusano, L; Tondini, C; Valagussa, P | 1 |
| Chamberlain, MC; Cole, BF; Glantz, MJ; Howell, SB; Jaeckle, KA; LaFollette, S; Maria, B; Phuphanich, S; Recht, L; Schumann, GB; Swinnen, LJ | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E | 1 |
| Hurley, F; Leung, H; Loew-Friedrich, I; Sharp, JT; Strand, V | 1 |
| Lindsley, HB; Moseley, AC; Skikne, BS; Tawfik, O | 1 |
| Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F | 1 |
| Drosos, AA; Katsaraki, A; Voulgari, PV; Zikou, AK | 1 |
| Balcerzak, SP; Dana, BW; Fisher, RI; Forman, JD; Gaynor, ER; Kjeldsberg, C; LeBlanc, M; Miller, T; Roy, V; Unger, JM | 1 |
| Bjorneboe, O; Breedveld, FC; Dahl, R; Dawes, PT; Emery, P; Gömör, B; Horslev-Petersen, K; Kaltwasser, JP; Lemmel, EM; Loew-Friedrich, I; Molloy, M; Nordström, D; Oed, C; Rodriguez De La Serna, A; Rosenburg, R; Tikly, M; Van Den Bosch, F | 1 |
| Ince, A; Ince, DO; Moore, TL | 1 |
| Bonadonna, G; Cipriani, S; Daidone, MG; Luisi, A; Silvestrini, R; Valagussa, P; Zambetti, M | 1 |
| Bennoun, M; Briand, P; Caron de Fromentel, C; Gillet, R; Grimber, G; Joulin, V | 1 |
| Blume, KG; Hoppe, RT; Horning, SJ; Hu, WW; Johnston, LJ; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Fenner, H; Herborn, G; Rau, R; Zueger, S | 1 |
| Bathon, JM; Finck, BK; Fleischmann, RM; Genovese, MC; Keystone, EC; Markenson, J; Martin, RW; Moreland, LW; Schiff, MH; Tesser, JR; Wasko, MC; Weaver, AL | 1 |
| Breedveld, FC; Emery, P; Feldmann, M; Furst, DE; Harriman, GR; Kalden, JR; Lipsky, PE; Maini, RN; Smolen, JS; St Clair, EW; van der Heijde, DM; Weisman, M | 1 |
| Jang, SJ; Kim, SY; Kim, TH; Lee, IH; Park, CK; Song, YH; Yang, SC | 1 |
| Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A; Pacor, ML | 1 |
| Mathieu, A; Passiu, G; Pittau, E | 1 |
| Aranoff, GS; Feldstein, NA; Garvin, JH; Hays, AP; Levine, LS; Oberfield, SE; Silfen, ME; Starkman, HS; Wong, B | 1 |
| Antoni, C; Dechant, C; Kalden, JR; Lüftl, M; Manger, B; Ogilvie, AL; Schuler, G | 1 |
| Bernardini, F; Kersten, RC; Kulwin, DR; Moin, M | 1 |
| Rau, R | 1 |
| Brzozowska, A; Mazurkiewicz, M; Szatkowska, L | 1 |
| Blume, KG; Chauncey, T; Feinstein, L; Flowers, C; Georges, G; Kiem, HP; Little, MT; Maloney, D; Maris, M; McSweeney, PA; Nash, RA; Niederwieser, D; Radich, J; Sandmaier, B; Shizuru, J; Storb, R; Woolfrey, A; Zaucha, JM | 1 |
| Hino, K; Shiozawa, K; Shiozawa, S | 1 |
| Bornstein, R; Fruehauf, JP; Li, KT; McLaren, CE; Mehta, RS; Nguyen, KP; Parker, RJ; Yu, IR | 1 |
| Murray, KJ; Nistala, K | 1 |
| Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R | 1 |
| Batchelor, T; Kaufman, D; Leahy, N | 1 |
| Scott, TE | 1 |
| Aizawa, Y; Aoki, S; Hashimoto, S; Takahashi, H; Takahashi, M; Toba, K; Tsuchiyama, J; Tsukada, N | 1 |
| Ahmed, AR; Baltatzis, S; Foster, CS; Miserocchi, E; Roque, MR | 1 |
| Diers, MD; Frandsen, JL; Gunther, R; McIvor, RS; Sweeney, CL; Verfaillie, CM | 1 |
| Badrising, UA; Breedveld, FC; de Jager, AE; de Visser, M; Ferrari, MD; Hoogendijk, JE; Höweler, CJ; Jennekens, FG; Koehler, PJ; Maat-Schieman, ML; van Doorn, PA; van Engelen, BG; Verschuuren, JJ; Viddeleer, A; Wessels, JA; Wintzen, AR; Zwinderman, AH | 1 |
| Freedman, MS; MacLean, HJ | 1 |
| Hara, T; Hattori, H; Ishii, S; Matsuzaki, A; Suminoe, A | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Creagan, ET; Edmonson, JH; Kugler, JW; Levitt, R; Mailliard, JA; Nair, S; Okuno, SH; Suman, VJ | 1 |
| Abrahamowicz, M; Chang, E; Ferland, D; Fortin, PR | 1 |
| Gerrard, M; Hobson, R; Imeson, J; McCarthy, K; Pinkerton, CR; Williams, DM | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Stefanou, S; Tsavaris, NB; Vartholomeou, M | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
104 review(s) available for methotrexate and Disease Exacerbation
| Article | Year |
|---|---|
Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: A case report and literature review.
Topics: Aged; Arthritis, Rheumatoid; Central Nervous System; Disease Progression; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Iatrogenic Disease; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Methotrexate; Neoplasm Recurrence, Local; Plasmacytoma | 2023 |
Single centre experience of 120 patients with non-infectious aortitis: Clinical features, treatment and complications.
Topics: Aortitis; Disease Progression; Female; Humans; Male; Methotrexate; Retrospective Studies | 2023 |
Management issues in rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Lung Diseases, Interstitial; Methotrexate; Prognosis | 2020 |
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azetidines; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Progression; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Janus Kinases; Methotrexate; Molecular Targeted Therapy; Pandemics; Peptide Fragments; Peptidyl-Dipeptidase A; Pneumonia, Viral; Purines; Pyrazoles; Receptor, Angiotensin, Type 1; SARS-CoV-2; Signal Transduction; STAT Transcription Factors; Sulfonamides | 2020 |
Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Treatment Failure | 2020 |
Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Lactation and Management of Postpartum Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Breast Feeding; Contraindications; Cyclophosphamide; Disease Progression; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Lactation; Lupus Erythematosus, Systemic; Methotrexate; Postpartum Period; Rheumatic Diseases; Tumor Necrosis Factor-alpha | 2017 |
Treatment of adult-onset still's disease: up to date.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis; Biomarkers; Disease Progression; Humans; Immunotherapy; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Interleukin-6; Macrophage Activation; Methotrexate; Still's Disease, Adult-Onset | 2017 |
Rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Epigenomics; Glucocorticoids; Humans; Mass Screening; Methotrexate; Quality of Life; Risk Factors | 2018 |
Structural joint damage and hand bone loss in patients with rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Resorption; Disease Progression; Hand Bones; Humans; Joints; Methotrexate; Radiography; Randomized Controlled Trials as Topic; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2018 |
Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Methotrexate; Network Meta-Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
[Juvenile dermatomyositis-what's new?]
Topics: Child; Dermatomyositis; Diagnosis, Differential; Disease Progression; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Methotrexate; Rituximab | 2019 |
The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Bias; Biological Products; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Immunoconjugates; Immunoglobulin G; Infliximab; Methotrexate; Radiography; Receptors, Tumor Necrosis Factor; Rituximab; Time Factors; Treatment Outcome | 2014 |
Increasing recognition of dermatomyositis with subcutaneous edema - is this a poorer prognostic marker?
Topics: Adrenal Cortex Hormones; Adult; Autoantibodies; Combined Modality Therapy; Dermatomyositis; Disease Progression; Drug Therapy, Combination; Edema; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Methotrexate; Muscle Weakness; Prognosis; Respiration, Artificial; Respiratory Insufficiency; Subcutaneous Tissue; Tracheostomy | 2014 |
Nonoperative management of pneumatosis intestinalis and pneumoperitoneum in mixed connective tissue disease.
Topics: Abdominal Pain; Aged; Disease Progression; Enteral Nutrition; Female; Follow-Up Studies; Humans; Methotrexate; Mixed Connective Tissue Disease; Monitoring, Physiologic; Pneumatosis Cystoides Intestinalis; Prednisone; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Disease Progression; Etanercept; Humans; Immunoconjugates; Immunoglobulin Fab Fragments; Immunoglobulin G; Inflammation; Infliximab; Magnetic Resonance Imaging; Methotrexate; Polyethylene Glycols; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Rituximab; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[Hemophagocytic lymphohistiocytosis].
Topics: Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease Progression; Doxorubicin; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Methotrexate; Multiple Organ Failure; Prednisolone; Prednisone; Rituximab; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Vincristine | 2014 |
Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cohort Studies; Disability Evaluation; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Patient Outcome Assessment; Prospective Studies; Surveys and Questionnaires; Treatment Outcome; United Kingdom; Young Adult | 2014 |
Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Humans; Methotrexate; Neoplasm, Residual; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha; Withholding Treatment | 2014 |
Combination conventional DMARDs compared to biologicals: what is the evidence?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Radiography; Randomized Controlled Trials as Topic | 2015 |
Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
Topics: Adult; Aged; Autoantibodies; Dermatomyositis; Disease Progression; Female; Glucocorticoids; Humans; Interferon-Induced Helicase, IFIH1; Lung Diseases, Interstitial; Magnetic Resonance Imaging; Male; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Young Adult | 2016 |
Advances in the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Early Diagnosis; Glucocorticoids; Humans; Methotrexate; Radiography; Remission Induction; Severity of Illness Index | 2015 |
Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Etanercept; Female; Humans; Male; Methotrexate; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Risk Assessment; Severity of Illness Index; Withholding Treatment | 2015 |
Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Diseases; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Observational Studies as Topic; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome; Tumor Necrosis Factor-alpha | 2016 |
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progression; Humans; Immunosuppressive Agents; Insurance, Health, Reimbursement; Keratolytic Agents; Medication Adherence; Methotrexate; Psoriasis; Symptom Flare Up; Thalidomide | 2016 |
[Abatacept].
Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Trials as Topic; CTLA-4 Antigen; Disease Progression; Drug Therapy, Combination; Humans; Lymphocyte Activation; Methotrexate; Molecular Targeted Therapy; Product Surveillance, Postmarketing; T-Lymphocytes | 2016 |
The safety of treatment options for pediatric Crohn's disease.
Topics: Aminosalicylic Acids; Child; Crohn Disease; Disease Progression; Glucocorticoids; Humans; Immunologic Factors; Methotrexate; Tumor Necrosis Factor-alpha | 2016 |
Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.
Topics: Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Disease Progression; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Disease Progression; Etanercept; Humans; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure | 2016 |
Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Deprescriptions; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Methotrexate; Radiography; Remission Induction; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2016 |
Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis.
Topics: Adolescent; Adult; Dapsone; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lupus Nephritis; Male; Methotrexate; Mycophenolic Acid; Thalidomide; Treatment Outcome | 2017 |
Epstein-Barr-virus-related mucocutaneous ulceration that mimics oral squamous cell carcinoma: the importance of recognising this new condition.
Topics: Aged, 80 and over; Antirheumatic Agents; Biopsy; Carcinoma, Squamous Cell; Diagnosis, Differential; Disease Progression; Epstein-Barr Virus Infections; Humans; Immunohistochemistry; Male; Methotrexate; Mouth Neoplasms; Oral Ulcer; Prednisolone; Radiography, Panoramic | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure | 2017 |
Morphea and Eosinophilic Fasciitis: An Update.
Topics: Administration, Cutaneous; Administration, Oral; Algorithms; Biopsy; Calcitriol; Dermatologic Agents; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Eosinophilia; Evidence-Based Medicine; Fasciitis; Glucocorticoids; Humans; Methotrexate; Phototherapy; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Scleroderma, Localized; Skin; Tacrolimus; Treatment Outcome; United States | 2017 |
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Quality of Life; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate.
Topics: Dermatologic Agents; Disease Progression; Epstein-Barr Virus Infections; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Polymerase Chain Reaction; Psoriasis; Severity of Illness Index | 2009 |
[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].
Topics: Abatacept; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; Immunoconjugates; Infliximab; Lymphocyte Activation; Methotrexate; Randomized Controlled Trials as Topic; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2009 |
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Cysteine; Disease Progression; Drug Therapy, Combination; Gold Sodium Thiomalate; Humans; Isoxazoles; Leflunomide; Methotrexate; Penicillamine; Radiography; Randomized Controlled Trials as Topic; Sulfasalazine; Tacrolimus | 2009 |
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Cyclophosphamide; Dasatinib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Thiazoles; Translocation, Genetic; Vincristine | 2009 |
Recent concepts in the inhibition of radiographic progression with biologics.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Humans; Methotrexate; Radiography; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
[Treatment of rapidly progressive glomerulonephritis].
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Blood Component Removal; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Humans; Immunosuppressive Agents; Methotrexate; Methylprednisolone; Mycophenolic Acid; Plasma Exchange; Pulse Therapy, Drug | 2009 |
Treatment of ankylosing spondylitis and other spondyloarthritides.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Disease Progression; Humans; Immunologic Factors; Methotrexate; Osteogenesis; Spondylarthritis; Spondylitis, Ankylosing; Tumor Necrosis Factor-alpha | 2009 |
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Rheumatoid Factor; Treatment Outcome | 2009 |
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood-Testis Barrier; Bone Marrow; Carboplatin; Central Nervous System Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Orchiectomy; Prednisone; Radiotherapy, Adjuvant; Remission Induction; Rituximab; Salvage Therapy; Testicular Neoplasms; Transplantation Conditioning; Treatment Failure; Vincristine | 2009 |
Purely intramedullary spinal cord primitive neuroectodermal tumor: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Etoposide; Humans; Infant; Magnetic Resonance Imaging; Male; Methotrexate; Neuroectodermal Tumors, Primitive; Paraparesis; Prognosis; Spinal Cord Neoplasms; Thoracic Vertebrae | 2009 |
Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients.
Topics: Adalimumab; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2009 |
ANCA-associated vasculitides: advances in pathophysiology and treatment.
Topics: Animals; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Disease Models, Animal; Disease Progression; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Mycophenolic Acid | 2010 |
Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Randomized Controlled Trials as Topic; Remission Induction; Severity of Illness Index; Treatment Outcome | 2010 |
Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Databases, Factual; Disease Progression; Female; Humans; Male; Methotrexate; Predictive Value of Tests; Radiography | 2010 |
[Diagnosis and management of small vessel vasculitides].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Disease Progression; Glucocorticoids; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Leflunomide; Methotrexate; Mycophenolic Acid; Plasmapheresis; Rituximab; Vasculitis | 2010 |
RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Certolizumab Pegol; Clinical Trials as Topic; Disease Progression; Drug Resistance; Humans; Immunoglobulin Fab Fragments; Methotrexate; Polyethylene Glycols; Quality of Life; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Biomarkers; Biopsy, Needle; Bronchoscopy; Comorbidity; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Methotrexate; Myositis; Prognosis; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Survival Analysis; Time Factors; Tomography, X-Ray Computed | 2010 |
[Plasmacytoid dendritic cell tumor].
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dendritic Cells; Disease Progression; Doxorubicin; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Prognosis; Remission Induction; Skin Neoplasms; Transplantation, Homologous; Vincristine | 2011 |
Understanding emerging treatment paradigms in rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clindamycin; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Infliximab; Methotrexate; Remission Induction; Tumor Necrosis Factor-alpha | 2011 |
Idiopathic inflammatory myopathies: definition and management of refractory disease.
Topics: Biomarkers, Pharmacological; Disease Progression; Drug Resistance; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Methotrexate; Myositis; Prognosis; Recurrence | 2011 |
Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Randomized Controlled Trials as Topic; Remission Induction; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Mooren's-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review.
Topics: Amnion; Antibodies, Monoclonal; Aza Compounds; Conjunctiva; Corneal Perforation; Corneal Ulcer; Dermatologic Agents; Disease Progression; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Middle Aged; Moxifloxacin; Prednisolone; Prednisone; Quinolines; Severity of Illness Index; Treatment Outcome; Visual Acuity | 2011 |
Mycosis fungoides stage IB progressing to cutaneous tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Black or African American; Disease Progression; Female; Humans; Interferon-alpha; Methotrexate; Mycosis Fungoides; Skin Neoplasms; Skin Pigmentation; Tetrahydronaphthalenes; Ultraviolet Therapy | 2011 |
What is the outcome of RA in 2011 and can we predict it?
Topics: Age of Onset; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Autoimmunity; Cardiovascular Diseases; Comorbidity; Disease Progression; Female; Humans; Joints; Lung Diseases; Male; Methotrexate; Middle Aged; Prognosis; Risk Factors; Sex Factors; Smoking; Survival Rate; Treatment Outcome | 2011 |
[Rheumatoid arthritis - target-oriented treatment focussing remission].
Topics: Ankle Joint; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppressive Agents; Methotrexate; Molecular Targeted Therapy; Patient Participation; Prognosis; Treatment Outcome; Wrist Joint | 2012 |
Relapsing polychondritis in the Department of Defense population and review of the literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis; Disease Progression; Ear Cartilage; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lung Diseases; Male; Methotrexate; Middle Aged; Military Medicine; Military Personnel; Polychondritis, Relapsing; Radiography, Thoracic; Respiratory Function Tests; Retrospective Studies; Scleritis; Spirometry; United States; United States Department of Defense; Young Adult | 2012 |
Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Humans; Methotrexate; Middle Aged; Radiography; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; Joints; Methotrexate; Prednisolone; Randomized Controlled Trials as Topic; Sulfasalazine | 2013 |
Evolution of treatment for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Disability Evaluation; Disease Progression; Humans; Methotrexate; Treatment Outcome | 2012 |
ACR/EULAR 2010 rheumatoid arthritis classification criteria.
Topics: Acute-Phase Proteins; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Europe; Humans; Joints; Methotrexate; Societies, Medical; United States | 2012 |
Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Radiography; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Therapeutic options for sarcoidosis: new and old.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Azathioprine; Disease Progression; Glucocorticoids; Humans; Immunosuppressive Agents; Methotrexate; Minocycline; Respiratory Mechanics; Sarcoidosis; Sarcoidosis, Pulmonary; Tumor Necrosis Factor-alpha | 2002 |
Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
Topics: Adjuvants, Immunologic; Autoimmune Diseases; Azathioprine; B-Lymphocytes; Cyclophosphamide; Disease Progression; Genetic Predisposition to Disease; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Interferon-beta; Magnetic Resonance Imaging; Methotrexate; Methylprednisolone; Mitoxantrone; Models, Theoretical; Multiple Sclerosis; Peptides | 2002 |
[Recommendations of the Deutschen Gesellschaft für Rheumatologie on therapy of rheumatoid arthritis with the interleukin-1-receptor-antagonist Akakinra (KINERET)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Contraindications; Critical Pathways; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Humans; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Interleukin-1; Sialoglycoproteins | 2002 |
Evaluation and management of psoriatic arthritis: the role of biologic therapy.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Disease Progression; Etanercept; Humans; Immunoglobulin G; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine; Tumor Necrosis Factor-alpha | 2003 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradiation; Cytarabine; Dementia; Dementia, Vascular; Demyelinating Diseases; Disease Progression; Doxorubicin; Epilepsy, Complex Partial; Etoposide; Eye Neoplasms; Fatal Outcome; Female; Gait Disorders, Neurologic; Humans; Immunocompetence; Intracranial Arteriosclerosis; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Procarbazine; Radiation Injuries; Retrospective Studies; Survival Analysis; Thiotepa; Vincristine | 2004 |
Granulocytic sarcoma of the testis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleolus; Chemotherapy, Adjuvant; Chromatin; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Humans; Leukemia, Myeloid, Acute; Male; Methotrexate; Orchiectomy; Radiotherapy, Adjuvant; Sarcoma, Myeloid; Testicular Neoplasms | 2004 |
The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Methotrexate; Receptors, Interleukin; Receptors, Tumor Necrosis Factor; Sialoglycoproteins; Treatment Outcome; Tumor Necrosis Factor-alpha | 2004 |
Rheumatoid arthritis: more aggressive approach improves outlook.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Complementary Therapies; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Methotrexate; Receptors, Tumor Necrosis Factor; Sulfasalazine; Time Factors | 2004 |
Azathioprine and methotrexate in multiple sclerosis.
Topics: Azathioprine; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Methotrexate; Multiple Sclerosis; Secondary Prevention; Treatment Outcome | 2004 |
[Internist's therapy of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Diagnosis, Differential; Disease Progression; Guidelines as Topic; Humans; Internal Medicine; Methotrexate; Patient Care Management; Practice Patterns, Physicians'; Severity of Illness Index; Treatment Outcome | 2004 |
Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Autoimmune Diseases; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Demyelinating Diseases; Disease Progression; Drug Therapy, Combination; Erythema; Heart Failure; Humans; Immunocompromised Host; Immunologic Factors; Interleukin-1; Methotrexate; Neoplasms; Opportunistic Infections; Tuberculosis; Tumor Necrosis Factor-alpha | 2004 |
Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction.
Topics: Arthritis, Rheumatoid; Azathioprine; Disease Progression; Humans; Hydroxychloroquine; Immunologic Factors; Isoxazoles; Leflunomide; Methotrexate; Sulfasalazine | 2004 |
Acute dermatomyositis with subcutaneous generalized edema.
Topics: Acute Disease; Adult; Dermatomyositis; Disease Progression; Edema; Fatal Outcome; gamma-Globulins; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Methotrexate; Prednisone; Subcutaneous Tissue; Treatment Failure | 2006 |
[The clinical spectrum of dermatomyositis].
Topics: Adult; Age Factors; Azathioprine; Biopsy; Child; Clinical Trials as Topic; Cyclophosphamide; Cyclosporine; Dermatologic Agents; Dermatomyositis; Disease Progression; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Muscles; Mycophenolic Acid; Paraneoplastic Syndromes; Plasmapheresis; Prognosis; Sex Factors; Time Factors | 2005 |
[Biologic therapy with anti-TNFα in rheumathoid arthritis].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Radiography; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2005 |
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Etanercept; Etretinate; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2006 |
Trilateral retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease Progression; Etoposide; Eye Enucleation; Eye Neoplasms; Fatal Outcome; Female; Humans; Idarubicin; Ifosfamide; Male; Methotrexate; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Pinealoma; Prognosis; Retinoblastoma; Vincristine | 2007 |
[Non-corticosteroid drug-induced metabolic bone disease].
Topics: Aged; Animals; Anticoagulants; Anticonvulsants; Antipsychotic Agents; Aromatase Inhibitors; Bone Density; Child; Cyclosporins; Densitometry; Disease Progression; Diuretics; Female; Follow-Up Studies; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; Iatrogenic Disease; Immunosuppressive Agents; Lithium Compounds; Male; Menopause; Methotrexate; Middle Aged; Osteomalacia; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Protease Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tacrolimus; Thyroid Hormones; Time Factors | 2006 |
Management of established rheumatoid arthritis with an emphasis on pharmacotherapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Outcome and Process Assessment, Health Care; Prognosis; Quality of Life | 2007 |
[Inhibition of radiographic progression in rheumatoid arthritis by anti-rheumatic drugs (DMARDs)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclosporine; Disease Progression; Humans; Isoxazoles; Joints; Leflunomide; Methotrexate; Radiography; Remission Induction; Sulfasalazine | 2007 |
[Pathologic condition of osteoporosis in rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Bone Remodeling; Bone Resorption; Cell Differentiation; Cyclosporine; Disease Progression; Glucocorticoids; Humans; Menopause; Methotrexate; Osteoclasts; Osteoporosis; RANK Ligand; Tumor Necrosis Factor-alpha | 2007 |
Established rheumatoid arthritis: clinical assessments.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Outcome and Process Assessment, Health Care; Prognosis; Risk Assessment; Risk Factors | 2007 |
An update on methotrexate pharmacogenetics in rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Pharmacogenetics; Polymorphism, Genetic | 2008 |
Tailor-made therapy in rheumatoid arthritis: fact or fiction?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Prognosis | 2008 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Flow Cytometry; Humans; Immunophenotyping; Male; Mercaptopurine; Methotrexate; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Primary Myelofibrosis; Remission Induction; Vincristine | 1996 |
Influence of treatment on the clinical course of pemphigus vulgaris.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Contraindications; Dermatologic Agents; Disease Progression; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Jews; Male; Methotrexate; Middle Aged; Pemphigus; Prednisone; Reproducibility of Results; Retrospective Studies; Survival Rate | 1996 |
The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis.
Topics: Adjuvants, Immunologic; Cholagogues and Choleretics; Colchicine; Disease Progression; Drug Therapy, Combination; Female; Gout Suppressants; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Methotrexate; Ursodeoxycholic Acid | 1997 |
The emergence of Hodgkin's disease in a patient with long-standing chronic lymphocytic leukemia--case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Disease Progression; Humans; Hydrocortisone; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Vincristine | 1997 |
Phenotypic characterization of bladder cancer.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Doxorubicin; Female; Humans; Immunotherapy; Lymphatic Metastasis; Male; Mass Screening; Methotrexate; Microscopy, Electron; Neoplasm Staging; Phenotype; Prognosis; Sensitivity and Specificity; Urinary Bladder Neoplasms; Vinblastine | 1998 |
Aggressive treatment of early rheumatoid arthritis to prevent joint damage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Management; Disease Progression; Humans; Methotrexate; Prednisone; Time Factors | 1998 |
Should methotrexate be a first-line treatment for rheumatoid arthritis?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Patient Selection; Time Factors | 1999 |
Molecular and cellular correlates of methotrexate response in childhood acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Child; Disease Progression; Folic Acid; Humans; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Risk Factors | 1999 |
Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Herpesvirus 4, Human; Hodgkin Disease; Humans; Lymphoproliferative Disorders; Methotrexate; Middle Aged; Tomography, X-Ray Computed; Virus Activation | 2000 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Disease Progression; Dogs; Forecasting; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Methotrexate; Middle Aged; Mycophenolic Acid; Neoplasms; Prednisone; Radiation Chimera; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2001 |
Pharmaceutical agents for the treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Drug Utilization; Humans; Methotrexate; Quality of Life; Tumor Necrosis Factor-alpha; United States | 2001 |
Immunologic therapy for relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Forecasting; Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Longitudinal Studies; Methotrexate; Mitoxantrone; Multiple Sclerosis; Peptides; Plasma Exchange; Plasmapheresis; Steroids; Treatment Outcome | 2001 |
Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.
Topics: Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Etoposide; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Mitoxantrone; Prednisolone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vincristine | 2001 |
Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Prednisolone; Recurrence; Risk; Thioguanine; United Kingdom; Vincristine | 2002 |
277 trial(s) available for methotrexate and Disease Exacerbation
| Article | Year |
|---|---|
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Humans; Methotrexate; Purines; Pyrazoles; Sulfonamides; Treatment Outcome | 2022 |
Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Retrospective Studies; Treatment Outcome | 2022 |
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; East Asian People; Humans; Methotrexate; Prednisolone; Treatment Outcome | 2023 |
Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Humans; Methotrexate | 2023 |
Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Rituximab; Transplantation, Autologous; Vincristine | 2023 |
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Treatment Outcome | 2019 |
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome | 2019 |
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Exercise; Female; Humans; Injections, Subcutaneous; Male; Methotrexate; Middle Aged; Neutrophils; Patient Safety; Placebos; Radiography; Receptors, Interleukin-6; Treatment Outcome | 2019 |
No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Bone Density; Child; Child, Preschool; Disease Progression; Etanercept; Female; Humans; Male; Methotrexate; Patient Care Planning; Radiography; Wrist | 2019 |
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Time Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2019 |
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Piperidines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Cytarabine; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Retrospective Studies; Risk Assessment; Survival Rate | 2020 |
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Methotrexate; Middle Aged; Netherlands; Prednisone; Proportional Hazards Models; Remission Induction; Time Factors; Time-to-Treatment; Treatment Outcome | 2020 |
Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers, Pharmacological; Blood Sedimentation; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Receptors, Interleukin-6; Remission Induction; Severity of Illness Index; Treatment Outcome | 2020 |
The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Prednisone; Severity of Illness Index; Treatment Outcome | 2020 |
Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Humans; Inflammation; Infliximab; Methotrexate; Resistin; Treatment Outcome; Tumor Necrosis Factor-alpha | 2022 |
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Joints; Male; Medication Therapy Management; Methotrexate; Middle Aged; Radiography; Remission Induction; Treatment Outcome | 2017 |
Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prednisolone; Radiography; Severity of Illness Index; Sulfasalazine; Survival Analysis; Treatment Outcome | 2017 |
Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Hemoglobins; Humans; Joints; Male; Methotrexate; Radiography | 2018 |
Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infliximab; Linear Models; Male; Methotrexate; Middle Aged; Netherlands; Prednisone; Remission Induction; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome | 2017 |
Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study.
Topics: Antirheumatic Agents; Anxiety; Arthritis, Rheumatoid; Depression; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Methotrexate; Middle Aged; Monitoring, Physiologic; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome | 2018 |
Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Joints; Male; Methotrexate; Middle Aged; Prednisone; Radiography; Remission Induction; Severity of Illness Index; Single-Blind Method; Sulfasalazine; Time Factors; Treatment Outcome | 2018 |
Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Drug Therapy, Combination; Female; Foot; Hand; Humans; Joints; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome | 2018 |
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Time Factors; Treatment Outcome; Withholding Treatment | 2018 |
Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Plant Extracts; Tripterygium | 2018 |
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Time Factors; Treatment Outcome | 2018 |
Effect of Treat-to-target Strategies Aiming at Remission of Arterial Stiffness in Early Rheumatoid Arthritis: A Randomized Controlled Study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Pulse Wave Analysis; Remission Induction; Severity of Illness Index; Treatment Outcome; Vascular Stiffness | 2018 |
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Severity of Illness Index | 2018 |
Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Topics: Adalimumab; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.
Topics: Adalimumab; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Retreatment; Severity of Illness Index; Treatment Failure | 2018 |
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; C-Reactive Protein; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Odds Ratio; Purines; Pyrazoles; Sulfonamides; Treatment Outcome | 2018 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck | 2019 |
Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Bone Resorption; Denosumab; Disease Progression; Double-Blind Method; Female; Humans; Japan; Male; Methotrexate; Middle Aged; Prognosis; Rheumatoid Factor; Treatment Outcome | 2019 |
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
Topics: Adalimumab; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Bendamustine Hydrochloride; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Foot Joints; Hand Joints; Humans; Male; Methotrexate; Middle Aged; Radiography; Young Adult | 2019 |
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Purines; Pyrazoles; Sulfonamides; Synovitis; Treatment Outcome | 2019 |
Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prednisolone; Prospective Studies; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2019 |
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Docetaxel; Follow-Up Studies; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Nivolumab; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Survival | 2019 |
Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Osteitis; Pilot Projects; Synovitis; Treatment Outcome | 2020 |
Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Purines; Pyrazoles; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2020 |
Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome; Withholding Treatment | 2020 |
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome | 2019 |
Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumab.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; CD40 Ligand; Disease Progression; Drug Therapy, Combination; Epidermal Growth Factor; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index | 2013 |
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Absorptiometry, Photon; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Early Diagnosis; Female; Hand Bones; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Odds Ratio; Predictive Value of Tests; Risk Assessment; Risk Factors; Sulfasalazine; Sweden; Time Factors; Treatment Outcome | 2013 |
Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Health Status; Humans; Hydroxychloroquine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Prognosis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sulfasalazine; Symptom Assessment; Time Factors; Treatment Outcome | 2013 |
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Topics: Adult; Aged; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Betamethasone; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Cyclosporine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Injections, Intra-Articular; Lumbar Vertebrae; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome; Young Adult | 2014 |
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome | 2013 |
Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Health Status; Humans; Hydroxychloroquine; Immunoglobulin G; Joints; Male; Methotrexate; Middle Aged; Prognosis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome | 2013 |
A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisone; Radiography; Remission Induction; Single-Blind Method; Sulfasalazine; Treatment Outcome | 2014 |
Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Treatment Outcome | 2013 |
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; Methotrexate; Middle Aged; Motor Activity; Radiography; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Marrow Diseases; Disease Progression; Drug Therapy, Combination; Early Diagnosis; Edema; Female; Humans; Magnetic Resonance Imaging; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Radiography; Synovitis; Wrist Joint | 2014 |
Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; CD4-Positive T-Lymphocytes; Chemokine CCL19; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Methotrexate; Middle Aged; Monocytes; Peptides, Cyclic; Radiography; Receptors, CCR7; Severity of Illness Index; Treatment Outcome; Up-Regulation | 2014 |
Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis.
Topics: Aged; Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Betamethasone; Biomarkers; Case-Control Studies; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interleukins; Longitudinal Studies; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Programmed Cell Death 1 Receptor; Radiography; Rheumatoid Factor; Severity of Illness Index | 2014 |
Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Methotrexate; Middle Aged; Observer Variation; Prospective Studies; Receptors, Tumor Necrosis Factor; Sensitivity and Specificity; Synovitis; Tumor Necrosis Factor-alpha; Ultrasonography, Doppler | 2013 |
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Disease Progression; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Treatment Outcome; Young Adult | 2014 |
Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Disease Progression; Female; Humans; Hydroxychloroquine; Male; Metacarpal Bones; Methotrexate; Middle Aged; Prednisone; Sulfasalazine | 2015 |
Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Foot; Hand; Humans; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Time Factors; Treatment Outcome; Wrist | 2014 |
Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Certolizumab Pegol; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Japan; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Quality of Life; Retreatment; Treatment Outcome | 2014 |
ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Autoantigens; Cyclosporine; Disease Progression; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prednisolone; Quality of Life | 2014 |
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Disease Progression; Drug Therapy, Combination; Female; Humans; Japan; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibody Formation; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome | 2014 |
The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Joints; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Osteitis; Synovitis; Treatment Outcome | 2014 |
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-c
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cross-Over Studies; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Foot Joints; Hand Joints; Humans; Interleukin-12 Subunit p40; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome; Ustekinumab | 2014 |
Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Certolizumab Pegol; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunoglobulin Fab Fragments; Japan; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Quality of Life; Retreatment; Treatment Outcome | 2014 |
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Radiography; Smoking; Sulfasalazine; Treatment Outcome | 2015 |
Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial.
Topics: Abatacept; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Foot Joints; Hand Joints; Humans; Immunoconjugates; Male; Methotrexate; Middle Aged; Radiography; Retreatment; Treatment Outcome | 2014 |
Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Methotrexate; Prednisolone; Receptors, Tumor Necrosis Factor; Remission Induction; Treatment Outcome | 2014 |
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Injections, Intramuscular; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Single-Blind Method; Sulfasalazine; Treatment Outcome | 2014 |
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Topics: Adipokines; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Chitinase-3-Like Protein 1; Disease Progression; Drug Therapy, Combination; Epidermal Growth Factor; Female; Foot Joints; Hand Joints; Humans; Hydroxychloroquine; Infliximab; Interleukin-6; Lectins; Leptin; Logistic Models; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Multivariate Analysis; Prognosis; Radiography; Receptors, Tumor Necrosis Factor, Type I; Resistin; Serum Amyloid A Protein; Severity of Illness Index; Sulfasalazine; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2015 |
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Juvenile; Bronchitis; Cellulitis; Child; Child, Preschool; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Maintenance Chemotherapy; Male; Methotrexate; Pneumonia; Receptors, Interleukin-6; Remission Induction; Treatment Outcome | 2015 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Disease Progression; Double-Blind Method; Female; Humans; Immunoglobulin Fab Fragments; Japan; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Treatment Outcome; Young Adult | 2014 |
Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome | 2014 |
Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome | 2015 |
Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Foot Joints; Hand Joints; Humans; Induction Chemotherapy; Longitudinal Studies; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome | 2015 |
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Topics: Adult; Aminopyridines; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Maximum Tolerated Dose; Methotrexate; Middle Aged; Morpholines; Oxazines; Patient Safety; Prognosis; Pyridines; Pyrimidines; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Remission Induction; Risk Factors; Sulfasalazine; Time Factors; Treatment Outcome | 2014 |
Can we prevent rapid radiological progression in patients with early rheumatoid arthritis?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Foot Joints; Hand Joints; Humans; Male; Methotrexate; Middle Aged; Models, Theoretical; Prednisone; Radiography; Risk Factors; Treatment Outcome | 2015 |
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Topics: Antibody Specificity; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Disease Progression; Drug Therapy, Combination; Female; Fibrinogen; Humans; Hydroxychloroquine; Infliximab; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Phosphopyruvate Hydratase; Radiography; Sulfasalazine; Sweden; Vimentin | 2016 |
Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Child; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Methotrexate; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2015 |
Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Infliximab; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Sulfasalazine; Sweden; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Respons
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Disease Progression; Disease-Free Survival; Doxorubicin; Europe; Female; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Grading; North America; Osteosarcoma; Osteotomy; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2015 |
Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Asia; Biological Products; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Europe; Humans; Joints; Methotrexate; Predictive Value of Tests; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome; United States | 2015 |
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Health Care Costs; Humans; Joints; Logistic Models; Male; Methotrexate; Middle Aged; Models, Biological; Pain; Quality-Adjusted Life Years; Severity of Illness Index | 2015 |
Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexa
Topics: Abatacept; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome | 2015 |
Interleukin-23 in early disease development in rheumatoid arthritis.
Topics: Adalimumab; Adult; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Interleukin-23; Male; Methotrexate; Middle Aged; Pain Measurement; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Endpoint Determination; Female; Foot Joints; Hand Joints; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Radiography; Reproducibility of Results; Research Design; Sample Size; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2016 |
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Radiography; Remission Induction; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2016 |
A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo.
Topics: Administration, Oral; Adolescent; Adult; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Pulse Therapy, Drug; Skin; Treatment Outcome; Vitiligo; Young Adult | 2015 |
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Injections, Subcutaneous; Methotrexate; Radiography; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of th
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Foot Joints; Hand Joints; Humans; Methotrexate; Radiography; Treatment Outcome | 2016 |
Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Injections, Intra-Articular; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Severity of Illness Index; Treatment Outcome; Triamcinolone | 2016 |
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Treatment Outcome | 2016 |
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Radiography; Severity of Illness Index; Treatment Outcome | 2016 |
Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Single-Blind Method; Sulfasalazine; Time Factors; Treatment Outcome | 2016 |
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.
Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Methotrexate; Osteitis; Remission Induction; Severity of Illness Index; Synovitis; Treatment Outcome | 2016 |
The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Biomarkers; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Interleukins; Leukocytes, Mononuclear; Male; Methotrexate; Microscopy, Confocal; Middle Aged; Osteoclasts; Receptors, Interleukin; Rheumatoid Factor | 2016 |
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Marrow; Bone Marrow Diseases; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Synovitis; Treatment Outcome; Wrist Joint | 2016 |
Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Foot; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Ultrasonography, Doppler; Wrist | 2016 |
Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Glucocorticoids; Humans; Infliximab; Joints; Methotrexate; Placebos; Treatment Outcome | 2016 |
A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis.
Topics: 4-1BB Ligand; ADAM17 Protein; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; CD8-Positive T-Lymphocytes; Cells, Cultured; Disease Progression; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Galectins; HEK293 Cells; Humans; Leukocytes, Mononuclear; Longitudinal Studies; Matrix Metalloproteinase 17; Methotrexate; Synovial Fluid; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2016 |
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemoradiotherapy; Cisplatin; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Conformal; Republic of Korea; Time Factors; Treatment Outcome | 2016 |
Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Biological Products; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Inflammation; Male; Methotrexate; Proportional Hazards Models; Prospective Studies; Recurrence; Remission Induction; Rheumatology; ROC Curve; Synovitis; Treatment Outcome; Ultrasonography | 2016 |
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Regression Analysis; Surveys and Questionnaires; Treatment Outcome | 2017 |
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Deprescriptions; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Male; Methotrexate; Middle Aged; Prognosis; Remission Induction; Retreatment; Treatment Outcome | 2017 |
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
Topics: Adult; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
Topics: Acute Disease; Aged; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infliximab; Joints; Linear Models; Male; Methotrexate; Middle Aged; Prednisone; Remission Induction; Sulfasalazine; Treatment Outcome | 2009 |
Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Methotrexate; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2009 |
Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Foot Joints; Hand Joints; Humans; Infliximab; Methotrexate; Middle Aged; Radiography; Tumor Necrosis Factor-alpha; Young Adult | 2009 |
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Radiography | 2008 |
Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data.
Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; Discriminant Analysis; Disease Progression; Double-Blind Method; Humans; Immunoconjugates; Methotrexate; Patient Satisfaction; Treatment Outcome | 2009 |
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.
Topics: Abatacept; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Prognosis; Quality of Life; Radiography; Treatment Outcome | 2009 |
Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Joints; Longitudinal Studies; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome | 2009 |
Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infliximab; Male; Methotrexate; Middle Aged; Osteoporosis | 2009 |
Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Humans; Methotrexate; Radiography; Time Factors | 2009 |
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Male; Methotrexate; Middle Aged; Prednisolone; Radiography; Sulfasalazine; Treatment Outcome | 2010 |
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Rheumatoid Factor; Treatment Outcome | 2009 |
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Female; Fluorouracil; Goserelin; Humans; Menopause; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Predictive Value of Tests; Prognosis; Treatment Outcome | 2010 |
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Radiography; Recovery of Function; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Repair of erosions occurs almost exclusively in damaged joints without swelling.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone Regeneration; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Etanercept; Foot Joints; Hand Joints; Humans; Immunoglobulin G; Methotrexate; Radiography; Receptors, Tumor Necrosis Factor | 2010 |
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmunity; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Risk; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Methotrexate; Middle Aged; Radiography; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2010 |
Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Arthritis, Juvenile; Chickenpox Vaccine; Child; Child, Preschool; Dermatomyositis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Injections, Subcutaneous; Male; Methotrexate; Scleroderma, Systemic; Vaccines, Attenuated; Young Adult | 2010 |
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Melphalan; Methotrexate; Middle Aged; Mycosis Fungoides; Myeloablative Agonists; Recurrence; Sezary Syndrome; Tacrolimus; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Double-Blind Method; Female; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Receptors, Interleukin-6; Treatment Outcome | 2010 |
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Rituximab; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Biomarkers; Bone Marrow Diseases; Cyclosporine; Disease Progression; Drug Therapy, Combination; Edema; Epidemiologic Methods; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prognosis; Radiography; Remission Induction | 2010 |
Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adult; Aged; Antibodies, Monoclonal; Arthritis, Rheumatoid; Bone Density; Disease Progression; Drug Therapy, Combination; Female; Foot; Hand; Humans; Infliximab; Logistic Models; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prednisone; Sensitivity and Specificity; Sulfasalazine | 2010 |
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Glucocorticoids; Humans; Infliximab; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prednisone; Radiography; Rheumatoid Factor | 2010 |
Validity of the disease activity score in undifferentiated arthritis.
Topics: Adult; Aged; Arthritis; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Severity of Illness Index | 2010 |
Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Joints; Male; Methotrexate; Middle Aged; Prospective Studies; Receptors, Tumor Necrosis Factor; Recovery of Function; Treatment Outcome; Withholding Treatment | 2010 |
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Finland; Follow-Up Studies; Foot Joints; Hand Joints; Humans; Hydroxychloroquine; Longitudinal Studies; Methotrexate; Prednisolone; Radiography; Sulfasalazine; Treatment Outcome | 2010 |
Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Foot Joints; Hand Joints; Humans; Infliximab; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Single-Blind Method; Synovitis; Treatment Outcome; Young Adult | 2010 |
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Methotrexate; Middle Aged; Prognosis; Urinary Bladder Neoplasms; Vinblastine | 2010 |
Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Hand Joints; Humans; Infliximab; Male; Methotrexate; Middle Aged; Osteoarthritis; Radiography; Tumor Necrosis Factor-alpha | 2010 |
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Radiotherapy Dosage; Remission Induction; Vincristine | 2011 |
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Joints; Male; Methotrexate; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Rituximab; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study.
Topics: Adalimumab; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Magnetic Resonance Imaging; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Synovitis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography | 2011 |
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Biomarkers; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infliximab; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prednisone; Recurrence; Remission Induction; Severity of Illness Index; Treatment Outcome | 2011 |
Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Quality of Life; Radiography; Remission Induction; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Time Factors; Treatment Outcome | 2011 |
The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Treatment Outcome | 2011 |
Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Disease Progression; Drug Therapy, Computer-Assisted; Epidemiologic Methods; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome | 2011 |
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Infliximab; Male; Methotrexate; Middle Aged; Prednisone; Quality of Life; Radiography; Remission Induction; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Drug Therapy, Combination; Early Diagnosis; Epidemiologic Methods; Female; Humans; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Remission Induction; Sex Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Prognosis; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Withholding Treatment | 2011 |
The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cartilage; Disease Progression; Female; Follow-Up Studies; Humans; Linear Models; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prospective Studies; Radiography; Severity of Illness Index; Time; Treatment Outcome | 2011 |
Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Middle Aged; Prospective Studies; Radiography; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2011 |
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Osteitis; Synovitis; Treatment Outcome; Wrist Joint | 2011 |
Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
Topics: Abatacept; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Female; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
A one-year evaluation of radiographic progression in patients with rheumatoid arthritis treated by Qingre Huoxue Decoction ().
Topics: Adult; Arthritis, Rheumatoid; Disease Progression; Drugs, Chinese Herbal; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Radiography | 2012 |
Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Topics: Abatacept; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunoconjugates; Longitudinal Studies; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
Topics: Abatacept; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunoconjugates; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Neoplasms; Opportunistic Infections; Quality of Life; Radiography; Severity of Illness Index; Treatment Failure; Treatment Outcome | 2011 |
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Early Diagnosis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Treatment Outcome | 2012 |
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Radiography; Recovery of Function; Rituximab; Severity of Illness Index; Treatment Outcome; Young Adult | 2012 |
Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Early Diagnosis; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Methotrexate; Middle Aged; Morocco; Prednisone; Prospective Studies; Young Adult | 2011 |
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Disease Progression; Drug Therapy, Combination; Humans; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome | 2012 |
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Drug Therapy, Combination; Humans; Immunologic Factors; Inflammation; Interleukin-6; Joints; Methotrexate; Middle Aged; Treatment Outcome | 2012 |
Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Resorption; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Osteitis; Synovitis; Treatment Outcome; Wrist Joint | 2011 |
Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Joints; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome | 2012 |
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Immunologic Factors; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Quality of Life; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2012 |
Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study.
Topics: Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Humans; Methotrexate; Radiography; ROC Curve | 2012 |
Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Adolescent; Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Remission Induction; Surveys and Questionnaires; Treatment Outcome | 2012 |
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Treatment Outcome | 2013 |
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Hydroxychloroquine; Induction Chemotherapy; Infliximab; Longitudinal Studies; Male; Methotrexate; Middle Aged; Prednisolone; Sulfasalazine; Treatment Outcome | 2013 |
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cartilage, Articular; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Employment; Female; Foot Joints; Hand Joints; Humans; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome; Work Capacity Evaluation | 2013 |
Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; B-Lymphocytes; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Progression; Drug Therapy, Combination; Female; Flow Cytometry; GPI-Linked Proteins; Granulocytes; Humans; Infliximab; Leukocyte Count; Leukocytes; Lipopolysaccharide Receptors; Male; Methotrexate; Methylprednisolone; Middle Aged; Monocytes; Receptors, IgG; Tumor Necrosis Factor-alpha | 2012 |
A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Etanercept; Female; Humans; Immunoglobulin G; Japan; Male; Methotrexate; Middle Aged; Radiography; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Treatment Outcome | 2013 |
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Joints; Male; Methotrexate; Middle Aged; Neoplasms; Radiography; Severity of Illness Index; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome | 2013 |
Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Biomarkers; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prognosis; Radiography; Remission Induction; Treatment Outcome | 2014 |
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Resistance; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Motor Activity; Piperidines; Pyrimidines; Pyrroles; Radiography; Treatment Outcome | 2013 |
Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: partial but detailed results of the GO-FORTH and GO-MONO studies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Japan; Male; Methotrexate; Middle Aged; Radiography; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Etanercept; Female; Humans; Immunoglobulin G; Male; Methotrexate; Middle Aged; Patient Dropouts; Radiography; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2002 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Disease Progression; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Methotrexate; Middle Aged; Nausea; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 2002 |
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Topics: Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Collagen Type I; Collagen Type II; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Peptide Fragments; Prednisolone; Prospective Studies; Radiography; Sensitivity and Specificity; Sulfasalazine | 2002 |
Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carbazoles; Disease Progression; Drug Administration Schedule; Edema; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pyridines; Survival Analysis; Treatment Outcome | 2003 |
Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Treatment Outcome | 2003 |
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lomustine; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Vinblastine | 2003 |
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Vincristine | 2003 |
Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Double-Blind Method; Female; Glycosides; Humans; Joints; Lignans; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome | 2003 |
Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis.
Topics: Adult; Cytarabine; Delayed-Action Preparations; Disease Progression; Humans; Injections, Spinal; Meningeal Neoplasms; Meningitis; Methotrexate; Neoplasms; Quality of Life; Survival Analysis | 2003 |
Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Radiography; Single-Blind Method; Treatment Outcome | 2003 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prognosis; Quality of Life; Statistics as Topic; Survival Analysis; Taxoids | 2003 |
Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years.
Topics: Adult; Aged; Behcet Syndrome; Dementia; Disease Progression; Drug Monitoring; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interleukin-6; Male; Methotrexate; Middle Aged; Paresis; Time Factors; Wechsler Scales | 2003 |
Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Palliative Care; Prospective Studies; Survival Rate; Urologic Neoplasms; Vinblastine | 2003 |
[Radiologic progression of rheumatoid arthritis lesions treated with methotrexate].
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Radiography; Treatment Outcome | 2003 |
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Taxoids; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2004 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Injections, Spinal; Lenograstim; Leucovorin; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prognosis; Recombinant Proteins; Salvage Therapy; Sepsis; Treatment Outcome; Vincristine | 2003 |
Infliximab in active early rheumatoid arthritis.
Topics: Acute Disease; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Finger Joint; Foot Joints; Humans; Infliximab; Male; Methotrexate; Middle Aged; Radiography | 2004 |
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Collagen; Collagen Type I; Collagen Type II; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Peptides; Prednisolone; Radiography; Sulfasalazine | 2004 |
Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Vaccines; Humans; Hydrocortisone; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Treatment Outcome; Venezuela; Vincristine | 2004 |
Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Methotrexate; Prednisone; Procarbazine; Prognosis; Risk Assessment; Treatment Outcome; Vinblastine | 2004 |
Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leucovorin; Male; Medulloblastoma; Mesna; Methotrexate; Risk Factors; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Data Interpretation, Statistical; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Reproducibility of Results | 2005 |
Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Hand; Humans; Interleukin 1 Receptor Antagonist Protein; Magnetic Resonance Imaging; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Prognosis; Radiography; Receptors, Interleukin-1; Sialoglycoproteins; Synovitis; Treatment Outcome; Wrist Joint | 2005 |
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Male; Methotrexate; Middle Aged; Radiography; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Treatment Outcome | 2005 |
Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cognition; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Humans; Leucovorin; Lymphoma; Methotrexate; Procarbazine; Radiation Injuries; Survival Rate; Vincristine | 2005 |
Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Health Status; Humans; Male; Methotrexate; Middle Aged; Recovery of Function; Severity of Illness Index | 2006 |
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Tumor Necrosis Factor-alpha | 2006 |
Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Carotid Artery Diseases; Disease Progression; Drug Resistance; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Disease Progression; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Radiography | 2006 |
The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Kinetics; Leukemia, Promyelocytic, Acute; Life Tables; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Tretinoin | 2006 |
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
Topics: Abatacept; Adult; Aged; Antibody Formation; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Resistance; Female; Humans; Immunoconjugates; Infections; Male; Methotrexate; Middle Aged; Quality of Life; Radiography; Treatment Outcome | 2006 |
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Analysis; Time Factors; Urinary Bladder Neoplasms; Vinblastine | 2006 |
Magnetic resonance imaging is more sensitive than radiographs in detecting change in size of erosions in rheumatoid arthritis.
Topics: Antirheumatic Agents; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Metacarpophalangeal Joint; Methotrexate; Patient Compliance; Prognosis; Rheumatic Diseases; Sensitivity and Specificity; Tumor Necrosis Factor-alpha; Wrist | 2006 |
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Arthrography; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Cross-Sectional Studies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Severity of Illness Index | 2007 |
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bacterial Infections; Disease Progression; Double-Blind Method; Female; Foot Joints; Hand Joints; Humans; Interleukin-6; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Treatment Outcome | 2007 |
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Protocols; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Computer-Assisted; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Severity of Illness Index; Treatment Outcome | 2007 |
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Receptor, ErbB-2; Thalidomide | 2007 |
Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Betamethasone; Combined Modality Therapy; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Injections, Intra-Articular; Male; Methotrexate; Middle Aged; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2008 |
Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
Topics: Adult; Aged; Antibodies, Monoclonal; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Edema; Female; Humans; Infliximab; Infusions, Intravenous; Joints; Magnetic Resonance Imaging; Male; Methotrexate; Methylprednisolone; Middle Aged; Pulse Therapy, Drug; Synovitis; Treatment Outcome | 2007 |
Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Etoposide; Female; Humans; Infant; Infusions, Intra-Arterial; Male; Methotrexate; Middle Aged; Neoplasms, Germ Cell and Embryonal; Prospective Studies; Survival Analysis; Treatment Outcome | 2008 |
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Epidemiologic Methods; Etanercept; Female; Foot Joints; Hand Joints; Humans; Immunoglobulin G; Male; Methotrexate; Radiography; Receptors, Tumor Necrosis Factor | 2008 |
Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation.
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Radiotherapy; Survival Rate; Time; Treatment Outcome | 2008 |
Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression; Female; Follow-Up Studies; Humans; Infliximab; Joints; Male; Methotrexate; Middle Aged; Pilot Projects; Prognosis; Remission Induction; Statistics, Nonparametric; Tumor Necrosis Factor-alpha | 2008 |
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis | 2009 |
Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cranial Irradiation; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Karnofsky Performance Status; Longitudinal Studies; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
Topics: Abatacept; Adolescent; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Drug Costs; Female; Health Care Costs; Humans; Immunoconjugates; Male; Methotrexate; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Radiography; Rituximab; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Disease Progression; Female; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Infliximab; Male; Membrane Transport Proteins; Methotrexate; Middle Aged; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; Rheumatoid Factor; Sulfasalazine | 2008 |
Synthesis of interleukin-1 beta in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicine and disease progression.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Colchicine; Disease Progression; Double-Blind Method; Female; Humans; Interleukin-1; Leukocyte Count; Leukocytes, Mononuclear; Liver; Liver Cirrhosis, Biliary; Male; Methotrexate; Middle Aged; Staphylococcus epidermidis | 1995 |
Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Data Interpretation, Statistical; Disability Evaluation; Disease Progression; Female; Gold; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Penicillamine; Prospective Studies; Surveys and Questionnaires; Treatment Outcome | 1994 |
Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Hemorrhage; Humans; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Prospective Studies; Radiotherapy, Adjuvant; Stomach Neoplasms; Vincristine | 1995 |
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diethylstilbestrol; Disease Progression; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Menopause; Methotrexate; Middle Aged | 1996 |
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Whole-Body Irradiation | 1996 |
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Liver Neoplasms; Lung Neoplasms; Methotrexate; Palliative Care; Pilot Projects; Remission Induction; Treatment Outcome; Tumor Cells, Cultured | 1996 |
A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Arthrography; Disease Progression; Double-Blind Method; Evaluation Studies as Topic; Gold Sodium Thiomalate; Humans; Methotrexate | 1995 |
PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fertility; Follow-Up Studies; Hematologic Diseases; Hodgkin Disease; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisolone; Retreatment; Treatment Outcome; Vincristine | 1997 |
Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Disease Progression; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; Urethral Neoplasms; Urinary Bladder Neoplasms; Vinblastine; World Health Organization | 1997 |
Long-term treatment of destructive rheumatoid arthritis with methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Disease Progression; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Radiography; Treatment Outcome | 1997 |
Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Transitional Cell; Confidence Intervals; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Salvage Therapy; Sepsis; Urinary Bladder Neoplasms | 1997 |
Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1998 |
[The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Prednisone; Radiography; Treatment Outcome | 1997 |
Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease.
Topics: Aged; Behcet Syndrome; Central Nervous System Diseases; Dementia; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged | 1998 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine | 1998 |
A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Female; Humans; Male; Methotrexate; Mitomycins; Prognosis; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 1998 |
Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumat
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Joints; Male; Methotrexate; Middle Aged; Prednisolone; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 1998 |
Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Collagen; Disease Progression; Double-Blind Method; Female; Humans; Immune Tolerance; Joints; Male; Methotrexate; Middle Aged; Mouth Mucosa; Treatment Outcome | 1998 |
Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Gold Sodium Thiomalate; Humans; Male; Methotrexate; Middle Aged; Radiography; Treatment Outcome | 1998 |
Radiologic progression in early rheumatoid arthritis treated with methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Radiography; Treatment Outcome | 1999 |
Smallest detectable difference in radiological progression.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Joints; Male; Methotrexate; Middle Aged; Observer Variation; Prednisolone; Radiography; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 1999 |
Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Regression Analysis; Survival Rate; Vincristine | 1999 |
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Postmenopause; Survival Analysis; Tamoxifen | 1999 |
Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Etoposide; Female; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Uterine Cervical Neoplasms | 1999 |
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cytarabine; Delayed-Action Preparations; Disease Progression; Female; Humans; Injections, Spinal; Lung Neoplasms; Male; Melanoma; Meningeal Neoplasms; Methotrexate; Middle Aged; Neoplasms; Prospective Studies; Survival Rate; Survivors | 1999 |
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Failure | 1999 |
Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Isoxazoles; Leflunomide; Methotrexate; Placebos; Radiography; Sulfasalazine | 2000 |
Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Female; Hand; Humans; Hypertension; Male; Methotrexate; Nausea; Prospective Studies; Radiography; Time Factors; Wrist | 2000 |
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Recombinant Proteins; Remission Induction; Vincristine | 2000 |
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Methotrexate; Outcome Assessment, Health Care; Radiography; Treatment Outcome | 2000 |
Effect of methotrexate on the temporomandibular joint and facial morphology in juvenile rheumatoid arthritis patients.
Topics: Adolescent; Age of Onset; Antirheumatic Agents; Arthritis, Juvenile; Cephalometry; Child; Disease Progression; Double-Blind Method; Facial Asymmetry; Female; Humans; Male; Mandibular Condyle; Maxillofacial Development; Methotrexate; Radiography; Range of Motion, Articular; Statistics, Nonparametric; Temporomandibular Joint Disorders | 2000 |
Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cell Division; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Italy; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Survival Analysis; Treatment Outcome | 2000 |
The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years.
Topics: Alleles; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Double-Blind Method; Female; Gene Frequency; Gold Sodium Thiomalate; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Male; Methotrexate; Rheumatoid Factor | 2000 |
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
Topics: Administration, Oral; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Bone and Bones; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Injections, Subcutaneous; Joints; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2000 |
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Drug Therapy, Combination; Female; Humans; Infliximab; Injections, Intravenous; Joints; Male; Methotrexate; Middle Aged; Tumor Necrosis Factor-alpha | 2000 |
Combination therapy with hydroxychloroquine, gold sodium thiomalate and methotrexate in early rheumatoid arthritis. An open 3-year study.
Topics: Adult; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prospective Studies; Treatment Outcome | 2000 |
Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Disease Progression; Drug Resistance; Humans; Infliximab; Methotrexate; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2001 |
[Low dose steroid therapy in rheumatoid arthritis: a model for therapy of inflammatory diseases?--Results of the LDPT Study].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gold Sodium Thiomalate; Humans; Long-Term Care; Male; Methotrexate; Middle Aged; Prednisolone | 2001 |
[Cisplatin and vinorelbine therapy of previously treated advanced breast cancer (preliminary studies)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Methotrexate; Middle Aged; Skin Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
Topics: Administration, Oral; Aged; Creatine Kinase; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Male; Methotrexate; Middle Aged; Muscle Weakness; Myositis, Inclusion Body; Placebos; Treatment Failure | 2002 |
Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neutropenia; Respiratory Tract Neoplasms; Survival Rate; Treatment Outcome; Vinblastine | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
360 other study(ies) available for methotrexate and Disease Exacerbation
| Article | Year |
|---|---|
Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
Topics: Adalimumab; Adolescent; Antirheumatic Agents; Arthralgia; Arthritis, Juvenile; BNT162 Vaccine; COVID-19; Disease Progression; Etanercept; Fatigue; Female; Headache; Humans; Injection Site Reaction; Male; Methotrexate; Myalgia; SARS-CoV-2; Tumor Necrosis Factor Inhibitors; Young Adult | 2022 |
Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
Topics: Adult; Antimetabolites, Antineoplastic; Chorionic Gonadotropin; Disease Progression; Drug Resistance, Neoplasm; Female; Gestational Trophoblastic Disease; Humans; Hydatidiform Mole; Logistic Models; Methotrexate; Nomograms; Precision Medicine; Predictive Value of Tests; Pregnancy; Risk Assessment | 2021 |
[Ankylosing spondylitis in Senegal: epidemiological, diagnostic, therapeutic and evolutionary features at the Hospital Center University Aristide Le Dantec, Dakar].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Biological Therapy; Cross-Sectional Studies; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Quality of Life; Retrospective Studies; Senegal; Spondylitis, Ankylosing; Young Adult | 2021 |
Low effectiveness of methotrexate in the management of localised scleroderma (morphea) based on an ultrasound activity score.
Topics: Adolescent; Adult; Child; Dermatologic Agents; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Retrospective Studies; Scleroderma, Localized; Severity of Illness Index; Treatment Outcome; Ultrasonography, Doppler, Color; Young Adult | 2021 |
Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Humans; Methotrexate; Purines; Pyrazoles; Sulfonamides; Treatment Outcome | 2022 |
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; Disease Progression; Female; Hematologic Neoplasms; Hospitalization; Humans; Incidence; Lenalidomide; Male; Methotrexate; Pneumonia; Pneumonia, Pneumococcal; Rituximab; Thalidomide | 2022 |
[Linear morphea in saber coup: about a case].
Topics: Disease Progression; Female; Headache; Humans; Methotrexate; Scleroderma, Localized; Skin | 2022 |
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).
Topics: Adolescent; Adult; Biological Factors; Biological Products; Child; COVID-19; Disease Progression; Humans; Methotrexate; Pandemics; Psoriasis; Registries | 2022 |
Chronic Lymphocytic Leukemia With Leptomeningeal Involvement Presenting as an Acute Encephalopathy.
Topics: Adult; Aged; Brain Diseases; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meninges; Methotrexate | 2022 |
Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders.
Topics: Arthritis, Rheumatoid; Disease Progression; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Iatrogenic Disease; Killer Cells, Natural; Lymphoproliferative Disorders; Methotrexate; Prognosis; Tumor Suppressor Protein p53 | 2022 |
Effect of co-medications and potential risk factors of high-dose methotrexate-mediated acute hepatotoxicity in patients with osteosarcoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Chemical and Drug Induced Liver Injury; Child; Cohort Studies; Disease Progression; Female; Humans; Methotrexate; Osteosarcoma; Proton Pump Inhibitors; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination | 2023 |
Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Hemoglobins; Humans; Methotrexate; Registries | 2023 |
Vasculitis Mimicking Pseudo Erysipelas in Systemic Lupus Erythematosus.
Topics: Adult; Biopsy, Needle; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Erysipelas; France; Humans; Immunohistochemistry; Lupus Erythematosus, Systemic; Male; Methotrexate; Prednisone; Risk Assessment; Severity of Illness Index; Treatment Outcome; Vasculitis | 2019 |
'Oil-drop' pigmentation in psoriatic arthritis.
Topics: Ankle Joint; Antirheumatic Agents; Arthralgia; Arthritis, Psoriatic; Disease Progression; Edema; Etanercept; Humans; Hyperpigmentation; Knee Joint; Male; Methotrexate; Middle Aged; Nail Diseases; Nails | 2020 |
Recurrent focal myositis developing into a generalised idiopathic inflammatory myopathy with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Disease Progression; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Immunosuppressive Agents; Methotrexate; Muscle, Skeletal; Myositis; Prednisolone | 2019 |
An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Risk Factors; Sensitivity and Specificity | 2020 |
Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Disease Progression; Female; Heart; Humans; Immunosuppressive Agents; Lung; Male; Methotrexate; Middle Aged; Prognosis; Registries; Scleroderma, Diffuse; Severity of Illness Index; Skin | 2020 |
Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Methotrexate; Middle Aged; Tumor Necrosis Factor Inhibitors | 2020 |
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Topics: Abatacept; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Severity of Illness Index; Treatment Outcome | 2020 |
Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
Topics: Abnormal Karyotype; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Biopsy; Cyclophosphamide; Disease Progression; DNA Nucleotidylexotransferase; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, Follicular; Mercaptopurine; Methotrexate; Middle Aged; Pancytopenia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Rituximab; Salvage Therapy; Splenic Rupture; Splenomegaly; Stomach; Vincristine | 2020 |
Extrapulmonary Sarcoidosis in the Orbit, Brain, and Heart.
Topics: Aged; Antirheumatic Agents; Brain Diseases; Cardiac Pacing, Artificial; Cardiomyopathies; Diagnostic Errors; Disease Progression; Female; Glucocorticoids; Heart Block; Humans; Methotrexate; Orbital Diseases; Peptidyl-Dipeptidase A; Positron Emission Tomography Computed Tomography; Prednisone; Radiography, Thoracic; Sarcoidosis; Tuberculosis | 2020 |
Lateral intraventricular primary central nervous system lymphoma (LIPCNSL): a review.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; China; Craniotomy; Disease Progression; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
A highlight on CD4
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Acids, Omega-3; Fluorescent Antibody Technique; Freund's Adjuvant; Humans; Male; Methotrexate; Rats; Rats, Inbred Strains; Spleen | 2020 |
Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
Topics: Administration, Ophthalmic; Adolescent; Adult; Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Blindness; Cataract; Cataract Extraction; Child; Child, Preschool; Disease Progression; Early Diagnosis; Female; Glaucoma; Glucocorticoids; Humans; Iritis; Male; Methotrexate; Ophthalmologic Surgical Procedures; Pediatrics; Physician's Role; Retrospective Studies; Rheumatologists; Time-to-Treatment; Transition to Adult Care; Transitional Care; Uveitis; Young Adult | 2020 |
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Disease Progression; Drug Therapy, Combination; Humans; Interleukin-6; Methotrexate; Pain Measurement; Patient Reported Outcome Measures; Prognosis; Randomized Controlled Trials as Topic | 2020 |
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Status; Humans; Male; Methotrexate; Pain; Retrospective Studies; Severity of Illness Index | 2020 |
Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study.
Topics: Adult; Aged; Disease Progression; Female; Humans; Immunosuppressive Agents; Lung; Male; Methotrexate; Middle Aged; Progression-Free Survival; Recurrence; Retrospective Studies; Sarcoidosis, Pulmonary; Time Factors; Tomography, X-Ray Computed | 2019 |
Contributing factors of clinical outcomes at 1 year post-diagnosis in early rheumatoid arthritis patients with tightly controlled disease activity in clinical practice: a retrospective study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Joints; Male; Methotrexate; Middle Aged; Rheumatoid Factor; Synovitis | 2021 |
Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Autoantibodies; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Methotrexate; Middle Aged; Myositis; Patient Reported Outcome Measures; Prognosis; Prospective Studies; Sjogren's Syndrome; Time Factors; Young Adult | 2021 |
Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Disease Progression; Humans; Methotrexate; Purines; Pyrazoles; Sulfonamides; Vimentin | 2020 |
Late Onset Nephrogenic Systemic Fibrosis in a Patient with Stage 3 Chronic Kidney Disease: a Case Report.
Topics: Aged; Contrast Media; Dermatologic Agents; Disease Progression; Gadolinium; Glomerular Filtration Rate; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Nephrogenic Fibrosing Dermopathy; Renal Insufficiency, Chronic; Severity of Illness Index; Skin; Ultraviolet Therapy | 2020 |
Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Humans; Methotrexate; Severity of Illness Index; Treatment Outcome | 2020 |
Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Biomarkers, Pharmacological; Cohort Studies; Disease Progression; Female; Humans; Longitudinal Studies; Male; Methotrexate; Middle Aged; Netherlands; Severity of Illness Index | 2020 |
Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Forecasting; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2020 |
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Off-Label Use; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Time Factors | 2020 |
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Bone and Bones; Disease Progression; Down-Regulation; Drugs, Chinese Herbal; Humans; Matrix Metalloproteinase 3; Medicine, Chinese Traditional; Methotrexate; Systematic Reviews as Topic | 2020 |
Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
A rare case of osseous sarcoidosis presenting as lytic lesions 20 years after initial diagnosis.
Topics: Aged; Bone Diseases; Diagnosis, Differential; Disease Progression; Female; Humans; Methotrexate; Positron Emission Tomography Computed Tomography; Sarcoidosis | 2020 |
[Clinical characteristics of elderly and younger onset rheumatoid arthritis].
Topics: Age of Onset; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged | 2020 |
New insights into the treatment of CTD-ILD.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Connective Tissue Diseases; Disease Progression; Humans; Indoles; Interleukin-6; Lung Diseases, Interstitial; Methotrexate; Prevalence; Protein Kinase Inhibitors; Pulmonary Fibrosis; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Vital Capacity | 2021 |
Frontal Fibrosing Alopecia: Successfully Treated with Methotrexate or Just the Natural Disease Progression?
Topics: Alopecia; Dermatologic Agents; Disease Progression; Female; Fibrosis; Humans; Methotrexate; Middle Aged; Scalp | 2020 |
Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Disease Progression; Drug Therapy, Combination; Humans; Hungary; Male; Methotrexate; Retrospective Studies; Treatment Outcome | 2021 |
Methylene tetrahydrofolate reductase A1298C polymorphisms influence the adult sequelae of chemotherapy in childhood-leukemia survivors.
Topics: Adolescent; Adult; Brain; Cancer Survivors; Child; Child, Preschool; Cognition; Diffusion Magnetic Resonance Imaging; Disease Progression; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Folic Acid Antagonists; Genotype; Humans; Intelligence Tests; Magnetic Resonance Imaging; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rest; Retrospective Studies; tau Proteins; Young Adult | 2021 |
Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Burden; Vinca Alkaloids; Young Adult | 2021 |
Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
Topics: Abatacept; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged | 2021 |
Methotrexate and theaflavin-3, 3'-digallate synergistically restore the balance between apoptosis and autophagy in synovial fibroblast of RA: an ex vivo approach with cultured human RA FLS.
Topics: Adult; Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Autophagy; Biflavonoids; Catechin; Cells, Cultured; Disease Progression; Drug Synergism; Female; Fibroblasts; Humans; Inhibitory Concentration 50; Male; Methotrexate; Middle Aged; Osteoarthritis; Synovial Fluid; Synoviocytes | 2021 |
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.
Topics: Adolescent; Adult; Antirheumatic Agents; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Recurrence; Takayasu Arteritis; Time Factors; Treatment Outcome; Young Adult | 2022 |
Dermatologic ultrasound in the management of childhood linear morphea.
Topics: Arm; Biopsy; Child; Dermatologic Agents; Disease Progression; Female; Humans; Hyperpigmentation; Methotrexate; Scleroderma, Localized; Skin; Subcutaneous Tissue; Ultrasonography; Ultrasonography, Interventional | 2021 |
Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Disease Progression; Female; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged | 2017 |
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Biomarkers; Child; Child, Preschool; Cohort Studies; Cytokines; Disease Progression; Female; Humans; Infant; Male; Methotrexate; Prospective Studies; Treatment Outcome | 2017 |
[
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Disease Progression; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Urinary Bladder Neoplasms; Vinblastine | 2017 |
Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Collagen; Disease Progression; Drug Administration Schedule; Female; Methotrexate; Rats; Rats, Inbred Lew | 2017 |
Tongue Involvement in Parry-Romberg Syndrome.
Topics: Adolescent; Atrophy; Child, Preschool; Disease Progression; Facial Hemiatrophy; Female; Glucocorticoids; Humans; Methotrexate; Prednisone; Tongue | 2017 |
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Early Diagnosis; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Treatment Outcome | 2017 |
Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers, Pharmacological; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Prospective Studies; Sensitivity and Specificity; Surveys and Questionnaires; Triggering Receptor Expressed on Myeloid Cells-1; Young Adult | 2017 |
Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.
Topics: Adalimumab; Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Disease Progression; Etanercept; Female; Follow-Up Studies; Humans; Infliximab; Logistic Models; Male; Methotrexate; Retrospective Studies; Sacroiliitis; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Kaplan-Meier Estimate; Linear Models; Longitudinal Studies; Male; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Remission Induction; Risk Factors; Sulfasalazine; Time Factors; Treatment Outcome | 2017 |
Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; Crohn Disease; Databases, Factual; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Infliximab; Kaplan-Meier Estimate; Male; Methotrexate; Multivariate Analysis; Proportional Hazards Models; Remission Induction; Risk Factors; Salvage Therapy; Time Factors; Treatment Outcome; Young Adult | 2017 |
Progressive nodular histiocytosis improved by methotrexate.
Topics: Aged; Disease Progression; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive Agents; Methotrexate | 2017 |
Severe Aortic Valve Regurgitation in Relapsing Polychondritis.
Topics: Adalimumab; Adult; Antirheumatic Agents; Aorta; Aortic Valve Insufficiency; Disease Progression; Echocardiography; Female; Humans; Methotrexate; Nose Deformities, Acquired; Polychondritis, Relapsing; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vascular Grafting | 2018 |
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Ethics, Research; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Remission Induction; Research Design; Research Subjects; Time Factors; Treatment Outcome; Vulnerable Populations | 2018 |
Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chitinase-3-Like Protein 1; Cyclosporine; Disease Progression; Female; Forefoot, Human; Hand Joints; Humans; Interleukin-6; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Randomized Controlled Trials as Topic; Remission Induction; Severity of Illness Index; Vascular Endothelial Growth Factor A | 2018 |
Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Male; Methotrexate; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Time Factors; Withholding Treatment; Young Adult | 2018 |
Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
Topics: Abatacept; Adalimumab; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prognosis; Quality-Adjusted Life Years | 2018 |
Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antineoplastic Agents; Arthritis, Juvenile; Biological Products; Disease Progression; Drug Resistance, Multiple; Female; Glucocorticoids; Humans; Macrophage Activation Syndrome; Medication Therapy Management; Methotrexate; Monitoring, Immunologic; Remission Induction; Young Adult | 2019 |
Rheumatoid Arthritis Magnetic Resonance Imaging Score Predicts Therapy Response: Results of the German ArthroMark Cohort.
Topics: Adult; Aged; Anti-Citrullinated Protein Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Germany; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prospective Studies; Rheumatoid Factor; Severity of Illness Index | 2018 |
Can a disaster affect rheumatoid arthritis status? A retrospective cohort study after the 2011 triple disaster in Fukushima, Japan.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Continuity of Patient Care; Disease Progression; Earthquakes; Female; Fukushima Nuclear Accident; Humans; Japan; Logistic Models; Male; Medical Records; Methotrexate; Middle Aged; Prognosis; Radiation Exposure; Residence Characteristics; Retrospective Studies; Risk Factors; Time Factors; Tsunamis | 2018 |
Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Treatment Outcome; United Kingdom | 2018 |
Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis.
Topics: Abatacept; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Methotrexate | 2019 |
Cerebral granulomatosis as a manifestation of Crohn's disease.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Brain Diseases; Crohn Disease; Disease Progression; Female; Granuloma; Humans; Immunosuppressive Agents; Methotrexate; Vasculitis, Central Nervous System | 2018 |
Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma.
Topics: Adolescent; Age of Onset; Antibodies, Antinuclear; Child; Child, Preschool; Cohort Studies; Disease Progression; Female; Glucocorticoids; Humans; Male; Medication Adherence; Methotrexate; Prognosis; Prospective Studies; Recurrence; Registries; Remission Induction; Retrospective Studies; Scleroderma, Localized | 2019 |
Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Topics: Adult; Aged; Brain; Central Nervous System Neoplasms; Disease Progression; Eye; Eye Neoplasms; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Prospective Studies; Risk; Young Adult | 2019 |
A lump on the palate.
Topics: Antirheumatic Agents; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Granuloma; Humans; Hydroxychloroquine; Injections, Intralesional; Methotrexate; Middle Aged; Mouth; Palate; Sarcoidosis; Triamcinolone | 2019 |
CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cells, Cultured; Disease Progression; Drug Therapy, Combination; G-Protein-Coupled Receptor Kinase 2; Glucosides; Leflunomide; Male; Methotrexate; Monoterpenes; Random Allocation; Rats; Rats, Sprague-Dawley | 2019 |
Predictors for Complicated Disease Course after Stepping Down from Combination to Antitumor Necrosis Factor Alpha Monotherapy in Children with Inflammatory Bowel Disease.
Topics: Adalimumab; Adolescent; Child; Colitis, Ulcerative; Crohn Disease; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Purines; Retrospective Studies; Risk Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2020 |
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Risk Factors; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2019 |
[Late-onset rheumatoid arthritis: clinical, biological, and therapeutic features About a retrospective study].
Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Comorbidity; Disease Progression; Female; Humans; Male; Methotrexate; Referral and Consultation; Retrospective Studies | 2019 |
Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.
Topics: Abatacept; Adult; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Odds Ratio; Prognosis; Proportional Hazards Models; Treatment Outcome | 2019 |
Evaluation of the expression of the stromal cell-derived factor-1 alpha (CXCL 12) in psoriatic patients after treatment with Methotrexate.
Topics: Adult; Arthritis, Psoriatic; Biopsy; Case-Control Studies; Chemokine CXCL12; Disease Progression; Down-Regulation; Female; Humans; Keratinocytes; Male; Methotrexate; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome | 2020 |
Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Female; Herpesvirus 4, Human; Humans; Immunocompromised Host; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Opportunistic Infections; Progression-Free Survival; Risk Assessment; Risk Factors; RNA, Viral; Time Factors | 2019 |
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Prospective Studies; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Periodontal treatment prevents arthritis in mice and methotrexate ameliorates periodontal bone loss.
Topics: Alveolar Bone Loss; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Autoantibodies; Chlorhexidine; Collagen; Disease Progression; Injections, Intraperitoneal; Male; Methotrexate; Metronidazole; Mice; Mice, Inbred DBA; Periodontitis; Porphyromonas gingivalis; X-Ray Microtomography | 2019 |
Systemic and prophylactic intrathecal chemotherapy for primary adrenal lymphoma: A retrospective study of 20 case reports.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mortality; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2019 |
[Renal amyloidosis complicating adult onset Still's disease: about three cases].
Topics: Adrenal Cortex Hormones; Adult; Amyloidosis; Biopsy, Needle; Colchicine; Disease Progression; Female; Humans; Kidney Failure, Chronic; Methotrexate; Middle Aged; Nephrotic Syndrome; Renal Insufficiency; Still's Disease, Adult-Onset | 2019 |
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2019 |
Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Body Weight; Collagen Type II; Disease Progression; Dose-Response Relationship, Drug; Edema; Inhibitory Concentration 50; Male; Methotrexate; Models, Biological; Rats; Rats, Inbred Lew; Swine; Time Factors | 2013 |
Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; Disease Progression; Disease-Free Survival; Female; Herpesvirus 4, Human; Humans; Immunoglobulin Heavy Chains; Immunohistochemistry; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Regression Analysis; Treatment Outcome; Virus Activation | 2013 |
Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis.
Topics: Antitubercular Agents; Choroiditis; Disease Progression; Drug Therapy, Combination; Female; Fluorescein Angiography; Humans; Immunosuppressive Agents; Intravitreal Injections; Methotrexate; Middle Aged; Tuberculin Test; Tuberculosis, Ocular; Visual Acuity | 2013 |
Derailed B cell homeostasis in patients with mixed connective tissue disease.
Topics: Adrenal Cortex Hormones; Antigens, CD; Autoantibodies; B-Lymphocyte Subsets; Cells, Cultured; Cyclophosphamide; Disease Progression; Homeostasis; Humans; Immunoglobulin Class Switching; Immunologic Memory; Immunophenotyping; Methotrexate; Mixed Connective Tissue Disease; Plasma Cells; Ribonucleoprotein, U1 Small Nuclear | 2013 |
Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cohort Studies; Disease Progression; Etanercept; Female; Foot Joints; Hand Joints; Humans; Immunoglobulin G; Infliximab; Logistic Models; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prospective Studies; Radiography; Receptors, Tumor Necrosis Factor; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Treatment of rheumatoid arthritis with methotrexate in Congolese patients.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Democratic Republic of the Congo; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Poverty; Prednisone; Remission Induction; Steroids; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2013 |
Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon-induced apoptosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Biopsy; Case-Control Studies; Cell Line; Disease Progression; Female; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Recombinant Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Tumor Suppressor Proteins; Up-Regulation; Young Adult | 2013 |
Irreversible myelopathy associated with nelaribine in T-cell acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Disease Progression; Fatal Outcome; Humans; Injections, Spinal; Male; Mediastinal Neoplasms; Mercaptopurine; Methotrexate; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Quadriplegia; Spinal Cord; Spinal Cord Diseases | 2013 |
Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Female; Humans; Interleukin-6; Male; Methotrexate; Middle Aged; Prospective Studies; Radiography; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Female; Glucocorticoids; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prognosis; Radiography; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2013 |
Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Biological Products; Disease Progression; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Rheumatoid Factor; Severity of Illness Index; Treatment Outcome | 2013 |
Alterations in both the activatory and inhibitory potential of peripheral blood CD4+ T cells in rheumatoid arthritis patients correlate with disease progression.
Topics: Antigens, CD; Arthritis, Rheumatoid; Biomarkers; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Proliferation; CTLA-4 Antigen; Disease Progression; Female; Humans; Inflammation; Lymphocyte Activation; Male; Methotrexate; Middle Aged; Tumor Necrosis Factor-alpha | 2014 |
Hypopigmented micropapules in apparently quiescent morphea lesions: a manifestation of disease activity.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Female; Folic Acid; Humans; Hypopigmentation; Immunosuppressive Agents; Male; Methotrexate; Methylprednisolone; Mycophenolic Acid; Scleroderma, Localized; Vitamin B Complex | 2013 |
Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Practice Guidelines as Topic; Remission Induction; Severity of Illness Index; Standard of Care; Treatment Outcome | 2013 |
Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Cohort Studies; Disease Progression; Female; Humans; Logistic Models; Longitudinal Studies; Male; Methotrexate; Middle Aged; Multivariate Analysis; Peptides, Cyclic; Prognosis; Prospective Studies; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Genitalia, Female; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Middle Aged; Neoplasm Invasiveness; Prednisone; Prognosis; Recurrence; Retrospective Studies; Rituximab; Vincristine; Young Adult | 2014 |
Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2015 |
Methotrexate re-challenge for recurrent primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Humans; Male; Methotrexate; Synovitis; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor A | 2014 |
Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Disease Progression; Female; Germany; Humans; Male; Methotrexate; Outcome Assessment, Health Care; Registries; Retrospective Studies; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome | 2014 |
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.
Topics: Aged; Arthritis, Rheumatoid; Disease Progression; Drug Interactions; Drug Therapy, Combination; Female; Finland; Humans; Incidence; Isoxazoles; Leflunomide; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Prognosis; Risk Assessment; Sampling Studies; Survival Rate | 2014 |
Advantages of a combined rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for hand and feet: does the RAMRIS of the hand alone underestimate disease activity and progression?
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Disease Progression; Foot Deformities, Acquired; Hand Deformities, Acquired; Humans; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Observer Variation; Prospective Studies; Reproducibility of Results; Severity of Illness Index; Young Adult | 2014 |
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation.
Topics: Age Factors; Aged; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Positron-Emission Tomography; Prednisone; Prognosis; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Rituximab; Sex Factors; Time Factors; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Vincristine | 2014 |
N-feruloylserotonin in preventive combination therapy with methotrexate reduced inflammation in adjuvant arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Freund's Adjuvant; Inflammation; Male; Methotrexate; NF-kappa B; Rats; Rats, Inbred Lew; Serotonin | 2014 |
Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prednisolone; Remission Induction; Rheumatoid Factor; Sex Factors; Treatment Outcome | 2014 |
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Foot Joints; Hand Joints; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Radiography; Retrospective Studies; Tacrolimus; Treatment Outcome | 2015 |
Optic nerve involvement of Waldenström's macroglobulinemia: with autopsy findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Blindness; Cytarabine; Disease Progression; Fatal Outcome; Humans; Lymphocytes; Magnetic Resonance Imaging; Male; Methotrexate; Optic Nerve; Prednisolone; Waldenstrom Macroglobulinemia | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Female; Humans; Hungary; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Data Interpretation, Statistical; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Joints; Male; Methotrexate; Middle Aged; Models, Biological; Predictive Value of Tests; Severity of Illness Index; Sulfasalazine; Time Factors; Treatment Outcome; Young Adult | 2015 |
[No best treatment for severe outbreaks: Maintenance, the key in colitis].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Disease Management; Disease Progression; Humans; Immunosuppressive Agents; Infliximab; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Patient Preference; Practice Patterns, Physicians'; Salicylates; Tumor Necrosis Factor-alpha | 2011 |
Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Topics: Animals; Antineoplastic Agents; Biopsy; Clone Cells; Cytarabine; Deoxycytidine Kinase; Dexamethasone; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Dosage; Heterografts; Humans; Male; Methotrexate; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Peptide Synthases; Polymorphism, Single Nucleotide; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Radiation Chimera; Sequence Analysis, DNA; Vincristine | 2015 |
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
Topics: Adult; Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Autoantibodies; Cohort Studies; Disease Progression; Female; Humans; Hydroxychloroquine; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Proportional Hazards Models; Remission Induction; Sulfasalazine; Time-to-Treatment; Treatment Outcome | 2015 |
Successful Elimination of Methotrexate by Continuous Veno-venous Haemofiltration in a Psoriatic Patient with Methotrexate Intoxication.
Topics: Disease Progression; Drug Overdose; Fatal Outcome; Hemofiltration; Humans; Male; Methotrexate; Middle Aged; Palliative Care; Psoriasis; Risk Assessment; Severity of Illness Index | 2015 |
Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease.
Topics: Adult; Aged; Aged, 80 and over; Behcet Syndrome; Chronic Disease; Disease Progression; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Nervous System Diseases; Prognosis; Retrospective Studies; Treatment Outcome | 2015 |
Oral and IV dosages of doxorubicin-methotrexate loaded- nanoparticles inhibit progression of oral cancer by down- regulation of matrix Methaloproteinase 2 expression in vivo.
Topics: 4-Nitroquinoline-1-oxide; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Male; Matrix Metalloproteinase 2; Methotrexate; Mouth Neoplasms; Nanoparticles; Quinolones; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Serum KL-6 elevation and possible pulmonary involvement in patients with rheumatoid arthritis treated with biological agents.
Topics: Arthritis, Rheumatoid; Biological Factors; Demography; Disease Progression; Fibrosis; Humans; Lung; Methotrexate; Middle Aged; Mucin-1; Radiography, Thoracic; Time Factors; Tomography, X-Ray Computed | 2014 |
Case 216: hypertrophic spinal pachymeningitis.
Topics: Combined Modality Therapy; Contrast Media; Diagnosis, Differential; Disease Progression; Dura Mater; Enzyme Inhibitors; Glucocorticoids; Humans; Laminectomy; Magnetic Resonance Imaging; Meningitis; Methotrexate; Prednisone; Spinal Diseases | 2015 |
Predictors of longterm changes in body mass index in rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hospitals, Veterans; Humans; Linear Models; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prednisone; Registries; Risk Assessment; Sex Factors; Time Factors; Treatment Outcome; United States; Weight Loss | 2015 |
Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers, Pharmacological; Bone and Bones; Bone Morphogenetic Proteins; Disease Progression; Female; Genetic Markers; Humans; Intercellular Signaling Peptides and Proteins; Methotrexate; Middle Aged; Osteoprotegerin; RANK Ligand | 2015 |
Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Rheumatoid Factor; Severity of Illness Index; Treatment Outcome | 2015 |
The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome | 2015 |
Aggressive Therapy Reduces Disease Activity without Skeletal Damage Progression in Chronic Nonbacterial Osteomyelitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Bone Density Conservation Agents; Child; Diphosphonates; Disease Progression; Drug Therapy, Combination; Female; Humans; Imidazoles; Infliximab; Magnetic Resonance Imaging; Male; Methotrexate; Osteomyelitis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Zoledronic Acid | 2015 |
[A case of neurolymphomatosis presenting extended involvement of spinal nerve roots].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cerebrospinal Fluid; Cyclophosphamide; Cytodiagnosis; Disease Progression; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Prednisone; Quadriplegia; Remission Induction; Rituximab; Spinal Nerve Roots; Vincristine | 2015 |
Diffuse systemic sclerosis presenting as Meniere's disease-like symptoms as part of autoimmune inner ear disease.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arrhythmias, Cardiac; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Hearing Loss, Sensorineural; Humans; Labyrinth Diseases; Meniere Disease; Methotrexate; Monitoring, Immunologic; Prednisone; Scleroderma, Systemic | 2015 |
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Memory Disorders; Methotrexate; Middle Aged; Mycosis Fungoides; Nystagmus, Pathologic; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes | 2015 |
Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Biological Products; Carotid Intima-Media Thickness; Case-Control Studies; Cyclosporine; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prevalence; Severity of Illness Index | 2015 |
[Biological treatment in severe Still's disease--a case report].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Juvenile; Certolizumab Pegol; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Interleukin-6; Methotrexate; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2015 |
Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Bone Density; Disease Progression; Female; Germany; Hand Joints; Humans; Isoxazoles; Leflunomide; Longitudinal Studies; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Radiographic Image Interpretation, Computer-Assisted; Retrospective Studies; Time Factors; Treatment Outcome | 2015 |
[CENTRAL NERVOUS SYSTEM INVOLVEMENT IN GRANULOMATOSIS WITH POLYANGIITIS (GPA)].
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Antimetabolites, Antineoplastic; Antineoplastic Protocols; Brain Neoplasms; Craniotomy; Disease Progression; Fatal Outcome; Female; Frozen Sections; Granulomatosis with Polyangiitis; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Methotrexate; Radiotherapy; Seizures; Temporal Lobe; Tomography, X-Ray Computed; Unconsciousness | 2015 |
Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.
Topics: Adult; Cyclosporine; Dermatomyositis; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Prednisolone; Prognosis; Retrospective Studies; Survival Rate; Time Factors | 2016 |
[18F]fluorodeoxyglucose uptake as a predictor of large joint destruction in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Fluorodeoxyglucose F18; Foot Joints; Hand Joints; Humans; Male; Methotrexate; Middle Aged; Prednisolone; Radiography; Radionuclide Imaging; Retrospective Studies | 2016 |
Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Autoantibodies; Cohort Studies; Disease Progression; Female; Finger Joint; Foot Joints; Hand Joints; HLA-DRB1 Chains; Humans; Japan; Linear Models; Male; Methotrexate; Middle Aged; Netherlands; Peptides, Cyclic; Radiography; Rheumatoid Factor; Severity of Illness Index; White People | 2015 |
Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis.
Topics: Adult; Aged; Alleles; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Female; Genetic Predisposition to Disease; HLA-DRB1 Chains; Humans; Logistic Models; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Rheumatoid Factor; Risk Factors; Smoking; Texas | 2015 |
MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Edema; Etanercept; Female; Glucocorticoids; Hand Bones; Humans; Inflammation; Magnetic Resonance Imaging; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Prednisolone; Prognosis; Remission Induction; Severity of Illness Index; Synovitis; Tenosynovitis; Wrist Joint | 2016 |
Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Follow-Up Studies; Humans; Joints; Methotrexate; Netherlands; Pain; Pain Measurement; Recurrence; Registries; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2015 |
Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Molecular Targeted Therapy; Pain Measurement; Randomized Controlled Trials as Topic; Risk Assessment; Time Factors; Treatment Outcome | 2015 |
Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate.
Topics: Adolescent; Adult; Aged; Child; Disease Progression; Drug Resistance; Drug Substitution; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Remission Induction; Retrospective Studies; Scleroderma, Localized; Severity of Illness Index; Skin; Time Factors; Treatment Outcome; Young Adult | 2016 |
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome | 2016 |
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2016 |
The Longterm Effect of Early Intensive Treatment of Seniors with Rheumatoid Arthritis: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement; Canada; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Remission Induction; Time Factors; Time-to-Treatment; Treatment Outcome | 2016 |
MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.
Topics: Aged; Antirheumatic Agents; Area Under Curve; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Female; Humans; Male; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Remission Induction; ROC Curve; Sensitivity and Specificity | 2016 |
Clinical Reasoning: A 71-year-old man with rapidly progressive dementia.
Topics: Aged; Brain Neoplasms; Cognition Disorders; Critical Care; Dementia; Diagnosis, Differential; Disease Progression; Humans; Lymphoma; Male; Methotrexate; Physical Examination; Treatment Outcome | 2016 |
Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Colombia; Disease Progression; Female; Follow-Up Studies; HLA-DRB1 Chains; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Prospective Studies; Radiography; Remission Induction; Rheumatoid Factor; Severity of Illness Index | 2016 |
Acute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for Pneumocystis jirovecii pneumonia: a case report.
Topics: Acute Disease; Aged; Anti-Infective Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Etanercept; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Methotrexate; Pneumocystis carinii; Pneumonia, Pneumocystis; Polymyxin B; Trimethoprim, Sulfamethoxazole Drug Combination | 2016 |
Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Medication Adherence; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2016 |
Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage.
Topics: Adalimumab; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Denmark; Disease Progression; Female; Humans; Joints; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Patient Acuity; Radiography; Remission Induction; Research Design; Statistics as Topic; Synovitis; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha; Ultrasonography | 2017 |
Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis.
Topics: Aged; Biomarkers; Diagnosis, Differential; Diagnostic Errors; Disease Progression; Female; Humans; Immunosuppressive Agents; Methotrexate; Muscle, Skeletal; Myositis, Inclusion Body | 2016 |
Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disease Progression; Drug Therapy, Combination; Humans; Male; Methotrexate; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome; Twins, Monozygotic; White People | 2016 |
The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Specimen Banks; Biomarkers; Cohort Studies; Disease Progression; Female; Foot; Hand; Humans; Male; Methotrexate; Middle Aged; Patient Acceptance of Health Care; Precision Medicine; Prognosis; Quality of Life; Radiography; Scotland; Severity of Illness Index; Specimen Handling; Translational Research, Biomedical | 2016 |
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Leucovorin; Liver; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Methotrexate; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prednisone; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Recurrence; Rituximab; Statistics, Nonparametric; Vincristine; Young Adult | 2017 |
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Topics: Adalimumab; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Colitis, Ulcerative; Colon; Constriction, Pathologic; Crohn Disease; Deprescriptions; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Ileum; Immunologic Factors; Incidence; Inflammatory Bowel Diseases; Infliximab; Male; Mesalamine; Methotrexate; Middle Aged; Proportional Hazards Models; Protective Factors; Recurrence; Remission Induction; Retreatment; Retrospective Studies; Risk Factors; Tumor Necrosis Factor-alpha; Young Adult | 2017 |
Left ventricular function at two-year follow-up in treatment-naive rheumatoid arthritis patients is associated with anti-cyclic citrullinated peptide antibody status: a cohort study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Case-Control Studies; Cohort Studies; Coronary Artery Disease; Denmark; Disease Progression; Echocardiography; Female; Humans; Male; Methotrexate; Middle Aged; Peptides, Cyclic; Tomography, X-Ray Computed; Vascular Calcification; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Biological Factors; Carotid Artery Diseases; Carotid Intima-Media Thickness; Case-Control Studies; Disease Progression; Female; Femoral Artery; Humans; Male; Methotrexate; Middle Aged; Plaque, Atherosclerotic; Prednisolone; Vascular Stiffness | 2017 |
Effects of antirheumatic drug underutilization on rheumatoid arthritis disease activity.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome | 2017 |
Course, Outcome and Complications in Children with Systemic Onset Juvenile Idiopathic Arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Juvenile; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Humans; India; Infant; Male; Methotrexate; Remission Induction; Severity of Illness Index | 2017 |
Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
Topics: Adalimumab; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome | 2017 |
[Generalized circumscribed scleroderma with blisters].
Topics: Administration, Oral; Administration, Topical; Biopsy; Blister; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Penicillins; Prednisolone; Recurrence; Scleroderma, Localized; Skin; Ultraviolet Therapy | 2017 |
High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Comorbidity; Disease Progression; Doxorubicin; Female; Humans; Kidney Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Sickle Cell Trait; Treatment Outcome; Vinblastine | 2008 |
[Treatment of advanced penile cancer. Do we need new methods for chemotherapy?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Disease Progression; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Palliative Care; Penile Neoplasms | 2008 |
Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Receptors, Tumor Necrosis Factor; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Lung Diseases, Interstitial; Methotrexate | 2008 |
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.
Topics: Adult; Algorithms; Bilirubin; Biopsy; Disease Progression; Fibrosis; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Methotrexate; Middle Aged; Multicenter Studies as Topic; Prognosis; Treatment Outcome | 2008 |
Juvenile localised scleroderma: a retrospective review of response to systemic treatment.
Topics: Adolescent; Adolescent Medicine; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antirheumatic Agents; Child; Child, Preschool; Connective Tissue; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Methylprednisolone; Penicillamine; Retrospective Studies; Scleroderma, Localized | 2008 |
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Feasibility Studies; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Universities; Urinary Bladder Neoplasms; Vinblastine | 2009 |
Subtle changes in individual joints result in both positive and negative change scores in a patient: results from a clinical trial in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Observer Variation; Receptors, Tumor Necrosis Factor; Reproducibility of Results; Treatment Outcome | 2009 |
Therapeutic vignette: old and new drugs in mixed connective tissue disease.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Comorbidity; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mixed Connective Tissue Disease; Potassium Iodide; Prednisone; Skin Ulcer; Tumor Necrosis Factor-alpha; Vasculitis | 2008 |
Pharmacokinetics of cisplatin and methotrexate after M-VAC chemotherapy for advanced urothelial cancer in hemodialysis patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Doxorubicin; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Renal Dialysis; Vinblastine | 2008 |
The up-regulation of monocyte chemoattractant protein-1 (MCP-1) in Ea.hy 926 endothelial cells under long-term low folate stress is mediated by the p38 MAPK pathway.
Topics: Atherosclerosis; Cell Line; Chemokine CCL2; Cytokines; Disease Progression; Enzyme Inhibitors; Folic Acid; Folic Acid Antagonists; Humans; Inflammation; Methotrexate; Models, Biological; p38 Mitogen-Activated Protein Kinases; Transcription, Genetic; Up-Regulation | 2009 |
Primary central nervous system lymphoma: an unusual presentation.
Topics: Adult; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Methotrexate | 2008 |
Marked regression of pulmonary rheumatoid nodules under etanercept therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Lung; Methotrexate; Middle Aged; Multiple Pulmonary Nodules; Receptors, Tumor Necrosis Factor; Tomography, X-Ray Computed; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway.
Topics: Adult; Age Distribution; Antirheumatic Agents; Arthritis, Psoriatic; Cohort Studies; Confidence Intervals; Disease Progression; Female; HLA-B27 Antigen; Humans; Incidence; Male; Methotrexate; Norway; Odds Ratio; Poisson Distribution; Probability; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Distribution; Spondylarthritis; Statistics, Nonparametric | 2009 |
[Present status and future perspective of RPGN in Japan].
Topics: Adrenal Cortex Hormones; Azathioprine; Blood Component Removal; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Humans; Immunosuppressive Agents; Japan; Methotrexate; Multicenter Studies as Topic; Prognosis; Recurrence; Severity of Illness Index; Surveys and Questionnaires | 2009 |
Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthroplasty; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Joints; Male; Methotrexate; Middle Aged; Prospective Studies; Receptors, Tumor Necrosis Factor; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha; Young Adult | 2009 |
Locomotion and muscle mass measures in a murine model of collagen-induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Body Weight; Cachexia; Disability Evaluation; Disease Models, Animal; Disease Progression; Gait Disorders, Neurologic; Image Processing, Computer-Assisted; Locomotion; Male; Methotrexate; Mice; Mice, Inbred DBA; Muscle, Skeletal; Muscular Atrophy; Severity of Illness Index; Treatment Outcome; Video Recording | 2009 |
Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer.
Topics: Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Disease Progression; Methotrexate; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Survival Analysis | 2010 |
Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
Topics: Adult; Amlodipine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Fingers; Follow-Up Studies; Hand Dermatoses; Humans; Methotrexate; Receptor, Endothelin A; Risk Assessment; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Treatment Outcome | 2009 |
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Finger Joint; Humans; Isoxazoles; Japan; Leflunomide; Male; Methotrexate; Middle Aged; Radiography; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Toe Joint; Treatment Outcome; Wrist Joint | 2009 |
[Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Topics: Adolescent; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Cephalosporins; Child; Child, Preschool; Cross Infection; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Female; Humans; Itraconazole; Male; Mercaptopurine; Methotrexate; Mouth Diseases; Mycoses; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Respiratory Tract Infections; Vincristine | 2009 |
Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2009 |
Juvenile idiopathic arthritis in adulthood and orthopaedic intervention.
Topics: Adolescent; Adult; Aged; Arthritis, Juvenile; Arthroplasty, Replacement; Combined Modality Therapy; Disease Progression; Female; Hospitals, Teaching; Humans; Immunosuppressive Agents; Joints; Male; Methotrexate; Middle Aged; Retrospective Studies; Time Factors; Young Adult | 2009 |
CXCL13 and CXCL12 in central nervous system lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Central Nervous System Neoplasms; Chemokine CXCL12; Chemokine CXCL13; Disease Progression; Female; Humans; Ifosfamide; Lymphoma; Male; Methotrexate; Middle Aged; Prognosis | 2009 |
Epstein-Barr virus negative large B-cell lymphoma during long term immunomodulatory therapy for T-cell large granular lymphocytic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Immunosuppressive Agents; Leukemia, Large Granular Lymphocytic; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Treatment Outcome; Vincristine | 2010 |
[Therapeutic management of central nervous system lymphomas in a single hematological institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Drug Administration Schedule; Epidural Space; Female; Humans; Hungary; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2009 |
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Histiocytosis, Langerhans-Cell; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Positron-Emission Tomography; Prednisone; Remission Induction; Retrospective Studies; Vincristine; Young Adult | 2010 |
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Glucocorticoids; Health Care Costs; Humans; Immunologic Factors; Methotrexate; Quality-Adjusted Life Years; Radiography; Treatment Outcome | 2009 |
A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Disease Progression; Female; Glucocorticoids; Health Status; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Quality of Life; Registries; Severity of Illness Index; Surveys and Questionnaires; Sweden; Treatment Outcome | 2010 |
Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu's arteritis.
Topics: Amyloidosis; Aorta, Thoracic; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Fluorodeoxyglucose F18; Glucocorticoids; Humans; Immunosuppressive Agents; Methotrexate; Positron-Emission Tomography; Prednisolone; Serum Amyloid A Protein; Takayasu Arteritis; Treatment Outcome; Young Adult | 2010 |
Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Inhibitor of Apoptosis Proteins; Male; Methotrexate; Microtubule-Associated Proteins; Middle Aged; Peptides, Cyclic; Prospective Studies; Proto-Oncogene Mas; Radiography; Rheumatoid Factor; Sulfasalazine; Survivin; Treatment Outcome | 2010 |
Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
Topics: Age of Onset; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Data Interpretation, Statistical; Disease Progression; DNA; Endpoint Determination; Genotype; Humans; Methotrexate; Odds Ratio; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2010 |
Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Disease Progression; Humans; Methotrexate; Middle Aged; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2010 |
A case of rapid progression and vision loss in a patient with primary intraocular lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blindness; Disease Progression; Eye Neoplasms; Fatal Outcome; Female; Humans; Lymphoma, B-Cell; Magnetic Resonance Imaging; Methotrexate; Procarbazine; Vincristine | 2010 |
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Belgium; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Health Surveys; Humans; Infliximab; Infusions, Intravenous; Kaplan-Meier Estimate; Longitudinal Studies; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome | 2010 |
Intrathecal methotrexate treatment in multiple sclerosis.
Topics: Adult; Aged; Disease Progression; Female; Humans; Immunosuppressive Agents; Injections, Spinal; Male; Methotrexate; Middle Aged; Multiple Sclerosis; Recovery of Function; Retrospective Studies | 2010 |
Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholagogues and Choleretics; Colchicine; Disease Progression; Drug Therapy, Combination; Fibrosis; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis, Biliary; Liver Function Tests; Methotrexate; Treatment Failure; Ursodeoxycholic Acid | 2010 |
Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?
Topics: Alkaline Phosphatase; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Biomarkers; Bone Resorption; Collagen Type I; Disease Progression; Drug Therapy, Combination; Female; Humans; Infliximab; Methotrexate; Middle Aged; Peptides; Prognosis; Psoriasis | 2011 |
Advanced aggressive fibromatosis: Effective palliation with chemotherapy.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease Progression; Doxorubicin; Female; Fibromatosis, Aggressive; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Palliative Care; Polyethylene Glycols; Radiography; Registries; Retrospective Studies; Treatment Outcome; Vinblastine; Young Adult | 2011 |
Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prognosis; Recurrence; Republic of Korea; Retrospective Studies; Survival Analysis; Young Adult | 2011 |
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Disease Progression; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Logistic Models; Male; Methotrexate; Prognosis; Radiography; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2011 |
Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study.
Topics: Adult; Alternative Splicing; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Infliximab; Longitudinal Studies; Male; Matrix Metalloproteinase 1; Methotrexate; Middle Aged; Prospective Studies; Radiography; Receptors, Tumor Necrosis Factor, Type II; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population.
Topics: Adolescent; Adult; Asian People; China; Disability Evaluation; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Female; Hip Joint; Humans; Immunoglobulin G; Immunologic Factors; Male; Methotrexate; Radiography; Receptors, Tumor Necrosis Factor; Recovery of Function; Spondylitis, Ankylosing; Time Factors; Treatment Outcome; Young Adult | 2012 |
Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Severity of Illness Index; Young Adult | 2011 |
Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infliximab; Male; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2011 |
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine; Vindesine | 2011 |
Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cysteine; Disease Progression; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Risk Factors; Severity of Illness Index; Sulfasalazine; Tacrolimus; Treatment Outcome | 2012 |
[Certolizumab pegol].
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Male; Methotrexate; Mice; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Pregnancy; Pregnancy Complications; Quality of Life; Tumor Necrosis Factor-alpha | 2011 |
Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dactinomycin; Disease Progression; Etoposide; Female; Gestational Trophoblastic Disease; Humans; India; Liver Neoplasms; Methotrexate; Middle Aged; Pregnancy; Retrospective Studies; Risk; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2011 |
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Disease Progression; Drug Therapy, Combination; Female; Humans; Japan; Male; Methotrexate; Middle Aged; Radiography; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Dose-Response Relationship, Drug; Elasticity; Elasticity Imaging Techniques; Female; Follow-Up Studies; Humans; Liver; Liver Cirrhosis; Male; Methotrexate; Middle Aged; Retrospective Studies | 2012 |
Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infliximab; Joints; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Female; Glucocorticoids; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Treatment Outcome; Withholding Treatment | 2012 |
Polymerized-type I collagen induces upregulation of Foxp3-expressing CD4 regulatory T cells and downregulation of IL-17-producing CD4⁺ T cells (Th17) cells in collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; CD4 Antigens; Collagen Type I; Disease Models, Animal; Disease Progression; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Immunomodulation; Immunotherapy; Interleukin-17; Joints; Methotrexate; Mice; Mice, Inbred DBA; Polymerization; T-Lymphocytes, Regulatory; Th17 Cells | 2012 |
Certolizumab: efficacy and safety profile of a novel pegylated TNF-alpha blocking agent.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Certolizumab Pegol; Disease Progression; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Immunologic Factors; Methotrexate; Polyethylene Glycols; Quality of Life; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infliximab; Logistic Models; Male; Methotrexate; Pain Measurement; Prednisone; Prognosis; Radiography; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Sulfasalazine; Surveys and Questionnaires; Treatment Outcome | 2012 |
Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Cohort Studies; Diagnostic Errors; Disease Progression; Early Diagnosis; Female; Foot Joints; Hand Joints; Humans; Longitudinal Studies; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rheumatoid Factor; Severity of Illness Index | 2012 |
[Rare association between chronic lymphocytic leukemia and systemic lupus erythematosus].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Disease Progression; Female; Humans; Immunosuppressive Agents; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Methotrexate | 2012 |
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.
Topics: Aged; Antineoplastic Agents; Autopsy; Brain; Brain Injuries; Chlorambucil; Cytarabine; Disease Progression; Fatal Outcome; Humans; Injections, Spinal; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Nervous System Diseases; Positron-Emission Tomography; Recurrence; Waldenstrom Macroglobulinemia | 2012 |
Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Cross-Sectional Studies; Disease Progression; Female; Foot; Hand; Humans; Infliximab; Inhibitor of Apoptosis Proteins; Male; Membrane Proteins; Methotrexate; Middle Aged; Predictive Value of Tests; Radiography; S100 Calcium-Binding Protein A4; S100 Proteins; Survivin | 2012 |
[Lyme disease with hepatitis and corticosteroids: a case report].
Topics: Adrenal Cortex Hormones; Aged; Disease Progression; Hepatitis; Humans; Lyme Disease; Male; Methotrexate; Prednisone | 2012 |
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Early Diagnosis; Etanercept; Female; Humans; Immunoglobulin G; Male; Methotrexate; Middle Aged; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
A novel combination of methotrexate and epigallocatechin attenuates the overexpression of pro-inflammatory cartilage cytokines and modulates antioxidant status in adjuvant arthritic rats.
Topics: Animals; Arthritis, Experimental; Catalase; Catechin; Disease Progression; Drug Combinations; Glutathione; Interleukin-6; Lipid Peroxidation; Male; Methotrexate; Mycobacterium; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2012 |
Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study.
Topics: Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid Artery Diseases; Comorbidity; Disability Evaluation; Disease Progression; Female; Health Status; Humans; Immunity, Innate; Incidence; Lipoproteins, LDL; Male; Methotrexate; Middle Aged; Phosphorylcholine; Prospective Studies; Severity of Illness Index; Survival Rate; Sweden; Ultrasonography | 2012 |
Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Diseases; Disease Progression; Early Diagnosis; Edema; Female; Humans; Magnetic Resonance Imaging; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Severity of Illness Index; Synovitis; Treatment Outcome; Wrist Joint | 2012 |
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Folic Acid; Health Status; Humans; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Synovitis; Treatment Outcome; Young Adult | 2012 |
Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Diseases; Disease Progression; Edema; Female; Finger Joint; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Radiography; Sulfasalazine; Tacrolimus; Treatment Outcome; Wrist Joint | 2013 |
Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prognosis; Radiography; Retrospective Studies; Rheumatoid Factor | 2013 |
Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Inflammation; Joints; Methotrexate; Radiography; Retrospective Studies; Rituximab | 2013 |
Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cohort Studies; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Metacarpophalangeal Joint; Methotrexate; Middle Aged; Osteophyte; Receptors, Tumor Necrosis Factor; Treatment Outcome; Tumor Necrosis Factor-alpha; X-Ray Microtomography | 2013 |
Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis--a prospective study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Prospective Studies; Pulse Wave Analysis; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Treatment Outcome; Vascular Stiffness | 2013 |
The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort.
Topics: Adult; Age Factors; American Indian or Alaska Native; Black People; Chi-Square Distribution; Comorbidity; Cyclophosphamide; Disease Progression; Educational Status; Female; Health Services Accessibility; Healthcare Disparities; Humans; Hypertension; Immunosuppressive Agents; Latin America; Logistic Models; Longitudinal Studies; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Medically Uninsured; Methotrexate; Multivariate Analysis; Odds Ratio; Prognosis; Racial Groups; Renal Dialysis; Residence Characteristics; Risk Factors; Rural Health; Socioeconomic Factors; Time Factors; Urban Health; White People; Young Adult | 2012 |
How much difference does the age at onset make in early arthritis patients? Comparison between the ACR 1987 and the ACR/EULAR 2010 classification criteria for rheumatoid arthritis at the time of diagnosis.
Topics: Adolescent; Adult; Age of Onset; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Prognosis; Sensitivity and Specificity; Severity of Illness Index | 2013 |
Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Retreatment; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2013 |
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Protein; Cohort Studies; Disease Progression; Female; Humans; Isoxazoles; Leflunomide; Logistic Models; Male; Methotrexate; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Peptides, Cyclic; Prognosis; Radiography | 2012 |
[Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings].
Topics: Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Disease Progression; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Expert Testimony; Female; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Isoxazoles; Leflunomide; Methotrexate; National Health Programs; Off-Label Use; Prednisolone; Tumor Necrosis Factor Inhibitors | 2013 |
Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clarithromycin; Cranial Irradiation; Cyclophosphamide; Disease Progression; Etoposide; Humans; Immunophenotyping; Immunosuppressive Agents; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Male; Meningeal Neoplasms; Methotrexate; Methylprednisolone Hemisuccinate; Orbital Neoplasms; Prednisolone; Remission Induction; Rituximab; Vincristine | 2013 |
Adult onset Still's disease: experience from a tertiary care rheumatology unit.
Topics: Adolescent; Adult; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; India; Male; Methotrexate; Middle Aged; Prednisolone; Remission Induction; Retrospective Studies; Still's Disease, Adult-Onset; Tertiary Care Centers; Time Factors; Treatment Outcome; Young Adult | 2012 |
Fibro-osseous pseudotumour of the digit in a patient with rheumatoid arthritis.
Topics: Amputation, Surgical; Arthritis, Rheumatoid; Biopsy, Needle; Bone Neoplasms; Disease Progression; Female; Fibroma, Ossifying; Fingers; Follow-Up Studies; Granuloma, Plasma Cell; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Rare Diseases; Treatment Outcome | 2013 |
Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Disability Evaluation; Disease Progression; Female; Health Status; Humans; Male; Methotrexate; Middle Aged; Severity of Illness Index; Treatment Outcome | 2013 |
Defining erosive disease typical of RA in the light of the ACR/EULAR 2010 criteria for rheumatoid arthritis; results of the data driven phase.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Diagnosis-Related Groups; Disease Progression; Europe; Female; Humans; Joints; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Rheumatology; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome | 2013 |
Best of the AASLD. Highlights from the 52nd Annual Meeting of the American Association for the Study of Liver Diseases. November 9-13, 2001, Dallas, TX.
Topics: Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Disease Progression; Hepatitis; Hepatitis, Viral, Human; Humans; Hypertension, Portal; Liver; Liver Cirrhosis, Biliary; Liver Diseases; Liver Neoplasms; Liver Transplantation; Methotrexate | 2002 |
The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
Topics: Aged; BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Disease Progression; Doxorubicin; Female; Humans; Life Tables; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Use of prognostic markets to guide biologic therapies for rheumatoid arthritis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Biomarkers; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Humans; Infliximab; Methotrexate; Rheumatology | 2002 |
Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Topics: Adult; Aged; Antigens, CD; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Cells, Cultured; Cohort Studies; Disease Progression; Etanercept; Female; Humans; Immunoglobulin G; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Leukocytes, Mononuclear; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prospective Studies; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Sialoglycoproteins; Tumor Necrosis Factor-alpha | 2003 |
Combined-modality treatment of leptomeningeal gliomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; Triethylenephosphoramide | 2003 |
Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain Diseases; Cerebral Arteries; Cerebral Infarction; Cytarabine; Disease Progression; Female; Humans; Injections, Spinal; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Ocular Motility Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recovery of Function; Syndrome; Tachycardia; Vasospasm, Intracranial | 2003 |
The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care Costs; Humans; Infliximab; Male; Markov Chains; Methotrexate; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sweden; United Kingdom | 2003 |
The utility of positron emission tomography in the evaluation of autoimmune hearing loss.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies; Autoimmune Diseases; Cochlea; Disease Progression; Double-Blind Method; Female; Hearing Loss, Sensorineural; HSP70 Heat-Shock Proteins; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisone; Reproducibility of Results; Tomography, Emission-Computed; Vestibule, Labyrinth | 2003 |
[The rheumatologist's conflict between "off-label" prescription and failure to render assistance].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disease Progression; Drug Approval; Drug Costs; Drug Therapy, Combination; Ethics, Medical; Germany; Humans; Immunosuppressive Agents; Insurance Coverage; Insurance, Pharmaceutical Services; Male; Methotrexate; Middle Aged; Mycophenolic Acid; National Health Programs; Refusal to Treat; Treatment Outcome | 2003 |
Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; L-Lactate Dehydrogenase; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Prognosis; Sclerosis; Treatment Outcome | 2003 |
Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis.
Topics: Acute Disease; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Female; Finger Joint; Foot Joints; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Radiography; Rheumatoid Factor; Time Factors | 2003 |
Psoriasis, vasculitis and methotrexate.
Topics: Adult; Aged; Biopsy, Needle; Disease Progression; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Failure, Chronic; Male; Methotrexate; Psoriasis; Renal Dialysis; Risk Assessment; Severity of Illness Index; Vasculitis | 2003 |
Response of cutaneous Crohn's disease to infliximab and methotrexate.
Topics: Adult; Antibodies, Monoclonal; Crohn Disease; Cutaneous Fistula; Dermatologic Agents; Disease Progression; Drug Therapy, Combination; Female; Humans; Infliximab; Methotrexate; Recurrence; Skin Diseases | 2003 |
[Advanced liver fibrosis secondary to methotrexate treatment].
Topics: Disease Progression; Female; Humans; Immunosuppressive Agents; Liver Cirrhosis; Methotrexate; Middle Aged | 2003 |
Cogan's syndrome: clinical evolution of deafness and vertigo in three patients.
Topics: Adult; Audiometry, Pure-Tone; Cochlea; Corneal Diseases; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Auditory, Brain Stem; Female; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Immunosuppressive Agents; Keratitis; Male; Methotrexate; Middle Aged; Syndrome; Vertigo; Vestibule, Labyrinth | 2005 |
Ten-year radiographic outcome in patients with rheumatoid factor positive rheumatoid arthritis treated with aggressive immunosuppressive combination therapy.
Topics: Administration, Oral; Adolescent; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclophosphamide; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Prospective Studies; Pulse Therapy, Drug; Radiography; Remission Induction; Rheumatoid Factor; Treatment Outcome | 2004 |
Safety of rituximab therapy during the first trimester of pregnancy: a case history.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant, Newborn; Lymphoma, Follicular; Male; Methotrexate; Mitoguazone; Peripheral Blood Stem Cell Transplantation; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Remission Induction; Rituximab; Safety; Transplantation, Autologous; Vincristine | 2004 |
Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Auranofin; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Radiography; Severity of Illness Index; Sulfasalazine; Treatment Outcome | 2005 |
Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prevalence; Prospective Studies; Quality of Life | 2004 |
Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity.
Topics: Age of Onset; Animals; Anti-Inflammatory Agents; Azathioprine; Disease Models, Animal; Disease Progression; Dogs; Female; Glucocorticoids; Immunosuppressive Agents; Male; Methotrexate; Methylprednisolone; Narcolepsy; Nucleic Acid Synthesis Inhibitors; Severity of Illness Index; Sleep; Time Factors; Treatment Outcome | 2004 |
Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Fever of Unknown Origin; Histiocytosis, Non-Langerhans-Cell; Humans; Karyotyping; Male; Methotrexate; Middle Aged; Pancytopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Rituximab; Splenomegaly; Vincristine | 2004 |
Atypical teratoid/rhabdoid tumour with leptomeningeal dissemination in an adult.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Humans; Ifosfamide; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Methotrexate; Neoplasm Invasiveness; Rhabdoid Tumor; Teratoma | 2004 |
High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine | 2004 |
Aggressive cutaneous T-cell lymphomas after TNFalpha blockade.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Crohn Disease; Cyclophosphamide; Cytomegalovirus Infections; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Gastritis; Gastrointestinal Hemorrhage; Heart Diseases; Humans; Lymphoma, T-Cell; Male; Methotrexate; Prednisone; Skin Neoplasms; Tumor Necrosis Factor-alpha; Vincristine | 2004 |
[Psoriatic arthritis (PsA)].
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Psoriatic; Disease Progression; Humans; Immunosuppressive Agents; Methotrexate; Nursing Diagnosis | 2004 |
Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Crohn Disease; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2004 |
Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aspartic Acid; Central Nervous System Neoplasms; Choline; Creatine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Immunocompetence; Lactic Acid; Lipid Metabolism; Lymphoma; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Protons; Survival Analysis | 2005 |
Use of local electroporation enhances methotrexate effects with minimum dose in adjuvant-induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Combined Modality Therapy; Disease Progression; Electroporation; Injections, Intraperitoneal; Male; Methotrexate; Radiography; Rats; Rats, Inbred Lew | 2005 |
Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution.
Topics: Administration, Oral; Adult; Airway Obstruction; Bronchi; Bronchial Diseases; Bronchoscopy; Constriction, Pathologic; Disease Progression; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Methotrexate; Middle Aged; Respiratory Function Tests; Retrospective Studies; Sarcoidosis | 2005 |
Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Basement Membrane; Disease Progression; Humans; Hypergammaglobulinemia; Immunoassay; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Kidney; Kidney Tubules; Male; Methotrexate; Middle Aged; Nephrotic Syndrome; Prednisolone; Vincristine | 2005 |
Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gold Sodium Thiomalate; Humans; Male; Methotrexate; Middle Aged; Pain Measurement; Prognosis; Radiography; Registries; Sensitivity and Specificity; Severity of Illness Index; Sulfasalazine; Sweden; Treatment Outcome | 2004 |
Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Child; Disease Progression; Drug Delivery Systems; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Lymphoma; Male; Methotrexate; Middle Aged; Neuroectodermal Tumors, Primitive; Oligodendroglioma; Survival Rate; Time Factors | 2005 |
Kernohan notch lesion after spinal tap.
Topics: Adult; Causality; Cerebral Veins; Disease Progression; Efferent Pathways; Female; Headache; Hematoma, Subdural, Intracranial; Hemiplegia; Humans; Injections, Spinal; Intracranial Hypotension; Magnetic Resonance Imaging; Mesencephalon; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Spinal Puncture; Thrombocytopenia | 2005 |
[So that the patients.would be able to move for a long time after first diagnosis of rheumatism. Approach as an emergency!].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Methotrexate; Osteoporosis; Receptors, Tumor Necrosis Factor; Time Factors; Tumor Necrosis Factor-alpha | 2004 |
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorometry; Fluorouracil; Humans; Methotrexate; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Quality Control; Retrospective Studies; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Choroid Diseases; Cyclosporine; Daclizumab; Disease Progression; Drug Therapy, Combination; Electroretinography; Female; Follow-Up Studies; HLA-A Antigens; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Retinal Diseases; Retrospective Studies; Treatment Outcome; Visual Acuity | 2005 |
[Personal experiences with methotrexate in tumor therapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Otorhinolaryngologic Neoplasms; Treatment Outcome | 1966 |
[Treatment of adult Berkitt-like lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Daunorubicin; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Prednisone; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 2005 |
Predictors of immunomodulator use as early therapy in pediatric Crohn's disease.
Topics: Adolescent; Azathioprine; Biomarkers; Chi-Square Distribution; Child; Child, Preschool; Crohn Disease; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Mercaptopurine; Methotrexate; Predictive Value of Tests; Prospective Studies; Statistics, Nonparametric | 2006 |
[Survival prospects of mesopharyngeal carcinoma patients treated primarily with intraarterial chemotherapy. A retrospective study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Methotrexate; Middle Aged; Pharyngeal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
[Fulminant course of a Takayasu's arteritis and rare mesenteric arterial maninfestion].
Topics: Angiography; Aorta, Abdominal; Aortitis; Aortography; Arterial Occlusive Diseases; Celiac Artery; Colectomy; Colon; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Etanercept; Fatal Outcome; Female; Humans; Immunoglobulin G; Ischemia; Jejunum; Mesenteric Artery, Superior; Mesenteric Vascular Occlusion; Methotrexate; Middle Aged; Prednisolone; Receptors, Tumor Necrosis Factor; Takayasu Arteritis; Tomography, X-Ray Computed; Ultrasonography, Doppler | 2006 |
The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis.
Topics: Antimalarials; Azathioprine; Cyclophosphamide; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Methotrexate; Methylprednisolone; Middle Aged; Panniculitis, Lupus Erythematosus; Pulse Therapy, Drug; Tacrolimus; Treatment Failure | 2007 |
Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Contraindications; Cyclosporine; Disease Progression; Disease Susceptibility; DNA, Neoplasm; Etanercept; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Gene Rearrangement, B-Lymphocyte, Light Chain; Genes, Immunoglobulin; Humans; Immunocompromised Host; Immunoglobulin G; Immunosuppressive Agents; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Methotrexate; Neoplasm Proteins; Receptors, Tumor Necrosis Factor; Rituximab; Tumor Necrosis Factor-alpha | 2006 |
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Inflammation; Joints; Methotrexate; Radiography; Receptors, Tumor Necrosis Factor; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Magnetic resonance imaging in rheumatologic practice: low field or standard.
Topics: Antirheumatic Agents; Disease Progression; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Methotrexate; Prognosis; Rheumatic Diseases; Tumor Necrosis Factor-alpha | 2006 |
Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children.
Topics: Adolescent; Child; Child, Preschool; Dermatologic Agents; Disease Progression; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Methotrexate; Prednisolone; Recurrence; Retrospective Studies; Scleroderma, Localized; Thermography; Treatment Outcome | 2006 |
Methotrexate-induced lymphoproliferative disorder in a patient with Sézary syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Disease Progression; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Lymphatic Diseases; Lymphoproliferative Disorders; Male; Methotrexate; Prognosis; Risk Factors; Sezary Syndrome | 2006 |
Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Penile Neoplasms; Retrospective Studies; Treatment Outcome | 2006 |
Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Methotrexate; Middle Aged; Quality-Adjusted Life Years; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2006 |
En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients.
Topics: Adolescent; Adult; Aged; Child; Dermatologic Agents; Disease Progression; Facial Hemiatrophy; Female; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Scleroderma, Localized; Seizures | 2007 |
A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Cohort Studies; Decision Support Techniques; Disease Progression; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis | 2007 |
[Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Ifosfamide; Methotrexate; Recurrence; Remission Induction; Rituximab; Translocation, Genetic; Vincristine | 2007 |
FBXW7 and DNA copy number instability.
Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Chromosomal Instability; Disease Progression; DNA; Drug Resistance, Neoplasm; Exons; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Genetic Techniques; Genomic Instability; Humans; Methotrexate; Mutation; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Ubiquitin-Protein Ligases | 2008 |
Low-dose oral methotrexate for the management of childhood Cogan's syndrome: a case report.
Topics: Administration, Oral; Child; Disease Progression; Follow-Up Studies; Hearing Loss, Sensorineural; Humans; Immunosuppressive Agents; Keratitis; Male; Methotrexate; Syndrome | 2007 |
Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis.
Topics: Adult; Age of Onset; Autoimmune Diseases; Disease Progression; Glomerulonephritis, Membranous; Humans; Immunosuppressive Agents; Kidney; Male; Methotrexate; Peripheral Nerves; Plasmapheresis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Treatment Outcome | 2008 |
Celastrus aculeatus Merr. suppresses the induction and progression of autoimmune arthritis by modulating immune response to heat-shock protein 65.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Bacterial Proteins; Bone and Bones; Cartilage, Articular; Celastrus; Chaperonin 60; Chaperonins; Cytokines; Disease Progression; Drugs, Chinese Herbal; Hindlimb; Immunosuppressive Agents; Local Lymph Node Assay; Lymph Nodes; Male; Methotrexate; Nitric Oxide; Rats; Rats, Inbred Lew; Synovial Membrane | 2007 |
Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disabled Persons; Disease Progression; Female; Humans; Japan; Male; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Severity of Illness Index | 2007 |
[Diagnosis and treatment of calcium pyrophosphate crystal-induced arthropathy].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Calcium Pyrophosphate; Cartilage, Articular; Chondrocalcinosis; Colchicine; Diagnosis, Differential; Disease Progression; Glucocorticoids; Gout Suppressants; Humans; Injections, Intra-Articular; Interleukin-1beta; Methotrexate; Middle Aged; Risk Factors; Synovial Membrane | 2007 |
Use of parenteral methotrexate significantly reduces the need for biological therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Middle Aged; Patient Selection; Retrospective Studies; Treatment Outcome | 2008 |
Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Disease Progression; Drug Administration Schedule; Humans; Longitudinal Studies; Methotrexate; Middle Aged; Radiography; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2008 |
Cholesterol crescents and plates in shoulder effusion of a rheumatoid patient.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy, Fine-Needle; Cholesterol; Disease Progression; Drug Resistance; Etanercept; Exudates and Transudates; Follow-Up Studies; Humans; Immunoglobulin G; Male; Methotrexate; Prednisolone; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Shoulder Joint; Synovial Fluid; Treatment Outcome | 2008 |
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
Topics: Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Confounding Factors, Epidemiologic; Disease Progression; Drug Therapy, Combination; Female; Humans; Isoxazoles; Leflunomide; Longitudinal Studies; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Isolated lymphoma of the anterior visual pathway diagnosed by optic nerve biopsy.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; Disease Progression; Fatal Outcome; Humans; Leucovorin; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Neoplasm Invasiveness; Optic Chiasm; Optic Nerve; Optic Nerve Neoplasms; Prednisone; Treatment Failure; Vision, Low; Vitamin B Complex | 2008 |
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisolone; Retrospective Studies; Sulfasalazine | 2008 |
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2008 |
Myeloma during a decade: clinical experience in a single centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisolone; Procarbazine; Recombinant Proteins; Remission Induction; Survival Rate; Vincristine | 1995 |
New perspectives on treating rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Drug Therapy, Combination; Humans; Methotrexate; Prednisolone | 1995 |
Rapidly progressive sclerosing cholangitis following surgical treatment of pancreatic pseudotumor.
Topics: Adult; Anti-Inflammatory Agents; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Common Bile Duct Diseases; Constriction, Pathologic; Disease Progression; Humans; Male; Methotrexate; Middle Aged; Pancreatic Diseases; Time Factors; Treatment Outcome | 1995 |
Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Ifosfamide; Inappropriate ADH Syndrome; Lymphoma, T-Cell, Peripheral; Methotrexate; Mitoguazone; Prednisone; Teniposide; Verapamil; Vincristine; Vindesine | 1995 |
Validation of the French version of the arthritis impact measurement scales 2 and comparison with the french version of the Nottingham Health Profile. "Quality of Life in Rheumatology" Task Force.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; England; Female; France; Health Status; Health Status Indicators; Humans; Male; Methotrexate; Middle Aged; Psychometrics; Quality of Life; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disease; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Female; Hepatic Encephalopathy; Hepatitis B; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1996 |
p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis.
Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Methotrexate; Middle Aged; Multivariate Analysis; Proliferating Cell Nuclear Antigen; Retrospective Studies; Survival Analysis; Tumor Suppressor Protein p53 | 1996 |
Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A or methotrexate: comment on the article by Pasero et al.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Humans; Joint Diseases; Methotrexate | 1997 |
Induction chemotherapy with versus without hormonal synchronisation in locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Disease Progression; Estrogens; Female; Fluorouracil; G1 Phase; Humans; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Remission Induction; Tamoxifen | 1997 |
Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Biopsy; Child; Diabetes Complications; Disease Progression; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Liver; Liver Cirrhosis; Male; Methotrexate; Middle Aged; Nova Scotia; Obesity; Psoriasis; Retrospective Studies; Risk Factors; Time Factors | 1996 |
Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Disease Progression; Doxorubicin; Fatal Outcome; Follow-Up Studies; Humans; Injections, Intravenous; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitoxantrone; Prostatic Neoplasms; Remission Induction; Vinblastine | 1997 |
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Humans; Leucovorin; Methotrexate; Middle Aged; Neutropenia; Survival Rate; Tegafur; Uracil | 1997 |
A case-control and nerve biopsy study of CREST multiple mononeuropathy.
Topics: Aged; Antirheumatic Agents; Biopsy; Case-Control Studies; CREST Syndrome; Disease Progression; Drug Therapy, Combination; Electromyography; Electrophysiology; Female; Glucocorticoids; Humans; Methotrexate; Middle Aged; Peripheral Nervous System Diseases; Prednisone; Sural Nerve | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cisplatin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Treatment Outcome | 1998 |
Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Disease Progression; Etoposide; Female; Humans; Lymphoma, AIDS-Related; Male; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin lambda-Chains; Injections, Spinal; Male; Meningeal Neoplasms; Methotrexate; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Staging; Ribs; Vincristine | 1998 |
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Carpal Bones; Child; Child, Preschool; Disease Progression; Female; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Radiography; Retrospective Studies | 1998 |
Drug-combination therapy of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; Cyclophosphamide; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Fluocortolone; Glucocorticoids; Humans; Kidney; Longitudinal Studies; Male; Methotrexate; Middle Aged | 1998 |
Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Disease Progression; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Inflammation; Male; Methotrexate; Middle Aged; Prognosis; Prospective Studies; Radiography; Risk Factors; Sulfasalazine | 1998 |
Methotrexate and radiographic disease progression in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Dose-Response Relationship, Drug; Humans; Methotrexate | 1999 |
Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cohort Studies; Collagenases; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Rheumatoid Factor; Time Factors; Tissue Inhibitor of Metalloproteinase-1 | 1999 |
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progression; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome | 1999 |
Rheumatoid arthritis: new concepts in disease evolution, pathogenesis, and treatment.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Organogold Compounds; Treatment Outcome | 1995 |
Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystectomy; Disease Progression; Disease-Free Survival; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Pituitary involvement by Wegener's granulomatosis: a report of two cases.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Diabetes Insipidus; Disease Progression; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Methotrexate; Pituitary Diseases; Pituitary Gland, Posterior; Prednisone; Remission Induction | 1999 |
Pityriasis rubra pilaris in black South Africans.
Topics: Acitretin; Adolescent; Adult; Age of Onset; Black People; Child; Child, Preschool; Dermatologic Agents; Disease Progression; Emollients; Female; Humans; Infant; Keratolytic Agents; Male; Methotrexate; Middle Aged; Pityriasis Rubra Pilaris; Prospective Studies; South Africa; Treatment Outcome; Treatment Refusal | 1999 |
Metaplastic breast cancer: prognosis and response to systemic therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Metaplasia; Methotrexate; Middle Aged; Neoplasms, Complex and Mixed; Palliative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease Progression; Germinoma; Humans; Ifosfamide; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1999 |
Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Chitinase-3-Like Protein 1; Disease Progression; Female; Glycoproteins; Humans; Lectins; Male; Methotrexate; Middle Aged; Prednisolone; Severity of Illness Index | 1999 |
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Humans; Methotrexate; Radiography | 1999 |
Diffuse large-cell lymphoma of the testis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Recurrence; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Treatment Outcome; Vincristine | 1999 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents.
Topics: Animals; Antigens, Polyomavirus Transforming; Apoptosis; bcl-2-Associated X Protein; Binding Sites; Body Weight; Cell Line, Transformed; Crosses, Genetic; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Disease Progression; DNA; DNA Damage; Doxorubicin; Gamma Rays; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, p53; Genotype; Hyperplasia; Liver; Liver Diseases; Liver Neoplasms, Experimental; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Transgenic; Nuclear Proteins; Organ Size; Precancerous Conditions; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Simian virus 40; Tumor Suppressor Protein p53; Ultraviolet Rays | 2000 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Purging; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Cystitis; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infections; Leucovorin; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Wegener's granulomatosis presenting as mediastinal soft tissue mass invading the tracheal wall.
Topics: Adult; Disease Progression; Female; Granulomatosis with Polyangiitis; Humans; Mediastinal Diseases; Methotrexate; Radiography; Steroids; Trachea; Tracheal Diseases; Treatment Outcome | 2000 |
Remitting asymmetrical pitting oedema in systemic lupus erythematosus: two cases studied with magnetic resonance imaging.
Topics: Adult; Ankle; Cyclosporine; Disease Progression; Drug Therapy, Combination; Edema; Female; Functional Laterality; Humans; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Methotrexate; Prednisone; Remission, Spontaneous; Treatment Outcome; Wrist | 2000 |
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Diabetes Insipidus; Disease Progression; Doxorubicin; Dwarfism, Pituitary; False Negative Reactions; Genetic Predisposition to Disease; Human Growth Hormone; Humans; Hydrocortisone; Hypopituitarism; Hypothyroidism; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Pituitary Hormones; Pituitary Neoplasms; Prednisone; Remission Induction; Vincristine | 2001 |
Destructive eyelid lesions in sarcoidosis.
Topics: Adult; Cicatrix; Disease Progression; Drug Therapy, Combination; Entropion; Humans; Immunosuppressive Agents; Male; Methotrexate; Prednisone; Sarcoidosis | 2001 |
Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction.
Topics: Alternative Splicing; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Arthrography; Disease Progression; Ectodysplasins; Enzyme-Linked Immunosorbent Assay; Female; Fibronectins; Humans; Knee Joint; Male; Membrane Proteins; Methotrexate; Middle Aged; Prospective Studies; Severity of Illness Index; Synovial Fluid; Treatment Outcome | 2001 |
Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Predictive Value of Tests; Survival Analysis | 2001 |
Co-existent sickle cell disease and juvenile rheumatoid arthritis. Two cases with delayed diagnosis and severe destructive arthropathy.
Topics: Adolescent; Anemia, Sickle Cell; Arthritis, Juvenile; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ibuprofen; Magnetic Resonance Imaging; Methotrexate; Physical Therapy Modalities; Risk Assessment; Severity of Illness Index; Time Factors | 2001 |
High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Brain; Brain Neoplasms; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Recurrence; Testicular Neoplasms | 2001 |
Acute T-lymphoblastic leukemia relapsed with the character of myeloid/natural killer cell precursor phenotype: a case report.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Lineage; Combined Modality Therapy; Daunorubicin; Disease Progression; Fatal Outcome; Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; Genes, Immunoglobulin; Glycophorins; HLA-DR Antigens; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphoid; Male; Methotrexate; Myeloid Cells; Neoplasm Proteins; Neoplastic Stem Cells; Peroxidase; Prednisolone; Recurrence; Remission Induction; T-Lymphocyte Subsets; Transplantation, Homologous; Vincristine | 2002 |
The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Azathioprine; Conjunctivitis; Cyclophosphamide; Dapsone; Disease Progression; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Pemphigoid, Benign Mucous Membrane; Prednisone; Visual Acuity | 2002 |
Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia.
Topics: Animals; Bone Marrow Transplantation; Cell Survival; Disease Progression; Drug Resistance, Neoplasm; Flow Cytometry; Folic Acid Antagonists; Hematocrit; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Mice; Mice, Inbred C3H; Organ Size; Survival Analysis; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 2002 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.
Topics: Adult; Antimetabolites, Antineoplastic; Attitude of Health Personnel; Disease Progression; Female; Humans; Longitudinal Studies; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Ontario; Outcome Assessment, Health Care; Patient Satisfaction; Quebec; Randomized Controlled Trials as Topic; Reproducibility of Results; Severity of Illness Index; Sickness Impact Profile | 2002 |
Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Disease Progression; Female; Humans; Injections, Spinal; Meningeal Neoplasms; Methotrexate; Middle Aged; Retrospective Studies; Spinal Cord Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2002 |